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11. THE RHYTHM OF ATTENTION DEFICIT 
HYPERACTIVITY DISORDER, METABOLIC 
SYNDROME, SLEEP AND AGING 
 “The domain of rhythm extends from the spiritual to the carnal.” Bruno Walter [1a]
Biological rhythms pervade every aspect of life. In this thesis, we explore a quartet of 
physiological functions which are believed to show rhythmic patterns. These are firstly, those risk 
factors associated with developing cardiovascular disease and diabetes, known as Metabolic 
Syndrome (MetSyn). Secondly, sleep and its disturbances, such as insomnia and circadian 
rhythm disorders, also show rhythmic fluctuations. A third part of the quartet is Seasonal 
Affective Disorder (SAD), depression occurring on a yearly basis at the onset of winter. Finally, 
aging is also an inevitable physiological process which shows an accelerated rhythm in some 
individuals and a more languid pace in others. 
Attention-Deficit/Hyperactivity Disorder (ADHD) is often thought of as a purely psychiatric 
disorder. In this thesis, we explore how its effects and associations extend to the somatic, or 
carnal, realm. Specifically, we investigate how ADHD is associated with MetSyn, sleep/
circadian rhythm disorders and SAD. The subsequent consequences on health and illness are 
examined. Sleep disorders are also investigated in relation to aging that occurs on a cellular 
level.
The quartet includes seemingly disparate physiological processes. How are they linked? In 
this thesis we propose that a pro-inflammatory state may be a common link in these disturbed 
rhythms.
1.1 AT TENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) – 
HISTORY
Many people believe that ADHD is a disorder that emerged in the modern era. But in the 
late 18th century, Sir Alexander Crichton described children with “mental restlessness”, a 
“disease of attention” and “the fidgets” [2]. Crichton’s recognition of this clinical entity and its 
subsequent effect on schooling was two hundred years ahead of its time. About a century later, 
the pediatrician Sir George Still, identified children with a “morbid defect of moral control”, 
displaying disinhibition, poor self-regulation  and “a quite abnormal incapacity for sustained 
attention” [3]. Until recently, ADHD was considered a disorder of childhood. Recently, several 
studies have shown that ADHD persists into adulthood in up to 60% of affected children [4] – 
and extends into old age in 2.8%  [5]. 
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1.2 ADULT ADHD – PREVALENCE, SYMPTOMS AND TREATMENT
“I prefer to distinguish ADD as attention abundance disorder. Everything is just 
so interesting . . . remarkably at the same time.” Frank Coppola [6]
The world cross-national estimated prevalence of adult ADHD is 2.8% [7], with a range of 2.5 
- 4.9% [8, 9]. Today, adult ADHD is considered a neurodevelopmental disorder characterized 
by inattention and/or impulsivity, hyperactivity, mood instability and mind wandering [10 
- 12]. In adult ADHD, inattention, disorganization and procrastination predominate [13]. 
Hyperactivity symptoms are less obvious and are often internalized as inner restlessness [14].
Adult ADHD is a rewarding condition to treat as positive results of pharmacological treatments 
versus placebo are impressive [15]. Stimulant medications such as amphetamines and 
methylphenidate are first line agents [16]. Non-stimulants such as atomoxetine are second 
line, and considered when there are tolerability, response or safety concerns with stimulants. 
Psychosocial treatments include cognitive behavioral therapy, with emphasis on organization, 
prioritizing, and time management. Combining pharmacotherapy and psychosocial treatments 
is considered most effective [17]. 
1.3 ADULT ADHD – COMORBIDITIES
ADHD in adults is highly comorbid with psychiatric and metabolic disorders, such as sleep, 
anxiety and mood disorders, Post Traumatic Stress Disorder (PTSD), autism spectrum disorder, 
personality disorders, obesity, amongst others [18 - 20]. In practice, clinicians frequently treat 
ADHD in the presence of several comorbidities. Of these, some are disorders of the biological 
rhythm. We now explore the quartet MetSyn, sleep/circadian rhythm disorders, SAD and 
aging in more detail. 
1.4 BIOLOGICAL RHY THMS
“We learned we are truly rhythmic organisms, it’s hard to find a cell that does not 
oscillate in response to these clocks.” Michael W. Young, joint recipient Nobel Prize in 
Physiology/Medicine 2017 [21]
Underpinning all life, from the simplest unicellular organisms to the most complex, are the 
biological rhythms. The study of biological timekeeping, or chronobiology, examines how 
these cyclical rhythms control vital aspects of our physiology [22]. Of relevance to this thesis 
are three types of biological rhythms:
GENERAL INTRODUCTION | 15
1Ultradian: occurring many times per day, for example the rhythmic control of digestive processes. Ultradian rhythm disorders may be associated with MetSyn [23].
Circadian: occurring approximately every 24 hours: circa (approximately) and dies (day). A 
rhythm disturbance here refers to desynchronization of the sleep-wake cycle.  
Circannual: occurring approximately once yearly. A disorder of this rhythm is for example 
SAD, where major depressive episodes occur yearly during fall and/or winter [10, 24]. 
The literature also describes infradian (repeating at intervals much longer than 24 hours) and 
tidal, weekly and circalunar (monthly) rhythms occurring in animals and plants [25]. 
2. THE RHYTHM OF INSOMNIA
Many sleep disorders have a higher prevalence in the presence of adult ADHD (illustrated in 
Figure 1). Of importance to this research are insomnia and delayed circadian rhythm.
ADHD
FIGURE 1. Some of the sleep disorders with increased prevalence in adult ADHD 
Two examples of delayed circadian rhythm are delayed chronotype and an extreme version of this, the Delayed Sleep 
Phase Syndrome. Examples of sleep-related movement disorders include periodic limb movements during sleep and 
restless legs syndrome. 
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2.1 INSOMNIA – HISTORY
“O sleep, O gentle sleep, Nature’s soft nurse, how have I frightened thee? That 
thou no more will weigh my eyelids down, and steep my senses in forgetfulness?” 
William Shakespeare [26]
The understanding of insomnia has changed over recent decades. Today, it is considered 
normal to go to bed before midnight and to sleep 7-8 uninterrupted hours per night. Yet, 
anthropological research and historical evidence show that this has not always been the case 
[27]. For example, before the industrial age there is ample (European) documentation of 
fragmented sleep occurring normally. A “first sleep” started 4 hours after dinner, followed by 2 
hours awake in bed after midnight, where people remained and ate, read, prayed and wrote 
– and then a “second sleep” of 4 hours commenced [28]. By the late 17th century, references 
to this interrupted pattern had disappeared and sleep was considered of no academic interest. 
Interestingly, a study from the early 1990s demonstrated a segmented sleep pattern when 
volunteers were placed in a dark environment for 14 hours per day [29]. The official birth of 
modern sleep science was in 1953, when Rapid Eye Movement sleep was first described [30]. 
2.2 INSOMNIA – PREVALENCE IN ADHD AND SYMPTOMS 
Insomnia is an important comorbid condition in adult ADHD, where the cross-sectional 
prevalence is 43-80% [31-33]. This association is complicated by the finding that 
pharmacological treatments for ADHD are also reported to cause insomnia. One of the most 
common sleep disorders, insomnia, is now classified as a sleep-wake disorder in DSM-5 [10]. 
Sufferers experience problems with the quality and quantity of sleep, and have decreased 
functioning during the daytime. The timing of sleep is also affected, with difficulty initiating or 
maintaining sleep; or early-morning awakening over at least 3 months, 3 nights per week [10]. 
2.3 ADHD AND INSOMNIA – RESEARCH QUESTIONS
The relationship between insomnia and ADHD is discussed in Chapter 2, where a literature 
review provides an update of cross-sectional and longitudinal studies, as well as discussing 
how insomnia is associated with pharmacological treatments for ADHD. Chapter 3 tests the 
relationship between ADHD and insomnia, sleep duration and ADHD in another population 
study, NEMESIS-2 (Netherlands Mental Health Survey and Incidence Study-2). Chapter 4 
briefly raises the possibility that the relationship between ADHD and insomnia is related to a 
pro-inflammatory state.
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13. THE RHYTHM OF DELAYED CIRCADIAN 
TIMING
“The circadian system has its tentacles around everything…It’s ticking away in 
almost every tissue in the human body.” Michael Robash, joint recipient Nobel Prize in 
Physiology/Medicine 2017 [34]
Several other sleep disorders that are studied in this thesis relate to a possible biological rhythm 
disturbance in ADHD. A delayed circadian rhythm is highly prevalent in ADHD: particularly the 
late chronotype and an extreme version of this, the Delayed Sleep Phase Syndrome (DSPS).    
3.1 THE SLEEP-WAKE CYCLE
As elegantly described by Bourguinon and Storch, many species on earth have evolved a self-
sustaining timing system, which facilitates robust 24 hour rhythms in physiology and behavior, 
despite non-24 hour variations in the environment [35]. Hence organisms function over a 24 
hour cycle, even when there are no cues in the form of changes in light and dark [22]. This 
adaptive, endogenous timing system is also known as the circadian clock. Interdisciplinary 
research over the past decades is uncovering its cellular and molecular basis. In 2017, the 
Nobel Prize for Medicine was awarded to Hall, Robash and Young, three scientists investigating 
the molecular mechanisms of circadian rhythm [34]. 













FIGURE 2. The circadian rhythm and physiological processes
Adapted from: The Nobel Assembly at the Karolinska Institutet, Stockholm [36]
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While most cells in the human body show circadian activity, the master clock is located in 
the suprachiasmatic nuclei (SCN) of the hypothalamus, anticipating and adapting human 
physiology to the different phases of the day (Figure 3). Disorders of circadian rhythm have 
far-reaching consequences.
3.2 DELAYED SLEEP PHASE SYNDROME - HISTORY
Several circadian rhythm sleep disorders are described in DSM-5 and of relevance to this 
thesis is DSPS [10]. Weitzman and colleagues first described a chronobiological disorder with 
sleep-onset insomnia in 1981. They named it “delayed sleep phase insomnia” [37]. Today, it is 
still poorly recognized by clinicians, often dismissed, or misdiagnosed as chronic insomnia due 
to the presence of sleep initiation problems and some overlap between its diagnostic criteria 
[38]. 
3.3 DELAYED SLEEP PHASE SYNDROME – PREVALENCE AND 
SYMPTOMS
Two types of DSPS are described: a temporary adolescent variety (more common among 
boys) in 7 - 16% of teenagers [39] and a lifelong variety, beginning in early childhood or 
puberty, with prevalence range from 0.13 to 10% [38]. In DSPS, there is believed to be a 
discrepancy between the internal setting of the biological clock and the sleep-wake schedule 
required by one’s occupational, social or educational obligations [10]. Difficulty in falling 
asleep at socially acceptable hours is thought to occur because sleep is being attempted at a 
time when the biological clock is strongly promoting wakefulness. 
The results are sleep-onset usually after midnight, shorter sleep duration, difficulty awakening 
and chronic sleep deprivation, resulting in daytime fatigue and impaired functioning. The other 
essential component of DSPS is the difficulty to shift one’s schedule to an earlier time. The 
circadian phase of sleep in DSPS is stable: individuals will fall asleep and awaken at consistent, 
albeit delayed times when left to their own schedule (e.g., on weekends or holidays). Once 
sleep is initiated, it is normal.
3.4 CHRONOTYPE
A person’s chronotype refers to the behavioral manifestation of underlying circadian rhythms, 
as evidenced by regular rising and sleep-onset times during 24 hours. Chronotype consists 
of morning, evening and intermediate types [40]. Timing of sleep and wakefulness may 
differ during work and free days, as sleep deficit accumulates during working days, but is 
compensated for on free days, when rising time can be later [41]. Phase and duration of 
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1sleep on free days are believed to reflect circadian rhythm most accurately as there are fewer externally enforced schedules [42].
3.5 ADHD AND DELAYED CIRCADIAN RHY THM – RESEARCH 
QUESTIONS
In this thesis, we investigate delayed circadian rhythm in two studies. Chapter 5 examines the 
well-recognized relationship between ADHD and SAD (discussed in the next paragraph), and 
particularly whether indicators of disturbed sleep and delayed circadian rhythm mediate this 
relationship. Chapter 7 tests the relationship between cellular aging and delayed circadian 
rhythm. 
4. THE RHYTHM OF SEASONAL AFFECTIVE 
DISORDER 
4.1 SEASONAL AFFECTIVE DISORDER – HISTORY
“Whoever wishes to pursue the science of medicine in a direct manner must first 
investigate the seasons of the year and what occurs in them.” Hippocrates [43] 
Observers of depression have long noted synchrony between the seasons and mood 
(extensively reviewed in [44]). In 1621, Burton1 remarked that “of all the seasons, the autumn 
is the most melancholy” [45]. In the 1980s, when psychiatrist Norman Rosenthal moved to 
the USA from South Africa, he noticed his own loss of productivity and increased depression 
during the short, dark days of winter. However, his functioning returned to normal as soon as 
spring arrived. Based on this personal experience, his own research and the collaboration of 
other experts investigating the neurohormone melatonin and circadian rhythm, the first paper 
on light therapy for SAD was published. SAD is now a well-documented disorder [24]. 
4.2 SEASONAL AFFECTIVE DISORDER – PREVALENCE AND SYMPTOMS
Winter depression or SAD has a prevalence of up to 27% in adult ADHD [46 - 48]. In the 
general population the estimated prevalence is much lower: 3-6% [47, 49]. SAD occurs four 
times more often in women than in men, and the age-of-onset is between 18 and 30 years [50]. 
1 The book is referred to as “The Anatomy of Melancholy”, but with a full title: “The Anatomy of Melancholy, What it 
is: With all the Kinds, Causes, Symptomes, Prognostickes, and Several Cures of it. In Three Maine Partitions with their 
several Sections, Members, and Subsections. Philosophically, Medicinally, Historically, Opened and Cut Up”.
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Symptoms of SAD occur during the fall and winter months and include sadness, thoughts of death 
or suicide attempts, feeling worthless or guilty, difficulty concentrating or making decisions, 
anhedonia, fatigue, forgetfulness, as well as the so-called atypical depressive symptoms: sleep 
disturbance (tendency to sleep longer), hyperphagia and weight increase, with carbohydrate 
cravings [51]. Without treatment, the symptoms of SAD tend to remit in the spring, so that SAD lasts 
about 40% of the year [52]. Depressive episodes can occur in summer too, but this is far less common.
4.3 ADHD, SEASONAL AFFECTIVE DISORDER, INSOMNIA AND 
CIRCADIAN RHY THM – RESEARCH QUESTIONS 
By studying the relationship between SAD, insomnia and delayed circadian rhythm, we are 
conceptualizing ADHD as a disorder of the biological rhythm. This has been suggested by 
genetic evidence, which shows underlying CLOCK gene (Circadian Locomotor Output 
Cycles Kaput) polymorphisms in ADHD [53]. In animal models with mutant circadian genes, 
ADHD-like symptoms and reduced dopamine levels have been observed [54]. Both SAD and 
DSPS are known disorders of biological rhythm and share genetic factors with ADHD [55]. 
In terms of treatment, symptoms of ADHD, SAD and DSPS improve when therapy involves 
‘phase resetting’ of the day-night rhythm [56, 57]. In Chapter 5, we explore whether the well-
recognized  association between SAD and ADHD is mediated by markers of circadian rhythm 
disturbance in a study from the NESDA cohort.
5. THE RHYTHM OF METABOLIC SYNDROME 
Metabolic disorders such as obesity frequently co-exist with ADHD, although this might 
seem counterintuitive: association of hyperactivity with raised Body Mass Index (BMI) does 
not appear consistent [18, 19]. However, impulsivity and inattention in ADHD may lead to 
disturbed eating patterns and weight gain. A recent meta-analysis reported a significant 
association between ADHD and obesity [58]. ADHD is also associated with sleep disorders, 
and recently, evidence has been accumulating  that sleep disorders may explain part of the 
relationship between ADHD and obesity [59]. Abnormal metabolic processes are among the 
risk factors associated with developing cardiovascular disease and type 2 diabetes mellitus. 
The MetSyn is a cluster of these frequently co-occurring disturbances. 
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15.1 METABOLIC SYNDROME – HISTORY
“The syndrome of affluence, (Wohlstandssyndrom)” [60]
The interdependence of vascular hypertension and type 2 diabetes was reported independently 
by European  physicians at the beginning of the 20th century, but the term “metabolic 
syndrome” was only coined in the 1950s [61]. In 1989, the term “deadly quartet” was coined 
to refer to the most dangerous type of MetSyn, including disorders of glucose intolerance, 
hypertriglyceridemia, obesity and hypertension [62].
5.2 METABOLIC SYNDROME – PREVALENCE AND DESCRIPTION
World-wide, obesity and type 2 diabetes have increased rapidly reaching epidemic 
proportions [63]. Excessive food intake and a sedentary lifestyle have been proposed to 
explain, at least in part, this increase. The prevalence of MetSyn in U.S. adults is over 25%, 
with higher rates among various race/ethnic minority groups [64]. 
According to the widely-used adjusted Adult Treatment Panel III (ATP-III) criteria, MetSyn may 
be diagnosed if three of the following risk factors co-exist: 
•	 Abdominal obesity: waist circumference > 102 cm in men and > 88 cm in women; 
•	 Hypertriglyceridaemia: triglyceride levels ≥ 1.7 mmol/l (150 mg/dl) or use of 
medication to reduce hypertriglyceridemia; 
•	 Low high-density lipoprotein (HDL) cholesterol: HDL < 1.03 mmol/l (40 mg/dl) in 
men and < 1.30 mmol/l (50 mg/dl ) in women, or use of medication to reduce  HDL 
cholesterol; 
•	 Hypertension: blood pressure ≥ 130/85 mm Hg, or use of antihypertensive medication; 
•	 Fasting plasma glucose ≥ 5.6 mmol/l (100 mg/dl) or use of anti-diabetic medication 
[63]. 
5.3 ADHD AND METABOLIC SYNDROME – RESEARCH QUESTIONS
Obesity has an increased prevalence in the presence of ADHD [58] and mood and anxiety 
disorders [65 - 67].  Anxiety and depressive disorders are highly comorbid with adult ADHD: 
occurring in 47% and in 38% respectively [68]. We were interested whether those with both 
ADHD and different stages of depressive/anxiety disorders had an increased risk for MetSyn. 
This study is reported in Chapter 6, using data from the NESDA cohort (the Netherlands Study 
of Depression and Anxiety). Here we ask: what is the association between MetSyn, obesity-
related outcomes and adult ADHD?
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6. THE RHYTHM OF CELLULAR AGING
“I am incapable of conceiving infinity, and yet I do not accept finiteness. I want 
this adventure that is the context of my life to go on without end.” Simone de 
Beauvoir [69] 
6.1 CELLULAR AGING AND TELOMERES – HISTORY
Aging is inevitable, and marked by a progressive decline in the function of multiple cells and 
organs, leading to vulnerability and finally death [70]. Apart from the overt signs of aging such 
as hair greying and altered adiposity, susceptibility to disease increases dramatically with age 
[71]. 
The science of aging was advanced by several key findings. Firstly, on a cellular level, the 
limited lifespan of normal human cells was described by Hayflick et al. in 1965 [71]. In a classic 
paper, they showed that normal human fibroblasts do not proliferate indefinitely in culture; 
they reach a limit after 50 to 70 cellular divisions - termed the Hayflick limit [72]. Thereafter, 
normal cells become senescent or die [73]. Secondly, on an intracellular level, telomeres are 
crucial to understanding normal aging. Telomeres are short DNA repeats found on the end 
of chromosomes, much like a plastic tip at the end of a shoelace. They were discovered in 
flies in the late 1930s, before DNA was known to be the genetic material [74]. In 1978, their 
exact base pair (bp) sequence was described by Elizabeth Blackburn, who later shared the 
Nobel prize for this work [75]. Over the lifespan, normal aging is accompanied by telomere 
shortening in human somatic cells. 
6.2 TELOMERIC AT TRITION – MECHANISMS
Before cell division, chromosomal DNA unwinds and separates so that replication can occur. 
The enzyme, DNA polymerase, reads the existing strands to build the new strands, with the 
help of short pieces of RNA primer. When copied, each matching strand is slightly shorter than 
the original strand because of the room needed for the primer, the so-called “end replication 
problem”. Hence, with each cell division, 50 to 100 bp are lost from the end of the telomeres 
[73]. For example, in leukocytes, telomere length ranges from 10,000 bp in newborns, to 3,000 
bp in adults, to 1,500 bp in the elderly [73]. To counteract telomere shortening or attrition, the 
enzyme telomerase adds bases to the ends of telomeres and thus delays their attrition [71]. This 
is especially important in young and constantly renewing cells such as hemopoetic cells, sperm 
and egg cells.
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1Telomeres have several protective functions for chromosomes [71].  As a plastic tip protects a shoelace’s end, telomeres prevent the end of chromosomal DNA from being “misrecognized” 
as a broken end. This halts the chromosome ends from being repaired, which would lead to 
instability. A specialized nucleoprotein complex known as shelterin makes the damage invisible 





FIGURE 3. The cell, chromosome and telomere
Telomeres are protective caps at the end of linear DNA strands. In humans, telomeres are made of non-coding 
sequences of the 4 nucleic acid bases: G for guanine, A for adenine, T for thymine and C for cytosine. One telomere 
strand has repeating sequences of TTAGGG, paired with AATCCC on the other strand. Thus, one section of telomere 
is a “’repeat” made of six “base pairs” (bp). [77]
6.3 SLEEP AND CELLULAR AGING – RESEARCH QUESTIONS
There is scant research on the biomarker for aging, leukocyte telomere length (LTL), and 
sleep. When LTL was measured in subjects with insomnia, obstructive sleep apnea, snoring 
and short and long sleep duration, results were mixed [78 - 85]. The association between 
circadian dysregulation and LTL has not been studied in humans. In animal models, circadian 
desynchronization triggers premature cellular aging [86]. In Chapter 6, we tested how 
insomnia, sleep duration and circadian rhythm are related to cellular aging over 6 years, using 
data from the NESDA study. 
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7. COHORTS STUDIED IN THIS THESIS
7.1 THE  NETHERLANDS STUDY OF DEPRESSION AND ANXIETY 
(NESDA)
NESDA is an ongoing study aiming to examine the course and consequences of depressive 
and anxiety disorders. This longitudinal, naturalistic cohort included 2,981 participants aged 
18-65 years at baseline assessment, performed between 2004 and 2007 [87]. Participants 
were recruited from different health care settings (community, primary and specialized mental 
health care), including a group without psychiatric symptoms (‘Controls’) and others in different 
developmental stages of affective disorders. Exclusion criteria included insufficient command 
of Dutch and a primary clinical diagnosis of bipolar disorder, obsessive-compulsive disorder, 
PTSD, severe substance use disorder or a psychotic disorder. Initial assessment included a 
4-hour clinic visit, followed by face-to-face assessments every two years thereafter. These 
follow-up assessments had a response rate of 87.1% (N = 2,596) at 2 years, 80.6% (N = 
2,402) at 4 years, and 75.7% (N = 2,256) at 6 years. A full description of NESDA has been 
described in the design paper by Penninx et al. [87]. 
7.2 THE  NETHERLANDS MENTAL HEALTH SURVEY AND INCIDENCE 
STUDY-2 (NEMESIS-2)
NEMESIS-2 is an epidemiological study examining the prevalence, incidence, course and 
consequences of psychiatric disorders in the Dutch general population. A full description has 
been reported elsewhere [88]. In short, NEMESIS-2 was based on a multistage, stratified, 
random sampling of households, with one respondent randomly selected from each household. 
Insufficient fluency in Dutch was an exclusion criterion. The first wave included 6,646 subjects 
aged 18 - 62, with a response rate of 65.1% (November 2007 to July 2009). All baseline 
respondents were approached for follow-up three years later (November 2010 to June 2012). 
Here, 5,303 persons were interviewed (response rate 80.4%, excluding those deceased). 
Three years later, 4,618 persons were interviewed (response rate 87.8%, excluding those 
deceased, November 2013 to June 2015).
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18. AIMS AND OBJECTIVES
The overall objective of this thesis is to explore the associations between MetSyn, sleep 
disorders and adult ADHD, conceptualizing ADHD as (partly) a disorder of biological rhythm 
disturbance. In addition, the association between disturbed sleep and cellular aging is tested. 
The following research areas are explored in the thesis: 
1. The rhythm of insomnia: What is the relationship between adult ADHD and 
insomnia? 
 The literature review in Chapter 2 provides an update of cross-sectional and longitudinal 
studies, as well as insomnia associated with pharmacological treatments for ADHD. 
Chapter 3 describes the association between insomnia, sleep duration and ADHD in the 
NEMESIS cohort. Chapter 4 briefly raises and discusses the possibility that this relationship 
is related to a pro-inflammatory state. 
2. The rhythm of SAD: Is the well-recognized association between SAD and ADHD 
mediated by markers of circadian rhythm disturbance? Chapter 5 explores how 
ADHD, circadian rhythm and SAD are related in a study from the NESDA cohort.
3. The rhythm of MetSyn: What is the association between MetSyn, obesity-
related outcomes and adult ADHD? Chapter 6 analyses these relationships with 
data from the NESDA cohort. 
4. The rhythm of aging: How are insomnia, sleep duration and circadian rhythm 
related to cellular aging? Telomere length as a biomarker for cellular aging is assessed 
in those with insomnia, altered sleep duration and circadian rhythm dysregulation in 
Chapter 7. 
Finally, Chapter 8 summarizes the main findings, their implications and possible directions for 
future research. 
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1. ABSTRACT 
Purpose of review: Insomnia is diagnosed when there is dissatisfaction with sleep quantity 
or quality. It has a prevalence in the general population ranging from 31 to 56%. Insomnia 
has previously been associated with adult attention-deficit/hyperactivity disorder (ADHD). In 
this review, we address three topics: (1) the cross-sectional relationship between ADHD and 
insomnia in adulthood, (2) the longitudinal relationship between ADHD and insomnia, and (3) 
insomnia as a side effect of pharmacological treatments for adult ADHD.
Recent findings: Three cross-sectional, clinical and population studies report a prevalence 
of insomnia in ADHD adults ranging from 43 to 80%. Longitudinal evidence for a link between 
childhood-onset ADHD and insomnia at later age is mixed, with one study confirming and 
another study not supporting such a longitudinal association. In randomized, placebo-
controlled trials, insomnia is reported significantly more often in the treatment arm than in the 
placebo arm. In varying percentages of trial participants, insomnia is a treatment-emergent 
adverse effect in triple-bead mixed amphetamine salts (40 – 45%), dasotraline (35 – 45%), 
lisdexamfetamine (10 – 19%), and extended-release methylphenidate (11%). Ten to seventeen 
percent of subjects in placebo-controlled trials of atomoxetine report insomnia, possibly related 
to poor metabolizer status. The mechanisms explaining the relationship between ADHD and 
sleep problems are incompletely understood, but both genetic and non shared environmental 
influences may be involved.
Summary: Adults with ADHD should be assessed for insomnia, which is frequently comorbid, 
and both conditions should be treated.
Keywords: Adult attention-deficit/hyperactivity disorder, sleep, insomnia, psychostimulants
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2. INTRODUCTION 
In the general population, the prevalence of insomnia symptoms ranges from 31% in Western 
Europe to 56% in the USA [1]. It is the most common sleep disorder in the general population, 
but almost half of people affected receive no treatment for insomnia [1, 2]. Following DSM-
5, insomnia is diagnosed when there is dissatisfaction with sleep quantity or quality, difficulty 
initiating or maintaining sleep, and early morning waking, for at least three nights per week 
over a period of at least three months [3]. The DSM-5 no longer distinguishes between primary 
and secondary insomnia [3]. In this broader conception, insomnia is considered a disorder that 
requires independent clinical study.
Adult attention-deficit/hyperactivity disorder (ADHD) is a childhood-onset neurodevelopmental 
disorder marked by inattentiveness, impulsivity, with or without hyperactivity [3, 4]. For 60% 
of children with ADHD, the disorder persists into adulthood [5], where the cross-national 
estimated prevalence of ADHD is 2.8% [6]. In 2012, Yoon et al. published a clinical review of 
sleep disorders in children and adults with ADHD, and stressed that the literature was scant [7·]. 
No longitudinal studies were included in this review. Seven studies among adults with ADHD, 
using both self-report and objective methods to assess insomnia symptoms, were discussed. The 
three studies using self-reports showed an increased prevalence of insomnia in adult ADHD 
[8–10]; however, one of these was referenced as another study by the same author [11]. Four 
of the listed studies using objective methods to measure insomnia, showed mixed results. Two 
actigraphy studies found decreased sleep quality and insomnia symptoms in adults with ADHD 
[12, 13]. One polysomnographic study showed sleep disturbance [14], but another did not 
[15]. Yet, both of the polysomnographic studies showed increased nocturnal motor activity in 
the ADHD patients [14, 15]. These preliminary studies in adult populations suggest that there is 
an association between adult ADHD and insomnia. While the review acknowledged insomnia 
in children with ADHD, the authors commented, “It is currently not known whether there are 
similar sleep problems in adults (with ADHD)” [7·].
Four years later, a systematic literature review by Instanes et al. (2016) on adult ADHD and 
comorbid somatic disease classified the relationship between adult ADHD and sleep disorders 
as well-established [16·]. Some new studies showing an increased prevalence of insomnia 
in clinical and non-clinical samples of adults with ADHD were included [17 – 19]. However, 
certain fundamental questions about ADHD and insomnia that were raised by Yoon et al., 
Instanes et al., and Hvolby (2015) cannot be fully answered [7·, 16·, 20·]. For example, what 
is the role of pharmacological treatments in the relationship between ADHD and insomnia?
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This current review summarizes recent findings of cross-sectional and randomized controlled 
studies exploring the relationship between insomnia and adult ADHD. For the first time, we also 
review longitudinal studies. We note that other sleep disorders, i.e. circadian rhythm disorders, 
sleep apnea, hypersomnia, and restless legs, are also associated with adult ADHD [16·] and 
may result in secondary insomnia. However, we do not review studies of these sleep disorders. 
We have retrieved key English language papers from Medline, Embase, and Psychnet searches, 
published since the review by Yoon et al. in 2012. These fall into the following three categories:
1. The cross-sectional relationship between ADHD and insomnia in adults (defined as 18 
years or over)
2. The longitudinal relationship between ADHD and insomnia
3. Insomnia associated with pharmacological treatments for ADHD
These subjects together will give more insight into the nature of the relationship between 
insomnia and ADHD.
3. FINDINGS FROM CROSS-SECTIONAL 
STUDIES
In a chart review, Fisher et al. (2014) investigated sleep problems in ADHD across the lifespan 
(N = 1828, of which n = 1163 adults) [21·]. This study distinguished between two ADHD 
categories: inattentive ADHD and “ADHDplus” (patients with hyperactive/impulsive ADHD 
symptoms and a documented secondary sleep or affective disorder requiring medication). 
No patients were assessed while on ADHD medication. Insomnia symptoms were found to be 
present in ADHD, regardless of sex, age, or ADHD subtype. There was no significant difference 
in insomnia symptoms between adult ADHD patients with and without other comorbid sleep 
disorders. In 80% of adults with ADHD, unrefreshing sleep, trouble falling asleep, frequent 
night-time awakenings, insufficient sleep, excessive sleep, and night-time restlessness were 
reported. These problems were also significant variables affecting neuropsychological test 
performance. Sleep complaints were reported significantly more often in adults (80%) than in 
children or adolescents, where they occurred in 74 and 41%, respectively [21·]. Sleep-onset 
insomnia (SOI, or difficulty falling asleep at the desired bedtime) and sleep maintenance 
problems were particularly significant difficulties in the ADHD adults. Several other studies 
have confirmed an association between SOI and adult ADHD [10, 14, 22].
A recently published, large Norwegian study by Brevik et al. (2017) compared the prevalence 
of self-reported insomnia symptoms in adult ADHD patients (n = 268) to that in a population-
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based control group (n = 202) [23·]. Where information was available, the prevalence of 
insomnia was compared in two ADHD subtypes (inattentive n = 54 and combined n = 81); for 
the rest, subtype was not specified. Even though adult ADHD is a highly comorbid condition, 
no formal exclusion criteria for comorbidities were applied to either group. Insomnia symptoms 
occurred in 67% of the adult ADHD patients, compared to 29% of controls. They were more 
common in the combined subtype (80%) compared to the inattentive subtype (56%) [23·].
Investigating women in a nationally representative Canadian population study (aged 20 – 
39 years, N = 3,908), Fuller-Thompson et al. (2016) found self-reported ADHD in 2.6% (n 
= 107) [24·]. Significant insomnia symptoms were present in 43% of those with self-reported 
ADHD compared to 12.2% in those without ADHD. When the association between ADHD 
and insomnia was analyzed after correcting for age, race, education, and income, the risk for 
insomnia was found to be five times greater in women with self-reported ADHD, compared 
to those without ADHD (OR = 5.08). However, it should be noted that Fuller-Thompson et al. 
did not report on concurrent or previous (stimulant) medication use, nor correct for affective 
disorder. Both of these may have accounted for the increased risk of insomnia. Indeed, the 
women who reported ADHD also had significantly more lifetime affective disorders than those 
without ADHD [24·]. Similarly, Brevik et al. applied no formal exclusion criteria for comorbid 
disorders, which may have influenced the associations with insomnia [23·].
Comorbid mental disorders tend to increase the prevalence of insomnia, both in population 
studies and clinical samples. This was shown in a Dutch general population study, where 
insomnia was common in those with current and remitted mental disorders [25]. In another 
study in adult ADHD patients, depressive symptoms increased the risk for insomnia [9]. Other 
factors associated with adult ADHD, such as substance use [26] or family history of affective 
disorder, also increase the risk for insomnia [25, 27·]. These cross-sectional findings are 
summarized in Table 1.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































40 | CHAPTER 2
4. THE LONGITUDINAL RELATIONSHIP 
BETWEEN ADHD AND INSOMNIA
A limitation of cross-sectional studies is that they cannot explain causal relationships. Both ADHD 
and insomnia are heterogeneous disorders, and the relationship between them is complex. 
Only longitudinal studies can illustrate how childhood events may affect outcomes later in life. 
While they cannot truly indicate causality, they may give closer insight into possible causality. 
In addition, longitudinal studies give a better indication on how long-lasting associations truly 
are, as cross-sectional associations may be more subject to report bias (e.g. ADHD patients 
reporting more negatively about sleep patterns) and reflecting short-term associations. Two 
recent studies have investigated how the early trajectory of ADHD and its age-of-onset affect 
insomnia in adulthood [27·, 28·].
In a large longitudinal twin study (N = 2,232), Gregory et al. (2017) investigated whether 
children diagnosed with ADHD were likely to have poor sleep quality later in life [28·]. ADHD 
was determined in childhood (at 5, 7, 10, and 12 years) from mother and teacher reports, using 
the DSM-IV criteria and Rutter Child Scales. At age 18, an ADHD diagnosis over the past year 
was made using the DSM-5 criteria in a structured interview. At age 18, sleep disturbance over 
the past month was ascertained using the Pittsburgh Sleep Quality Index (PSQI), derived as the 
sum of overall sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, 
use of sleep medications, and daytime dysfunction. A PSQI global score > 5 is considered to 
be the cut-off indicating insomnia [29].
A total of 8.1% of the total sample had the ADHD diagnosis at age 18 (n = 166). Of these, 
67.5% (n = 112) did not meet criteria for ADHD during childhood and were considered late-
onset ADHD. The remaining  21.9% (n = 54) met diagnostic criteria in both in childhood and at 
age 18 and were therefore classified as having persistent ADHD. The study went on to examine 
the associations between insomnia at age 18 and childhood-onset ADHD that remitted, 
childhood-onset ADHD that persisted and late-onset ADHD, respectively. Only persistent 
ADHD (diagnosed in childhood and present at age 18), or late-onset ADHD (diagnosed at 
18 years only), was associated with insomnia at age 18. However, childhood ADHD that had 
remitted by age 18 showed no increased risk for insomnia in early adulthood.
From this study, it appears that longitudinally, the presence of insomnia in early adulthood 
is associated with the course of ADHD. Only where ADHD symptoms are concurrent, does 
insomnia appear to occur. These associations remained significant after adjusting for many 
potential confounders such as maternal insomnia, a diagnosis of depression, generalized 
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anxiety, alcohol dependence, cannabis dependence or conduct disorder in young adulthood, 
the presence of young children at home, and taking ADHD medication.
Contrary to the approach of Gregory et al., Goldman-Mellor et al. (2014) examined whether 
childhood ADHD predicted insomnia in adulthood in a longitudinal study from Dunedin, New 
Zealand [27·]. They investigated whether a childhood history of mental health problems and 
family psychiatric history predicted insomnia at age 38 years. At this age, rates of insomnia are 
high [27·]. A cohort of 1,037 children was followed from birth through to their fourth decade.
Subjects were examined and interviewed 12 times prospectively, with a 95% retention rate. 
During childhood (5 – 11 years), hyperactive and inattentive behavior was determined from 
parents and teachers using the Rutter Child Scales. During adolescence (11 – 15 years), ADHD 
was examined using DSM-III criteria. At the 38-year assessment, insomnia (in the last month) 
and psychiatric diagnoses (affective disorders/alcohol/drug dependence) were diagnosed 
over the last 12 months according to DSM-IV criteria and the Diagnostic Interview Schedule, 
respectively.
One fifth of the participants were diagnosed with insomnia at age 38. At this age, insomnia 
was highly comorbid with psychiatric disorders. Those with family histories of depression or 
anxiety, and lifelong affective disorders beginning in childhood, were at a uniquely high risk of 
developing insomnia in adulthood. In contrast, unlike the associations reported by Gregory et 
al. [28·], no significant association was found between childhood hyperactive and inattentive 
behavior (5 – 11 years) and insomnia at age 38. Furthermore, neither conduct disorder nor 
ADHD during adolescence (11 – 15 years) increased the risk for insomnia in adulthood.
However, this study differs from that of Gregory et al. in that neither the presence of ADHD in 
adulthood nor a possible onset of ADHD after 15 years was reported. Therefore, the question 
of whether late-onset ADHD or ADHD persisting into adulthood was linked to insomnia at 
age 38 cannot be answered. An interesting finding from another publication from the Dunedin 
study could explain the apparent lack of association between ADHD symptoms in childhood 
and insomnia at 38 years. Moffitt et al. (2015) reported that in the same cohort, the groups with 
childhood ADHD and adult ADHD were virtually non-overlapping: 90% of adult ADHD cases 
lacked a history of childhood ADHD [30]. Further analysis of this cohort would determine 
whether age-of-onset of ADHD was independently associated with insomnia in adulthood, 
and whether the 10% with persistent ADHD from childhood to adulthood had a greater risk 
of insomnia at age 38. This analysis however has so far not been reported. The longitudinal 
studies referred to here are reported in Table 1.
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While the mechanisms for the relationship between ADHD and sleep problems are not 
understood, Hvolby (2015) proposes several possible scenarios that may explain this finding 
[20·]. Perhaps ADHD and sleep problems are comorbid disorders which interact? Where 
ADHD is present, insomnia occurs—and vice versa—with reciprocal causation. Poor sleep may 
worsen ADHD symptoms, as sleep regulates cognitive and emotional brain processes [31, 32]. 
Symptoms associated with insomnia may also present as ADHD [20·]. Secondly, sleep problems 
may be intrinsic to ADHD; therefore, insomnia symptoms are part of the ADHD presentation. 
Symptoms of ADHD such as inattention, difficulty with planning, or nocturnal motricity may 
lead directly to poor sleep hygiene and insomnia [20·, 33]. Difficulty in organizing tasks and 
procrastination may delay bedtime. In this scenario, ADHD and insomnia in young adulthood 
may have a shared neuropathological origin [20·]. In a recent genome-wide association 
study, strong positive genetic correlations were found between insomnia, anxiety/depressive 
symptoms, and major depression [34·]. This suggests that insomnia in adult ADHD is often 
comorbid with depressive symptoms. Interestingly, there was no correlation between the genes 
found for insomnia and self-reported ADHD symptoms. The top genetic association in this study 
was found between insomnia and restless legs syndrome (RLS), which is also associated with 
ADHD [16·]. RLS is a neurological disorder where patients experience an unpleasant sensation 
in the limbs and feet, combined with an urge to move to relieve the discomfort. It is associated 
with initial insomnia and poor sleep quality controls [16·]. The population prevalence is wide-
ranging, from 3 to 34% [16·]. In small studies, the prevalence of RLS has been shown to be 
elevated in persons with ADHD compared with controls, and ADHD was more common in 
patients with RLS compared to controls [16·]. While more research is needed to clarify this 
association, the relationship between ADHD and insomnia may be mediated through RLS.
Environmental influences on insomnia in ADHD are also relevant, as found by Gregory et al. 
[28·]. In their twin study, individual differences in ADHD and sleep quality were explained 
by genetic and non-shared environmental factors, with moderate genetic overlap. In young 
adulthood, genes explained 55% of the association between ADHD symptoms and sleep quality, 
and non-shared environmental influences explained 45%. These environmental influences may 
include (maternal) exposure to neurotoxins, alcohol, drugs, and mobile telephones, which may 
all impact on sleep and ADHD [28·, 35]. Marital conflict and inconsistent parenting styles are 
family environmental processes that may play a role in ADHD through the dopamine system, 
which is believed to be dysregulated in ADHD. A study showed that the tandem repeat insertion 
allele of the dopamine receptor D4 gene increased susceptibility to ADHD in the context of 
marital conflict [36].
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5. INSOMNIA ASSOCIATED WITH
 PHARMACOLOGICAL TREATMENT FOR ADHD 
Another factor complicating the relationship between ADHD and insomnia is that 
pharmacological treatments of ADHD may cause, worsen [33], or improve insomnia symptoms 
[10, 13, 14, 37]. However, it is important to acknowledge that even non-medicated adults 
with ADHD experience insomnia symptoms [9, 10, 13, 14, 17, 18, 21, 22]. In the Norwegian 
cross-sectional study referred to above, Brevik et al. found that ADHD patients currently using 
stimulant medication (n = 94) had significantly lower insomnia scores than patients without 
stimulant treatment (n = 34). Treatment included methylphenidate (n = 69), amphetamines (n = 
12), the non-stimulant atomoxetine (ATX, n = 3), or a combination (n = 7). No further information 
about the dosing or pharmacological agents was given. Insomnia symptoms occurred in 66% 
of patients currently on stimulants compared to 72% in those off treatment [23·]. These findings 
could indicate that ADHD medication may be helping patients with managing their insomnia. 
However, as the authors note, those off medication may also have chosen to stop because 
of insomnia [23·]. So, interpretation is difficult, and one would require placebo-controlled 
interventions to evaluate truly whether ADHD medication impacts on insomnia. In this section, 
we review recent findings concerning the association between insomnia and the stimulants 
(methylphenidates and amphetamines), non-stimulants (ATX), and an antidepressant, 
bupropion. The studies reviewed are included in Table 2.
5.1 STIMULANTS
Extended-release formulations of the stimulants were developed to reduce multiple daily 
dosing and adverse effects [42]. They include compounds under investigation such as the 
multi-layer, extended-release methylphenidate (PRC-063) and dasotraline, a novel inhibitor 
of dopamine and norepinephrine reuptake. The triple-bead formulation of mixed amphetamine 
salts (triple-bead MAS) is awaiting registration in adults. Osmotic controlled-release oral 
delivery system methylphenidate (OROS-MPH), extended-release mixed amphetamine salts, 
and lisdexamfetamine dimesylate (LDX) are already licensed and in clinical use in several 
countries. Possibly because of their neurotransmitter action, stimulants are wake-promoting 
in most people. Methylphenidate has α2 and dopamine D1 receptor actions and increases 
norepinephrine and dopamine in the prefrontal cortex. Amphetamine is believed to compete 
with endogenous monoamines for transport into nerve terminals [43·]. Stimulants may be 
associated with increased difficulty in falling asleep, longer sleep-onset latency, and overall 
shorter duration of sleep, as extensively reviewed by Stein et al. [44]. While insomnia is a 
common treatment-emergent adverse event (TEAE), there is inter-individual variability in 
response to these medications [43·].
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In several recently published, placebo-controlled studies of the extended-release stimulants, 
the TEAE insomnia occurred significantly more frequently in the treatment arm (11 – 45%) than 
in the placebo arm (4 – 16%) [38·, 39·, 40·]. Medications and dosages used in these studies 
were triple-bead MAS (dosage 25, 50, or 75 mg once daily, N = 412) [38·], dasotraline 
(dosage 4 or 8 mg once daily, N = 341) [39·], and extended-release methylphenidate 
(PRC-063, dosage 25 – 100 mg, once daily, N = 59) [40·]. Insomnia was listed as the most 
frequently reported TEAE for triple-bead MAS and dasotraline [38·, 39·]. In the triple-bead 
MAS study (2017), insomnia occurred in 41% on active treatment, as opposed to 12.5% on 
placebo. There was no dose-response relationship between active drug and insomnia. This 
was a forced-dose trial, meaning that the entire randomized group moved through a series 
of rising doses, allowing for comparisons. This high rate of insomnia might have been lower 
with a slower upward titration, as is habitual in clinical practice [38·]. In the fixed-dose trial of 
dasotraline (2015), insomnia occurred in 35% (4 mg/day dose), in 45% (8mg/day dose), 
and in 15.5% in the placebo group. There was a dose-response relationship between active 
drug and insomnia in this study. The high percentage with insomnia may have been related 
to the fixed-dose methodology, where patients were initiated on dasotraline 4 or 8 mg once 
daily, without titration [39·].
Somewhat lower rates for insomnia were reported in a systematic review of LDX by Coghill 
et al. (2014). In short-term trials, insomnia occurred in 10 – 19% of those on LDX (dosage 
30, 50, or 70 mg) and in 4 – 5% of those on placebo [45·]. Insomnia was reported even 
less frequently in a (smaller) randomized, double-blind, placebo-controlled, cross-over of trial 
of extended-release methylphenidate (PRC-063, 2016) [40·]. During the initial open-label, 
dose optimization phase (n = 59), insomnia occurred in 31% (doses 25-100 mg). During the 
subsequent 2-week, double-blind phase, insomnia was reported in 11% of the treatment group 
and in 4% of the placebo group (n = 53, doses 45 – 100 mg). The authors suggest that this 
lower rate of insomnia in the blinded period was related to a decrease of adverse effects as the 
trial continued, and as the doses were optimized. Sleep efficiency (the ratio of hours of sleep to 
hours spent in bed) was poorer on PRC-063 than in the placebo arm. There were no differences 
observed between extended-release methylphenidate (PRC-063) and placebo for four other 
items on the PSQI (sleep latency, sleep disturbance, needs medications to sleep, or daytime 
dysfunction) [40·]. These results are promising, but larger trials are needed to confirm the lower 
incidence of insomnia. As noted by Childress (2017), extended-release methylphenidate (PRC-
063) has efficacy for up to 16 h after dosing, so it will be important to monitor sleep in future 
research [43·].
When self-reported sleep quality at the start and end of the trial with extended-release 
methylphenidate (PRC-063) was compared, an interesting finding emerged. Neither the 
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overall sleep quality nor the PSQI global score showed any significant difference between the 
treatment and placebo groups [40·]. By the end of the triple-bead MAS trial, sleep quality had 
improved in the active group by the trial end, based on PSQI score [38·]. Similarly, during the 
2-week randomized, blinded phase of the dasotraline trial, there was no significant difference 
in PSQI score or overall sleep quality between the active and placebo groups [39·]. Findings 
were similar in the LDX trials reviewed, where available data from all studies indicated no 
overall worsening of sleep quality in adults, as measured by the PSQI [45·]. 
The reports of insomnia in both the treatment and placebo arms of all mentioned studies on 
long-acting stimulants, and an overall sleep quality which improved by trial end in some 
studies, implies that adult patients with ADHD may begin with poor sleep. These findings were 
confirmed in a post hoc analysis of two large placebo-controlled trials of amphetamines (triple-
bead MAS and LDX). Insomnia was reported in similar proportions in both the active and 
placebo groups [37]. Some long acting stimulants, such as triple-bead MAS, the extended-
release methylphenidate (PRC-063), and LDX, may not worsen overall sleep quality for the 
duration of the trial [38·, 40·, 45·]. Moreover, a group with ADHD may exist for whom insomnia 
improves with treatment [37, 38·]. On the other hand, the PSQI which measured insomnia in 
these trials also measures daily function. One would expect this to improve with treatment for 
ADHD. Hence, the improvement in overall sleep quality as reflected by the PSQI may reflect 
daytime improvement rather than a lessening of insomnia. In addition, the onset of insomnia is 
determined by the drug formulation, the length of the trial, the timing of dosing, and whether 
maximum doses are fixed, forced, or titrated upwards.
5.2 NON-STIMULANTS
Insomnia has been reported in studies of the non-stimulant, ATX [46], but it is less common 
compared to studies of the long-acting stimulants [47, 48]. A lower incidence of insomnia 
may be related to differences in pharmacology, as ATX inhibits the presynaptic norepinephrine 
transporter and may have less dopaminergic action than the stimulants [43·]. Walker et al. 
(2015) reviewed studies of ATX published from 1998 to 2014 and concluded that insomnia 
was mostly non-serious, occurred early and resolved during treatment. Interestingly, insomnia 
was reported was more frequently with twice daily dosing (17%) than with once daily dosing 
(10%) [49].
ATX is predominantly metabolized by cytochrome P450 2D6 (CYP2D6), which is encoded by 
the highly polymorphic CYP2D6 gene [41·]. Genetic polymorphisms are important determinants 
of CYP2D6 enzymatic activity, which results in variability in the metabolism of ATX. Individuals 
can be categorized into four metabolizer groups: ultra rapid, extensive, intermediate, and 
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poor. The plasma half-life of ATX is approximately four times longer in poor metabolizers, 
who experience more frequent adverse events than the other groups, significantly more 
insomnia. A 12-week, open-label study confirmed an increased incidence of insomnia in the 
poor metabolizer group, compared to the other three groups [41·]. This genetic polymorphism 
may help explain the heterogeneity in the association between atomoxetine and insomnia, 
particularly with twice daily dosing and in poor metabolizers.
De Oliveira et al. (2017) conducted a systematic review of the safety profiles of several ADHD 
treatments [48]. Ten studies were included in a mixed treatment comparison, allowing for the 
comparison of more than two interventions, even when these were not directly compared in 
the literature. The findings concerning the ranking of treatments in terms of their probability to 
provoke insomnia are unclear, as the text of this paper contradicts the results depicted in the 
figure. According to the figure, when ATX, bupropion, extended-release mixed amphetamine 
salts, and placebo were compared, extended-release mixed amphetamine salts had the 
highest probability to provoke insomnia (79% of probability). The safest option (after placebo) 
was bupropion (29% of probability). Ideally, all available treatments should be compared to 
give comprehensive results.
6. CONCLUSIONS 
Based on cross-sectional studies, in clinical and population samples, insomnia is associated 
with adult ADHD in 43 – 80% [21·, 23·, 24·], regardless of pharmacological treatment for 
ADHD [23·]. Longitudinal studies give conflicting results. In one, the persistence of ADHD 
into early adulthood was strongly associated with insomnia symptoms at age 18 [28·]. In a 
second, there was no association between childhood or adolescent ADHD and insomnia at 
age 38 [27·]. Future longitudinal studies are necessary and should consider age-of-onset and 
the persistence of ADHD symptoms, which appear to be relevant. Certainly, there is a strong 
association between affective disorders and insomnia in adulthood [25, 27·, 34·]. Therefore, 
when studying insomnia in adult ADHD, it is important to correct for affective disorders, which 
also disturb sleep. The strong genetic correlation between insomnia and anxiety/depressive 
symptoms and major depression was recently shown in a genome-wide association study 
[34·]. Furthermore, while there was no correlation between the genes found for insomnia and 
self-reported ADHD symptoms, those for insomnia and RLS were strongly correlated. Therefore, 
the relationship between ADHD and insomnia may be mediated through RLS. Environmental 
influences may include (maternal) exposure to neurotoxins, alcohol, drugs, and child self-
blame for marital conflict [35, 36]. In the twin study, environmental influences explained 45% 
of the association between ADHD and sleep quality [28·].
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There are some important caveats to consider. Firstly, while an association between adult 
ADHD and poor sleep quality has been reported in the population-based studies, causality 
cannot be inferred. The questions remain, how does ADHD in adulthood lead to poor sleep 
and does poor sleep lead to ADHD symptoms? Furthermore, results from population-based 
studies may not be applicable in the clinical setting; hence, both settings should be investigated. 
Secondly, the improvements in sleep quality reported in trials of pharmacological treatments 
may be related to improvements in daytime functioning. Thirdly, the pharmacological trials had 
different sizes and designs, which may also have affected the frequency of insomnia. ADHD 
treatments may also remedy comorbid conditions (such as depression), with the result that sleep 
improves.
7. TREATMENT RECOMMENDATIONS 
Many adults with ADHD have disturbed sleep patterns. For these patients, restoration of 
healthy sleep may be one of the treatment goals. Sleep quality should be evaluated before 
and during treatment. Any changes should be carefully tracked. Psychoeducation, sleep 
hygiene interventions, and cognitive behavioral therapy may minimize the adverse effects of 
insomnia in adults with ADHD [50]. Extended-release stimulants are frequently associated 
with insomnia in adult ADHD, but this adverse event should not present a barrier to treatment. 
There is much individual variation in response to the pharmacological treatments of ADHD. In 
the trials reviewed, extended-release methylphenidate (PRC-063) showed the least insomnia 
(11%) [40·]. From the systematic review of LDX, rates of insomnia were higher (10 – 19%) 
[45·]. Insomnia appeared to be most frequent in triple-bead MAS and dasotraline (40 – 45%) 
[38·, 39·]. The frequency of insomnia with ATX is relatively low (10 – 17%) [48] and may 
be related to poor metabolizer status [41·]. For many patients, insomnia exists before any 
treatment starts. For others, overall sleep quality may improve with extended-release stimulants 
[37, 38·]. If treatment-emergent insomnia is intolerable with extended-release stimulants, it may 
be beneficial to switch to another agent. Adjunctive agents such as melatonin and/or light 
therapy may also be considered to manage insomnia if non-pharmacological methods fail 
[51]. Clinicians treating ADHD should evaluate sleep quality and insomnia symptoms using 
standardized instruments, prior to starting treatment.
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1. ABSTRACT 
Study Objectives: Insomnia and short or long sleep duration are important comorbid 
conditions in adults with attention-deficit hyperactivity disorder (ADHD), but reports of the 
association vary. In a general population study, we evaluated the relationship between ADHD 
symptom severity, insomnia symptoms, and sleep duration in adults.
Methods: Data were from the third wave of the Netherlands Mental Health Survey 
and Incidence Study-2 (NEMESIS-2; n = 4,618). ADHD symptom severity and symptom 
dimensions (hyperactivity and inattention) were assessed using the Adult ADHD Self-Report 
Scale screener. Self-reported insomnia symptoms (Insomnia Rating Scale; IRS) were defined as 
clinically relevant if IRS ≥ 9. Self-reported short sleep duration was defined as ≤ 6 hours, and 
long sleep duration as ≥ 10 hours.
Results: Within the group with clinically relevant ADHD symptoms, 43% reported significant 
insomnia symptoms (odds ratio [OR] = 2.66, 95% confidence interval [CI] 1.74 – 4.07); 41% 
short sleep duration (relative risk ratio [RRR] = 1.94, 95% CI 1.31 – 2.85) and 6% long sleep 
(RRR = 5.87, 95% CI 1.97 – 17.45). Increased inattention symptoms were associated with IRS 
≥ 9, short and long sleep duration in fully adjusted models (OR = 1.10, 95% CI 1.06 – 1.14; 
RRR = 1.06, 95% CI 1.02 – 1.09; RRR = 1.16, 95% CI 1.05 – 1.28, respectively). Increased 
hyperactivity symptoms were associated with IRS ≥ 9 (OR = 1.17, 95% CI 1.11 – 1.23) and 
short sleep duration (RRR = 1.12, 95% CI 1.05 – 1.19).
Conclusions: Both clinically significant ADHD symptoms and inattention and hyperactivity 
symptom dimensions were consistently associated with insomnia symptoms and altered sleep 
duration. These associations confirm that sleep disturbances should be assessed and given 
appropriate clinical attention in adults with ADHD.
Keywords: ADHD, adults, attention-deficit hyperactivity disorder, general population survey, 
insomnia, sleep duration
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2. BRIEF SUMMARY 
Current Knowledge/Study Rationale: Insomnia and altered sleep duration are important 
comorbid conditions in adults with attention-deficit hyperactivity disorder (ADHD). Several 
cross-sectional clinical and population studies reported a prevalence of insomnia of 43% to 
80% in adults with ADHD. One longitudinal study described an association between ADHD 
and insomnia; another did not. In a general population study, we evaluated the relationship 
between self-reported ADHD symptom severity, ADHD symptom dimensions, insomnia 
symptoms, and sleep duration in adults.
Study Impact: Clinically significant ADHD symptoms (four to six symptoms on the Adult 
ADHD Self-Report Screener) and the inattention and hyperactivity symptom dimensions were 
consistently associated with insomnia and altered sleep duration. We have confirmed that 
insomnia and altered sleep duration occur commonly in adults with ADHD; hence, they should 
be appropriate assessed and treated.on
3. INTRODUCTION 
Attention-deficit hyperactivity disorder (ADHD) is a childhood-onset neurodevelopmental 
disorder that is marked by inattention and impulsivity, with or without hyperactivity [1]. ADHD 
persists into adulthood in two-thirds of children with ADHD [2], where the cross-national 
estimated prevalence of ADHD is 2.8% [3]. Some researchers view ADHD as a dimensional 
disorder, where symptoms are best considered as continuous traits across the general population 
[4]. At a certain threshold of symptom severity, in combination with significant dysfunction in 
daily life, a clinical diagnosis of ADHD may be made [1]. Adult ADHD is highly comorbid with 
other psychiatric disorders: 52% of adults with ADHD have any comorbid psychiatric disorder 
[3]. The most common comorbidities are anxiety, mood, behavioral, and sleep disorders [3].
There is evidence for an increased prevalence of several sleep disorders in adult ADHD, 
including insomnia, circadian rhythm disturbances, restless legs syndrome, and obstructive 
sleep apnea, comprehensively reviewed by Instanes et al. [5]. Several cross-sectional, clinical, 
and population studies reported a prevalence of insomnia in adults with ADHD ranging from 
43% to 80% [6 - 9]. Two longitudinal studies described conflicting findings; in one there was 
a significant association between persistent childhood ADHD and insomnia at age 18 [10]. 
The other showed no association between childhood or adolescent ADHD and insomnia 
diagnosed at age 38 years [11]. ADHD symptom severity correlated with worsening of sleep 
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quality in a small study among adults [12], but a community study of young adults (aged 
18–20 years) did not find this association [13]. Some studies within adult ADHD populations 
have examined insomnia symptoms, such as subjective sleep quality, which was reported as 
poorer in adults with ADHD than in controls [reviewed in Instanes et al., 5].
Reports of sleep duration in adult ADHD vary, with the literature reporting no change as well 
as a combination of both short and long sleep duration. A very large population study (N = 
30,858; ADHD cases n = 1,122) found that both increased and decreased sleep duration 
were associated with increasing odds of reporting ADHD symptoms [14]. Two other studies 
reported a mean total sleep duration less than 6 hours in adults with ADHD [15,16]; however, 
the latter included a very small ADHD sample (N = 24). In contrast, in three small studies 
(ADHD samples N = 20 – 40) measuring total sleep duration objectively using actigraphy or 
polysomnography, no significant difference in sleep duration was found between those with 
ADHD and healthy controls [17 - 19]. Two large studies using self-reported sleep duration also 
showed no difference in sleep duration in (young) adults with and without ADHD (N = 64 and 
N = 175, respectively) [13,20].
The clinical implications of suboptimal sleep include worsening of ADHD symptoms, as sleep 
regulates learning and consolidation of memory [21]. Sleep loss in the general population is 
well known to impair performance on attention and executive control tasks [22]. These authors 
showed that 6 hours of sleep restriction for 14 days produced detrimental effects on sustained 
attention and working memory that were comparable to the effects of 2 nights of full sleep 
deprivation. In view of the deleterious effects of sleep loss on cognitive functioning, and the 
conflicting results in the literature, it is important to clarify the relationship between ADHD and 
sleep duration in a larger adult sample.
Two main symptom dimensions are present in ADHD: hyperactivity/impulsivity and inattention 
[1]. Research specifically investigating sleep disorders and these two symptom dimensions 
is preliminary and has given mixed results in adults, as reported in two reviews [5,23]. The 
relationship between specific ADHD symptom dimensions and sleep problems is important 
because patients with these separate clinical profiles may require different treatments.
In this study, we aimed to clarify if the burden of insomnia and disturbed sleep duration increases 
with higher ADHD symptom severity. We examined ADHD symptom severity, ADHD symptom 
dimensions, insomnia symptoms, and sleep duration among the Dutch general population, 
taking a range of sociodemographic and lifestyle factors, comorbid mental disorders, and 
medical conditions into account.




Subjects (aged 18 – 64 years) participated in the Netherlands Mental Health Survey and 
Incidence Study-2 (NEMESIS-2), an epidemiological study of the prevalence, incidence, 
course, and consequences of psychiatric disorders in the Dutch general population. A full 
description of NEMESIS-2 has been reported elsewhere [24]. In short, NEMESIS-2 is based 
on a multistage, stratified, random sampling of households, with one respondent randomly 
selected from each household. Insufficient fluency in Dutch was an exclusion criterion [24]. 
The baseline wave included 6,646 subjects, and was conducted from November 2007 to 
July 2009. The response rate was 65.1%. The sample was nationally representative, although 
younger participants were somewhat underrepresented [24]. This study is based on wave 
3, where 4,618 persons of the 5,303 who had completed wave 2 were interviewed (from 
November 2013 to June 2015). The response rate at wave 3 was 87.8%. Attrition at wave 3 
was not significantly associated with all individual 12-month mental disorders at baseline after 
controlling for sociodemographics [25]. The research proposal was approved by a medical 
ethics committee. At each wave, all participants gave written informed consent at enrollment, 
after the study procedures had been fully explained.
4.2 MEASURES
4.2.1 ADULT ADHD SYMP TOMS
At wave 3, the Adult ADHD Self-Report Scale (ASRS) Screener version 1.1 [26] was used to 
assess adult ADHD symptoms. There are six items: four indicating inattention symptoms and two 
indicating hyperactivity symptoms. Symptom frequency was rated over the past 6 months, on 
a five-point Likert scale ranging from 0 (never) to 4 (very often). Scores on the six items were 
converted into binary values according to the official scoring system. The ASRS screener has 
been shown to have moderate sensitivity (68.7%), excellent specificity (99.5%), and excellent 
total classification accuracy (97.9%) for ADHD [26]. Internal consistency reliability of the 
ASRS Screener has been shown to fall in the range 0.63–0.72 [27]. Compared to the 18-
item version, the ASRS screener is more sensitive and specific, suggesting better classification 
accuracy [26, 27]. In this study, severity of ADHD symptoms was determined by the number of 
scored ADHD symptoms on the ASRS screener, where 0 symptoms was labeled “none,” 1 - 3 
symptoms as “few,” and 4 – 6 as “clinically relevant ADHD symptoms” which is an indication 
for a diagnosis of ADHD [27, 28]. In addition, we assessed ADHD symptoms continuously, 
using a sum score of possible ratings on the six questions, (range 0–24). For this sum score, we 
allowed for a maximum of two missing items on the six questions. Where there were missing 
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values, we used the mean of the responses of that individual for the other questions. The ADHD 
symptom dimensions of hyperactivity and inattention were assessed as continuous variables 
using a sum score, with a range of 0 – 8 for the hyperactivity (no missings imputed) and 0 
– 16 for the inattention symptom dimensions (maximally one missing imputed by the mean), 
respectively.
4.2.2 SLEEP MEASURES
Insomnia symptoms were measured with the Women’s Health Initiative Insomnia Rating Scale 
(IRS) [29], which consists of five questions addressing sleep in the past 4 weeks. These address 
difficulties initiating and maintaining sleep, early morning awakening (two questions), and 
overall sleep quality. Answers were on a five-point scale, ranging from 0 “less than once a 
week” to 4 “five times or more a week” for the first four questions, and the last question on 
sleep quality ranged from 0 “very sound or restful” to 4 “very restless.” For each item, a score 
of 3 or 4 was considered to suggest pathology. The IRS has good test-retest reliability and has 
high convergent correlation with objective actigraphy sleep measures [30]. In all analyses, the 
total summary IRS score (0 – 20) was dichotomized at the cutoff point of 9 or higher, which 
indicated clinically significant insomnia symptoms [29]. We were interested in the contribution 
of each of the four domains of insomnia symptoms; hence, we examined these separately in 
relation to ADHD symptoms.
An additional question investigated total sleep duration. Participants were asked to estimate the 
average number of hours of sleep per night during the past 4 weeks. Answer options were: “10 
or more hours,” “9 hours,” “8 hours,” “7 hours,”“6 hours,” “5 or less hours.” In all analyses, the 
single variable sleep duration was subcategorized into short (≤ 6 h/night), normal (7 – 9 h/
night), and long (≥ 10 h/night), in accordance with the American Academy of Sleep Medicine 
and the Sleep Research Society’s consensus statement on the recommended amount of sleep 
for healthy adults [31].
4.2.3 COVARIATES
Worse insomnia symptoms have previously been associated with increased age, female sex, 
partner status, and lower income [32]. Shorter sleep duration has been associated with worse 
health status, increased cardiovascular risk, presence of depression, and increased body mass 
index (BMI) [33]. In the NEMESIS cohort, insomnia was found to be prevalent across different 
categories of mental disorders [34]. Therefore, in this study, we controlled for age, sex, living 
with a partner (yes/no), having a paid job (yes/no), chronic somatic disease (presence of 
one or more of 17 chronic physical disorders treated or monitored by a medical doctor in the 
previous 12 months, as assessed with a standard checklist), BMI, smoking last month (yes/no), 
exercise (< 1 h/wk versus ≥ 1 h/wk); and the presence of any 12-month period of a mood, 
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anxiety, or substance use disorder, as determined by the Composite International Diagnostic 
Interview, version 3.0 — a fully structured, lay-administered diagnostic interview. Very few 
participants (n = 11, 0.2%) reported ADHD medication use. Therefore, we did not include 
ADHD medication use as a covariate.
4.3 STATISTICAL ANALYSES
We reported general characteristics of the sample using frequencies and percentages 
for categorical data, in terms of ADHD symptom severity (none, few, clinically relevant). 
Multivariate logistic regression analyses were performed to demonstrate how the sum scores of 
ADHD symptom severity and ADHD symptom subtype dimension (hyperactive or inattentive) 
were associated with the outcome, insomnia symptoms. Multivariate multinomial regression 
analyses were performed to demonstrate how these associated with sleep duration. Results 
were adjusted for sex and age in model 1, and additionally for partner status, job status, any 
chronic somatic disorder, BMI, smoking last month, exercise last week, any 12-month mood, 
anxiety or substance use disorder in model 2. Results were expressed as adjusted odds ratios or 
relative risk ratios. All analyses were performed with STATA version 12.1 (Stata-Corp, College 
Station, Texas, United States), using weighted data to correct for differences in the response 
rates in several sociodemographic groups and differences in the probability of selection of 
respondents within households at baseline, with statistical significance inferred at α < .05.
5. RESULTS
Table 1 describes the sample characteristics of the total sample, across ADHD symptom severity 
categories (none, few and clinically relevant). No ADHD symptoms were found in 43% of the 
sample, 51% reported few symptoms, and 6% reported clinically relevant ADHD symptoms. 
Clinically relevant ADHD symptoms were significantly associated with female gender (p = 
0.017), younger age group (p < 0.001), living without a partner (p < 0.001), not having a paid 
job (p = 0.005), smoking in the last month (p < 0.001), and any 12-month mood/anxiety/
substance use disorder (all p < 0.001).
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TABLE 1. Sociodemographic and health characteristics of the total Dutch general population sample (N 
= 4,618) and across ADHD symptom severity categories (none, few and clinically relevant)
Total sample  ADHD symptoms
P value
(N = 4,618)







n (%)* % % %
Sex male 2,059 (49.8) 51.9 49.3 39.5 .017
female 2,559 (50.2) 48.1 50.7 60.5
Age 23-37 year 767 (26.0) 17.7 31.9 34.5 < .001
38-47 year 1,079 (22.7) 22.2 22.8 26.6
48-57 year 1,178 (24.2) 25.8 22.5 26.8
58-70 year 1,594 (27.1) 34.3 22.8 12.1
Education primary or lower 
secondary education
1,379 (29.2) 30.0 28.0 33.4 .085
higher secondary 
education
1,479 (41.3) 42.4 39.9 44.8
higher professional 
education, or university
1,760 (29.5) 27.6 32.1 21.8
Partner living without partner 1,268 (27.8) 25.6 27.8 43.5 < .001
Job without paid job 1,471 (28.2) 29.2 26.2 38.9 .005
Any chronic 
somatic disease
yes 2,016 (40.9) 40.7 40.6 44.5 0.644
BMI Underweight 
(BMI<18.5)
55 (1.4) 0.9 1.4 4.1 .082
Normal (BMI 18.5-
24.9)
2,237 (48.1) 46.1 49.6 49.6
Overweight (BMI 25-
29.9)
1,674 (36.4) 38.2 35.1 34.0
Obese (BMI≥30) 645 (14.2) 14.8 13.9 12.3
Smoking last 
month
yes 1,076 (25.4) 23.1 25.8 37.9 < .001
Exercise number 
of hours/week
< 1 hour 1,709 (37.2) 35.5 38.0 42.0 0.241
Any 12-month 
mood disorder
yes 238 (5.4) 1.5 6.0 29.5 < .001
Any 12-month 
anxiety disorder




yes 131(4.1) 2.4 4.8 10.4 < .001
*  in unweighted numbers and weighted percentages. ADHD = attention-deficit hyperactivity disorder.
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The prevalence of insomnia symptoms and sleep duration across the three ADHD symptom 
severity groups is described in Table 2. The group with clinically relevant ADHD symptoms 
had the highest prevalence of clinically significant insomnia symptoms (IRS ≥ 9): 43% reported 
significant insomnia symptoms, as opposed to 18% in the group with no ADHD symptoms. 
Those with clinically relevant ADHD symptoms also had the highest prevalence of the separate 
symptoms defining insomnia (difficulty initiating and maintaining sleep, early morning 
awakening, poor sleep quality); all p < .001. They also reported longer sleep duration as well 
as shorter sleep duration more often.
TABLE 2. Percentages of insomnia symptoms and other sleeping problems across ADHD symptom 
severity categories (none, few and clinically relevant) in the general Dutch population (N = 4,618)







Insomnia Rating Scale ≥ 9 1,109 (22.9) 17.9 24.7 42.9 < .001
Difficulty initiating sleep 379 (8.3) 5.5 9.0 22.2 < .001
Difficulty maintaining sleep 1,439 (29.7) 26.9 30.3 44.8 < .001
Early morning awakening 1,074 (22.6) 19.1 23.5 40.0 < .001
Poor sleep quality 574 (11.7) 8.2 12.8 28.5 < .001
Total Sleep Duration
Short (≤ 6h/night) 1,376 (29.7) 27.4 30.3 41.2 < .001
Normal (7-9h/night) 3,170 (68.9) 71.7 68.5 52.8
Long (≥ 10h/night) 70 (1.4) 0.9 1.3 5.9
*  in unweighted numbers and weighted percentages. ADHD = attention-deficit hyperactivity disorder.
When we tested the associations between the insomnia variables and ADHD symptom severity 
groups (with no symptoms as the reference) in partially and fully adjusted logistic regression 
analyses, the groups with few and clinically relevant ADHD symptoms were significantly 
associated with all outcome variables in both models (Table 3). The p for trend was also 
significant for each outcome variable, meaning that across the three categories of increasing 
ADHD symptom severity (none, few, clinically relevant), there was a significant increase in the 
odds ratios for insomnia symptoms and relative risk ratios of short and long sleep duration. 
In the fully adjusted models, the group with clinically relevant ADHD symptoms had more 
than double the risk of insomnia symptoms and almost double the risk of short sleep duration, 
compared to the group with no ADHD symptoms. 
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The prevalence of both short (≤ 6 hours) and long (≥ 10 hours) sleep duration was highest in 
subjects with clinically relevant ADHD symptoms: 6% had long sleep duration, and 41% had 
short sleep duration (Table 2). An unexpected finding was the significant relationship between 
clinically relevant ADHD symptoms and long sleep duration (≥ 10 h), although the significance 
level was less strong and the confidence interval quite large (for this specific category p < 0.01). 
Overall, these findings as well as those in Table 3 suggest that worsening ADHD symptom 
severity is significantly associated with insomnia symptoms and altered sleep duration, after 
adjustment for a wide range of possible confounders, indicating a dose-response association. 
TABLE 3. Ratios of insomnia symptoms and other sleeping problems across ADHD symptom severity 
categories (none, few and clinically relevant) in the general Dutch population (N = 4,618), using partly 
and fully adjusted models
Number of ADHD symptoms 
(Ref = None)
Number of ADHD symptoms 
(Ref = None)
Few Clinically relevant Few
Clinically 
relevant
Model 1 P for 
trend
Model 2 P for 


















































































Asterisks indicate statistical significance: * = p < .05, ** = p < .01; *** = p < .001. Model 1 is adjusted OR/RRR for 
sex and age. Model 2 is adjusted for the factors in Model 1 and additionally adjusted for partner status, job status, 
any chronic somatic disorder, body mass index, smoking last month, exercise last week, any 12-month mood, anxiety 
or substance use disorder. ADHD = attention-deficit hyperactivity disorder, CI = confidence interval, OR = odds ratio, 
Ref = reference, RRR = relative risk ratio.
Table 4 describes the associations between insomnia symptoms, sleep duration, total ADHD 
symptom score, and the two symptom dimensions hyperactivity and inattention. Again, the 
continuous variables for ADHD symptoms, hyperactivity and inattention all show a strongly 
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significant relationship with clinically significant insomnia symptoms in the fully adjusted models 
(all p < .001). All the separate symptoms defining insomnia showed a significant relationship 
with ADHD symptoms, hyperactivity and inattention dimensions, assessed continuously, in both 
models. The predictor variables for all insomnia and sleep duration outcomes did not change 
markedly with full correction in model 2, demonstrating that the association between ADHD 
and sleep disturbance is robust, and not attributable to confounding factors. The hyperactivity 
dimension was significantly associated with short sleep, but not related to long sleep duration. 
TABLE 4. Ratios of insomnia symptoms and other sleeping problems across total ADHD symptoms, 
hyperactivity and inattention as continuous ADHD dimension variables, in the general Dutch population 
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Asterisks indicate statistical significance: * = p < .05, ** = p < .01; *** = p < .001. Model 1 is adjusted OR/RRR for 
sex and age. Model 2 is adjusted for the factors in Model 1 and additionally adjusted for partner status, job status, 
any chronic somatic disorder, body mass index, smoking last month, exercise last week, any 12-month mood, anxiety 
or substance use disorder. ADHD = attention-deficit hyperactivity disorder, CI = confidence interval, OR = odds ratio, 
Ref = reference, RRR = relative risk ratio.
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6. DISCUSSION
In this study, we evaluated the independent association between adult ADHD symptom 
severity, ADHD symptom dimensions, insomnia symptoms and sleep duration. Our results 
showed two main findings. Firstly, clinically significant insomnia symptoms were strongly and 
consistently associated with increasing severity of ADHD symptoms, and with the symptom 
dimensions of hyperactivity and inattention. There was a dose-response relationship between 
insomnia symptoms and ADHD symptom severity and ADHD symptom dimensions. Secondly, 
while self-reported short sleep duration was significantly associated with both inattentive and 
hyperactive symptom dimensions, long sleep duration was only associated with inattention 
and not with hyperactivity. After correcting for comorbid psychiatric disorders in the last year 
(mood, anxiety and substance use disorders), these associations remained significant. This 
is noteworthy, as it indicates that even in the general population, these relationships are not 
attributable to another comorbid disorder.
A dose-response relationship between ADHD symptom severity and insomnia was also found 
in two large [8, 35] and one smaller clinical studies [12]. Ours and these three studies included 
adults aged up to 74 years [8, 12, 35]. However, in a community study of young adults (18 - 20 
years), Gau et al. found no such dose response relationship (N = 2,284) [13]. The study of Gau 
et al. may indicate that in young adults, there is less difference in insomnia between those with 
and without ADHD. Our larger age range may account for more variability in self-reported 
ADHD and insomnia symptoms. It is also recognized that ADHD persisting into adulthood 
causes more severe impairment [36]. Similarly, insomnia symptoms worsen with increasing age 
[37] and poorer sleep quality in adult ADHD has been attributed to the presence of depressive 
symptoms [35]. We therefore also adjusted for mood and anxiety disorders and yet still found 
a dose-response relationship between increasing ADHD symptom severity and insomnia.
In terms of the ADHD symptom dimensions and insomnia symptoms, we found that clinically 
significant insomnia symptoms correlated strongly and significantly with both inattention  and 
hyperactivity symptom dimensions. The research on ADHD subtypes and sleep disturbance 
to date has been mixed. Insomnia symptoms have been associated with: (1) the number of 
hyperactivity/impulsivity symptoms [12]; (2) the combined ADHD and inattentive subtype [8]; 
(3) inattentive symptoms only [7, 13, 38, 39]. However, one study reported no association [6]. 
We found that insomnia correlated strongly with both inattentive and hyperactive symptoms, 
even after adjusting for multiple possible confounders, and despite using a population sample, 
where symptoms tend to be milder than in clinical studies. The clinical study by Fisher et al. 
(2014, ADHD adult N = 1,163) also demonstrated a strong association between adult ADHD 
and insomnia, in both ADHD subtypes [6].  
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Our second significant finding was that ADHD symptoms were associated with self-reported 
short and long sleep duration, as opposed to normal sleep. Our finding replicates the large 
population study of Bogdan et al., although they did not correct for comorbid affective disorder 
[14]. In other clinical studies, ADHD patients reported shorter sleep duration than controls [40, 
41]. When sleep duration was objectively measured, it was found to be normal in three studies 
[17 - 19]. Normal sleep duration was also found in two studies using self-report measures [13, 
20]. It is possible that findings for altered sleep duration are less strong when objective sleep 
measures are used. Finally, a study of 22 ADHD adults found no correlation between number 
of ADHD symptoms and sleep duration, a negative finding which may be explained by the 
small sample size [12]. 
Short sleep duration has been well described in the ADHD literature. Some authors have 
related it to increased nocturnal motor activity, as measured objectively by polysomnography 
[17, 42 - 44], although one study did not confirm this [45]. Our results significantly associated 
short sleep and ADHD symptoms. This relationship may be also explained by the presence 
of a comorbid delayed circadian rhythm disorder, such as delayed sleep phase syndrome, 
DSPS [5]. Generally, DSPS is characterized by a preference for sleep onset after midnight, with 
consequent difficulty awaking, daytime sleepiness and impaired functioning [1]. Individuals 
with DSPS have sleep-onset insomnia when trying to fall asleep early [46]. When early rising 
is necessary, a cumulative sleep debt may arise – meaning that total sleep duration is shorter.
In terms of long sleep in ADHD, we found a strong and significant association with ADHD 
symptom severity and the inattention symptom dimension, showing a dose-response 
relationship. Long sleep was far less prevalent than short sleep duration in the ADHD group.
A first possible way to explain long sleep duration associated with ADHD is the presence 
of an (undiagnosed) comorbid disorder [14]. In general, sleep duration shows a U-shaped 
association with overall mortality, cardiovascular disease, obesity and diabetes [47]. Hence 
both short and long sleep duration are detrimental to health. In ADHD, such a comorbid 
disorder might include hypersomnia, affective disorder, or medical illness. Just as it is important 
to control for comorbid disorders when investigating insomnia (as mentioned above), this 
is also true when investigating sleep duration. We did correct for mood, anxiety, substance 
and somatic disorders in the last year, unlike some other studies [12,14,19,48,49]. Still, we 
found that ADHD symptoms and long sleep duration were significantly associated. This implies 
that an (atypical) subgroup of those with ADHD may exist on the continuum of adult ADHD. 
Hypersomnia, characterized by excessive daytime sleepiness and prolonged night-time sleep, 
is increased in adult ADHD compared to controls [5]. Hypersomnia may be misdiagnosed as 
ADHD [5]. Hence, where ADHD patients present with long sleep duration, hypersomnia should 
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be excluded or treated. In general, the group with ADHD and long sleep may be at increased 
risk for overall mortality [47]. 
A second possible explanation for long sleep in ADHD comes from the pediatric literature, 
where some authors have proposed that instability of the sleep-wake system is a characteristic 
of children with ADHD [50]. This instability (some with long sleep duration, some with short) 
may also be present in adult ADHD. 
Regarding the two ADHD symptom dimensions and sleep duration in adults, there is a dearth 
of literature. Concurring with two studies, we found that short sleep duration was significantly 
associated with hyperactivity symptoms [12, 13]. In a minority of subjects, long sleep duration, 
was significantly associated with both hyperactive and inattentive symptoms. Regarding 
insomnia symptoms, significant findings in hyperactivity and inattention dimensions were very 
similar.
A question we were unable to address in our study is whether the treatment of sleep problems 
in those with ADHD improves the symptoms of inattention and hyperactivity. The cross-sectional 
nature of our analysis prevented us analyzing this, however, future studies should examine this 
important clinical outcome.
Another striking finding was that 60.5% of those with clinically significant ADHD symptoms 
were women, as opposed to 39.5% men. This result contrasts with findings from the pediatric 
literature, where male children are more than twice as likely to have ADHD than female children 
[51]. However, ADHD in adult women has been described as underdiagnosed because the 
symptoms are less overt [52]. It has also been shown that the higher prevalence of ADHD in 
males tends to decrease with increasing age [52]. A recent study using the ASRS showed that 
while more men screened positive for ADHD, the difference between the genders was not 
statistically significant [52]. Beyond this, we are unable to explain the increased prevalence of 
clinically relevant ADHD symptoms in females.
Despite the strengths of our study, several limitations should be noted. First, as this study is based 
on the third wave only and thus uses cross-sectional analyses, a clear causal direction of the 
relationships found cannot be demonstrated. Second, we relied on retrospective self-reports 
for ADHD symptoms present over the last 6 months using the Adult ADHD Self-Report Scale 
screener, which did not include a question about childhood-onset of the symptoms. We used 
retrospective self-reporting for insomnia symptoms (present over the last 4 weeks). According 
to the Diagnostic and Statistical Manual of Mental Disorders, fifth Edition diagnostic criteria, 
insomnia occurs where symptoms occur at least 3 nights per week over a period of three months 
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[1]. The IRS does not take duration of symptoms into account, hence we probably studied 
subjects with less severe symptoms, yet still we found significant associations between ADHD 
and insomnia symptoms. Sleep duration in the past 4 weeks were self-reported measures, 
where the categories of sleep duration may have limited variability. Yet, previous studies using 
both self-report measures and polysomnography indicate that long sleepers overestimate and 
short sleepers underestimate their true sleep duration [47]. Thirdly, we controlled for anxiety, 
depressive and bipolar disorders but we did not explore the potential overlap between ADHD 
and bipolar disorders. Bipolar disorder 2 can remain undiagnosed for years and exhibit 
similar symptoms to ADHD. In NEMESIS-2, the prevalence of all bipolar disorders was 0.8% 
in the last 12 months [53]. The 12-month prevalence of bipolar 2 disorder was 0.6%. This 
potential overlap would be interesting to investigate further. Fourthly, as regards concomitant 
medication use, very few subjects used ADHD medication (0.2%), so we did not correct for 
them as we felt the results would not be meaningful. Neither did we correct for medications 
treating insomnia or hypersomnia. It would be interesting to note whether treatment of sleep 
disturbance in ADHD improves the core symptoms of this disorder. Finally, in terms of the ADHD 
symptom dimensions, hyperactivity was determined by only two questions and there was no 
assessment of impulsivity, a component of ADHD, meaning that we are unable to comment on 
the relationship between impulsivity symptoms and insomnia/sleep duration.
In conclusion, we have confirmed that increasing symptom severity of ADHD is significantly 
associated with clinically significant insomnia symptoms, long and short sleep duration, after 
correction for a range of potential confounders. Both long and short sleep duration were 
also significantly associated with inattentive symptoms, in fully adjusted models, whereas 
hyperactive symptoms were associated with short sleep duration only. Adult ADHD and sleep 
disturbance symptoms are therefore linked with consistent and strong associations. This has 
serious implications for morbidity in ADHD, as insomnia, short and long sleep duration are all 
associated with significantly worse daily functioning [34] and adverse health outcomes [33, 
47]. Where the comorbidities of adult ADHD are unrecognized and untreated, it has been 
shown that treatment costs increase and patients suffer more adverse long-term outcomes [54]. 
Sleep deprivation also worsens cognitive function [22]. In adult ADHD, attention and executive 
control are already compromised, hence insomnia should be recognized and treated. Insomnia 
can be successfully managed pharmacologically [54] and with cognitive behavioral therapy 
and light therapy [56, 57]. Such treatments could be used to ameliorate the sleep disturbance 
we have found to be so prevalent in ADHD. Comorbid insomnia and altered sleep duration 
should be considered by clinicians treating these complex patients, to reduce suffering and 
improve functioning. 
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We thank Dr Araz Altay for raising the important issue of inflammation, sleep and ADHD 
[1] and the editors of the Journal of Clinical Sleep Medicine for giving us the opportunity to 
respond. 
Our group previously investigated adult ADHD symptoms, Metabolic Syndrome (MetSyn) 
and obesity-related variables in a large population study with different stages of comorbid 
affective disorders (Netherlands Study of Depression and Anxiety, NESDA) [2]. Interestingly, 
we showed few clear associations: ADHD was not associated with MetSyn. It is possible 
that these associations are difficult to detect and therefore we failed to find them. Also, both 
the concept and definition of MetSyn have been questioned [3] as it is possible that not all 
MetSyn risk factors contribute significantly to cardiovascular diseases/diabetes in the general 
population [4]. 
Concerning obesity, a meta-analysis showed that it was significantly associated with ADHD 
[5]. Both obesity and MetSyn are considered pro-inflammatory conditions [6]. 
Another possible link includes sleep disturbance, which was associated with systemic 
inflammation markers in the NESDA cohort [7].  ADHD is comorbid with insomnia, RLS and 
circadian dysregulation [8].  Preliminary evidence links ADHD to inflammatory processes 
[9]. The circadian system and clock genes control both the sleep-wake cycle and metabolism 
[10].  Fasting glucose, lipid levels, blood pressure and the sleep-wake cycle are rhythmically 
coordinated by the biological clock. Disruption of either the circadian or metabolic system 
can lead to derangement of the other, predisposing to MetSyn, obesity or diabetes [10]. 
Once again, inflammatory processes may be the link between ADHD, circadian rhythm 
and metabolic disturbance. We therefore support further investigation of these overlapping 
processes, as causality is unknown.
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1. ABSTRACT 
Objective: We evaluated whether the association between Adult Attention-Deficit/
Hyperactivity Disorder (ADHD) and Seasonal Affective Disorder (SAD) was mediated by the 
circadian rhythm. 
Method: Data of 2,239 persons from the Netherlands Study of Depression and Anxiety 
(NESDA) were used. Two groups were compared: with clinically significant ADHD symptoms 
(N = 175) and with No ADHD symptoms (N = 2,064). Sleep parameters were sleep-onset 
and offset times, mid sleep and sleep duration from the Munich Chronotype Questionnaire. We 
identified the prevalence of probable SAD and subsyndromal SAD using the Seasonal Pattern 
Assessment Questionnaire (SPAQ). Clinically significant ADHD symptoms were identified by 
using a T score > 65 on the Conners Adult ADHD Rating Scale. 
Results: The prevalence of probable SAD was estimated at 9.9% in the ADHD group (vs. 
3.3% in the No ADHD group) and of probable s-SAD at 12.5% in the ADHD group (vs 4.6% 
in the No ADHD group). Regression analyses showed consistently significant associations 
between ADHD symptoms and probable SAD, even after adjustment for current depression 
and anxiety, age, sex, education, use of antidepressants and benzodiazepines (B = 1.81, p < 
.001). Late self-reported sleep-onset was an important mediator in the significant relationship 
between ADHD symptoms and probable SAD, even after correction for confounders (total 
model effects: B = 0.14, p ≤ .001). 
Conclusion: Both seasonal and circadian rhythm disturbances are significantly associated 
with ADHD symptoms. Delayed sleep-onset time in ADHD may explain the increase in SAD 
symptoms. Treating patients with SAD for possible ADHD and delayed sleep-onset time may 
reduce symptom severity in these complex patients.
Keywords: Seasonal affective disorder; attention deficit/hyperactivity disorder; delayed 
sleep phase; circadian rhythm
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2. INTRODUCTION 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that 
commences in childhood, and often persists throughout the lifespan [1]. The estimated 
prevalence of ADHD is 3.4% in adults [2]. The clinical presentation of ADHD in adults is marked 
by inattentiveness and impulsivity, with fewer hyperactivity symptoms than in childhood. Adult 
hyperactivity may be internalized as inner restlessness [3]. Adult inattention is characterized by 
difficulty in planning and organizing tasks, poor listening skills, distraction and procrastination 
[4]. Impulsivity may result in interrupting others, poor self-control, reckless driving and 
impatience [4].
 
In addition, adult ADHD is comorbid with mood, anxiety and sleep disorders, amongst others 
[2, 5, 6]. Seasonal Affective Disorder (SAD) is a type of recurring major depression with a 
seasonal pattern. It frequently co-occurs with adult ADHD, with a prevalence of up to 27%, as 
compared to 6% in the general population [7 - 9]. SAD is characterized by major depressive 
episodes during autumn and/or winter, which remit in spring [10, 11]. Symptoms include 
difficulty concentrating, anhedonia, fatigue, forgetfulness, as well as the co-called atypical 
depressive symptoms: sleep disturbance (tendency to sleep longer), hyperphagia and weight 
increase [10]. 
ADHD is also associated with circadian sleep problems, as recently reviewed by Coogan 
[12]. In particular, delayed sleep phase syndrome (DSPS) and late chronotype are frequently 
comorbid in adults with ADHD [10, 13, 14] and adolescents with ADHD [15]. Individuals with 
DSPS have sleep-onset insomnia if they try to go to sleep early: sleep-onset is usually after 
midnight, with consequent difficulty awaking, daytime sleepiness and impaired functioning. 
The duration of symptoms is at least 6 months [10]. Chronic sleep deprivation and short sleep 
duration have also been associated with ADHD [16]. 
A subject’s chronotype refers to the behavioral manifestation of underlying circadian rhythms, 
as evidenced by regular rising and sleep-onset times during 24 hours [17]. Chronotype, 
regulated by the biological clock in the suprachiasmatic nuclei (SCN), consists of morning, 
evening and intermediate types [18]. Timing of sleep and wakefulness may differ during work 
and free days, as sleep deficit accumulates during working days, but is compensated for on 
free days, when rising time is later [19]. Phase and duration of sleep on free days are believed 
to reflect circadian rhythm most accurately as there are fewer externally enforced schedules 
[17]. Adults with ADHD are often evening types, up to 78% have initial insomnia if they go to 
bed early; and initial insomnia in ADHD is associated with a delayed secretion of the sleep 
hormone, melatonin [20].
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SAD and DSPS appear to be overlapping conditions in terms of clinical presentation and 
comorbidity [21, 22]. Both may result from “phase shifts” in the circadian rhythm. For most SAD 
patients, it is argued that a phase shift occurs during winter, when the dawn occurs later. Here, 
the natural daily rhythms of light are out of phase with the patient’s sleep/wake cycle, and 
hence, this cycle is delayed [21]. Therefore, depression occurs in winter when the photoperiods 
become shorter. Recovery is induced with increasing exposure to sunlight in spring [23]. In 
DSPS, the late sleep-onset reflects an inability to regulate to the external cue of diminished light, 
resulting in a phase delay [24]. 
Several mechanisms for the relationship between disturbed sleep and ADHD have been 
explored [25]. Sleep disturbance in ADHD may result from nocturnal hyperactivity, where 
stimulant treatment may ameliorate sleep [25]. Alternatively, sleep problems may precipitate 
the behavioral and cognitive symptoms of ADHD. This interaction between ADHD and sleep 
disturbance has been elegantly depicted as a feed-forward loop, where sleep problems cause 
neurobehavioral morbidity in ADHD, and ADHD results in the sleep problems associated with 
its comorbid disorders, depression and anxiety [25].
ADHD, DSPS and SAD share features which suggest they are all disorders of the biological 
rhythm. The mechanism underlying the circadian rhythm disturbance in ADHD is unclear, but 
a recent animal model showed that disruption of a circadian clock gene elicits an ADHD-like 
syndrome, with alteration in dopamine levels [26]. Body temperature changes and delayed 
melatonin secretion are also implicated in ADHD [20, 27]. In winter, SAD and DSPS present 
with low mood [28] and problems synchronizing to external cues such as daylight, especially 
when these cues are weak. In terms of treatment, symptoms of ADHD, SAD and DSPS improve 
when therapy involves ‘phase resetting’. Both DSPS and SAD respond to morning bright light 
therapy and/or evening melatonin administration [21, 29]. In an open study of patients with 
ADHD and SAD, core ADHD symptoms improved when remediated with light therapy [30]. 
Finally, the three conditions may have shared genetic factors [31]. ADHD is highly heritable 
[32] and evidence points to underlying polymorphisms in clock genes in all three disorders 
[12]. This comorbidity and shared genetic etiology may explain the symptomatic overlap of 
ADHD, SAD and DSPS.
However, to our knowledge, only one study has investigated all three conditions. Bijlenga 
and colleagues found an association between ADHD, late sleep and seasonal depressive 
symptoms [33] and our prior study showed that ADHD symptoms add risk to circadian rhythm 
sleep problems in depression and anxiety [13]. Our aim in this study was to add new knowledge 
about the relationships between these disorders. Specifically, we investigated whether 
indicators of a delayed circadian rhythm (sleep-onset and offset times, mid-sleep) as well as 
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short sleep duration, mediated in the relationship between ADHD symptoms and seasonal 
depressive symptoms. If indeed circadian rhythm plays a role in the high prevalence of SAD in 
ADHD patients, then effective treatments could ameliorate symptoms of both disorders in this 
group [14]. Improving mood and sleep disorders may well decrease health resource utilization 
and improve quality of life in ADHD [34].
3. METHOD 
3.1 PARTICIPANTS
Subjects participated in the Netherlands Study of Depression and Anxiety (NESDA), an ongoing 
longitudinal, naturalistic cohort study of 2,981 participants, aged 18 - 65 years. Participants 
were recruited from different health care settings (community, primary and specialized mental 
health care) and included a group without psychiatric symptoms (‘Controls’) and others with 
current and remitted affective disorders. A full description of NESDA has been reported 
elsewhere [35]. Ethical Review Boards of all participating centers approved the NESDA 
study protocol and it was carried out in accordance with the latest Declaration of Helsinki. All 
participants gave written informed consent at enrolment after the study procedures had been 
fully explained. All measures in this study were taken from the 2-year follow-up assessment 
of NESDA, except the assessment of ADHD symptoms, (performed at the 4-year follow-up). 
Subjects included were those participating in both of these follow-up visits (2,239 respondents, 
75.1% of the total sample). 
3.2 ADHD SYMPTOMS
To identify clinically significant ADHD symptoms, the Conners Adult ADHD Adult Rating Scale–
Self report: Screening Version (CAARS-S:SV) was used at the 4-year follow-up assessment. The 
CAARS-S:SV is a 30-item questionnaire that assesses ADHD symptoms and behaviors. The 18-
item Total symptom scale identifies the presence of DSM-IV criteria for ADHD (range of possible 
scores 0-54) [10]. The CAARS-S:SV uses a 4-point Likert-scale format in which respondents 
are asked to rate items pertaining to current behavior and problems. Ratings range from 0 
(not at all, never) to 3 (very much, very frequently). The validity and reliability of the CAARS-
S:SV have been confirmed [36]. For this study, the raw CAARS-S:SV scores were converted 
into standardized scores (T-scores) using age- and sex-corrected norm values, following the 
CAARS manual [37]. The ADHD group was defined as those participants obtaining a T-score 
of 65 or above, indicating clinically significant ADHD symptoms; and the No ADHD group 
obtained a T-score < 65 (on either the ADHD Total symptom or Index scales). This instrument 
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has excellent test-retest reliability, with a median α = 0.89, over the period of approximately 
one month [38]. We used data from the 4-year follow-up assessment for ADHD, and from the 
2-year follow-up for other parameters, because the ADHD assessment took place later than 
the others. ADHD has a chronic course in the majority of cases, based on follow-up studies [3, 
39]. It extends from childhood [40] even into old age [41]. Symptom stability has been shown 
for adults retrospectively reporting childhood ADHD [42] and the negative impact of ADHD 
on occupational, social and emotional functioning also persists [43]. Hence we feel that the 
fact ADHD was measured 2 years after the other parameters would not impact on our results. 
3.3 SAD SYMPTOMS
The Seasonal Pattern Assessment Questionnaire (SPAQ), is a self-rating scale assessing 
seasonal changes in sleep length, social activity, mood, weight, appetite, and energy level in 
the last year [44]. Likert scales range from (0) ‘no change’ to (4) ‘extreme/marked change’ for 
each item and do not identify time span of symptoms. We used a modified version of the SPAQ 
that reported symptoms in the last year. The SPAQ is widely used as a screening questionnaire 
for SAD [45]. It shows a specificity of 94%, but a low sensitivity of 44% [46]. We calculated 
the Global Seasonality Score (GSS, range 0 - 24) from the SPAQ. The GSS is a composite 
measure for seasonal change in the six symptoms assessed and has good internal consistency 
(Cronbach’s alpha 0.85), [46].
To identify probable SAD cases, we used the three criteria formulated by Kasper et al. using the 
SPAQ: 1) GSS score of 11 or more; 2) a ‘problem’ rating of seasonal mood changes of at least 
‘moderate’ (a score ≥ 2 on a 0 - 5 scale range); 3) a time window of symptoms to diagnose 
winter SAD, in which subjects feel worst between December and February [45].
Subsyndromal-SAD (s-SAD) is defined as a cluster of milder seasonal complaints less impairing 
than SAD. We used the following modified Kasper criteria for s-SAD: (1) a GSS score of 11 or 
more, with a ‘problem’ rating of  ‘no’ or ‘mild’ (scores 0 or 1 on a 0-5 scale range); or (2) a 
GSS score of 9 or 10 and a ‘problem’ rating of at least ‘mild’ (≥ 1) [28, 47]. The time window 
criterion is the same as for SAD cases.
3.4 CHRONOTYPE
Sleep characteristics and chronotype were assessed with the Munich Chronotype Questionnaire 
(MCTQ) [17]. The MCTQ is a self-report measure with questions on sleep timing on nights 
before work and free days. Parameters of circadian rhythm used were: sleep-onset and offset 
times, sleep duration on nights before free days and mid -point of sleep on free days corrected 
for sleep debt during the work week (MSFsc), [17, 48]. 
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3.5 AFFECTIVE DISORDERS
Depressive (major depressive disorder, dysthymia) and anxiety disorders (panic disorder, 
social phobia, agoraphobia, generalized anxiety disorder) were assessed using the DSM-IV 
Composite International Diagnostic Interview (CIDI-2.1) by trained clinical research staff [49]. 
Test-retest reliability of the CIDI has been described as satisfactorily high [50] and inter-rater 
kappa values were all 0.94 or higher for depressive and anxiety disorders in the original 
validation studies [51]. We do not have specific kappa values for the NESDA CIDI interviews 
but we believe they did not differ from the WHO field trial values, as we used the instrument 
designed and tested by the WHO in field trials for use in cross-national comparison studies 
[50]. We assessed affective disorders in three categories: none; remitted (present during the 
lifetime history but not in the last year) and current (present in the last year). Affective disorder 
severity was investigated using the Inventory of Depressive Symptomatology (IDS-SR) and the 
Beck Anxiety Inventory (BAI) scales, respectively. 
3.6 COVARIATES
Sociodemographic variables included age, sex and years of education. Current employment 
status, presence of a partner, and children in the household were shown to be significant 
predictors in a NESDA study on chronotype, and hence were included [52]. Potential 
confounders associated with ADHD, depressive, and anxiety disorders included smoking 
(non-smoker/current smoker) [53];  alcohol use (number of alcohol consumptions/week: 
Alcohol Use Disorders Identification Test) [54]; Body Mass Index (BMI) [55]; and the use of 
psychotropic medications. These included selective serotonin reuptake inhibitors (SSRI; ATC 
code: N06AB), serotonin-norepinephrine reuptake inhibitors (SNRI; N06AX16, N06AX21), 
tricyclics (N06AA) and tetracyclics (N06AX03, N06AX05, N06AX11), benzodiazepines 
(N05BA, N05CF, N05CD, N03AE), and psychostimulants (N06BA). The use of any of these 
medications was rated positive if used on at least 50% of days during the past month. 
3.7 STATISTICAL ANALYSES
We divided the subjects into those with clinically significant ADHD symptoms (ADHD group, N 
= 175) and those without clinically significant ADHD symptoms (No ADHD group, N = 2,064). 
Means and standard deviations for continuous data, and frequencies and percentages for 
categorical data, were reported. We categorized the dates of assessment of the SPAQ into four 
seasonal categories (spring: March 21–June 20, summer: June 21–September 20, autumn: 
September 21–December 20, winter: December 21–March 20), to determine if season of 
assessment varied in the three groups, as this was shown to influence GSS significantly in a 
previous NESDA study [56]. Between-group comparisons of covariates were made using Chi-
90 | CHAPTER 5
square and ANOVA tests. In the multivariate analysis, we included covariates which were 
significantly different between the two groups. Lifetime depressive episodes have been shown 
to be significantly associated with ADHD symptom severity in adults [57] and depressive 
disorders comorbid with ADHD increased the severity of attention problems in both children 
[58] and (longitudinally) in adults [59]. Therefore, we did not include affective disorder 
severity as covariate in multivariate analyses. Linear regression was performed with GSS as the 
dependent variable, and clinically significant ADHD symptoms (no/yes) as the independent 
variable, controlling for covariates. In the multinomial logistic regression, s-SAD and SAD were 
the two levels of the outcome variable of interest. The ADHD predictor variables used in separate 
analyses were clinically significant ADHD symptoms (yes/no) and continuous CAARS score 
using the Total symptom scale. All regression models were adjusted for current anxiety and 
depression (last year), age, sex, education, and medication use (antidepressants SSRI, SNRI, 
tricyclics, and benzodiazepines). We conducted mediation models following Hayes, with 
5000 bootstrapping samples [60]. Here, the effect of ADHD on GSS was entered, with two 
mediators: sleep-onset time and sleep duration, while controlling for current depressive and 
anxiety disorders, age, sex, education, and medication use. We excluded 3 outliers from the 
mediation analysis with a sleep-onset time after 5:00 AM. Data were analyzed using SPSS for 
Windows (version 23; IBM Company, Chicago, IL, USA). Statistical significance was inferred 
at p ≤ .05.
4. RESULTS 
General characteristics of the groups are described in Table 1. Participants in the clinically 
significant ADHD symptoms (ADHD) group were significantly older and had significantly less 
education than those in the No ADHD group. Ninety eight percent of the ADHD group had a 
lifetime history of depressive and/or anxiety disorders and it was hence largely a comorbid 
group. The ADHD group had three times the prevalence of current affective disorders as 
opposed to remitted affective disorders, whereas in the No ADHD group, remitted affective 
disorders were more common than current. Scores for measures of severity of both depressive 
and anxiety disorders were significantly higher in the ADHD group. Apart from SSRI use, 
few used psychotropic drugs. Significantly more in the ADHD group used antidepressants, 
benzodiazepines, and psychostimulants.
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TABLE 1. General characteristics of the NESDA subgroups: Clinically significant ADHD symptoms 








Age in years at baseline, mean (SD) 46.9 (11.6) 44.0 (13.3) F(1,2237) =7.78 .005
Females, n (%) 117 (66.9) 1068 (66.1) Χ²(1)=0.04 .454
Years of education, mean (SD) 11.6 (3.2) 12.8 (3.3) F(1,2237) =21.46 <.001
Partner present, n (%) 94 (53.7) 1231 (59.6) Χ²(1)=2.35 .126
Presence of children in household, n (%) 59 (33.7) 637 (30.9) Χ²(2)=2.37 .306
Life style and Health
Current smoker, n (%) 59 (33.7) 605 (29.3) Χ²(1)=1.50 .221
Number of alcoholic drinks per week, mean (SD) 7.18 (12.0) 6.70 (9.26) F(1,2191)=0.40 .527
BMI, mean (SD) 26.29 (5.70) 25.74 (4.77) F(1,2165)=2.00 .157
Psychopathology, n (%)
Depressive disorder: Χ²(2)=186.81 <.001
- None 5 (2.9) 724 (35.1)
- Current (last year) 124 (70.9) 498 (24.1)
- Remitted 46 (26.3) 842 (40.8)
Anxiety disorder: Χ²(2)=145.77 <.001
- None 18 (10.3) 863 (41.8)
- Current (last year) 118 (67.4) 524 (32.8)
- Remitted 39 (22.3) 677 (43.0)
Depressive symptom severity (IDS)a, mean (SD) 31.3 (13.5) 13.8 (10.8) F(1,2237)=410.31 <.001
Anxiety symptom severity (BAI)b, mean (SD) 18.5 (10.9) 7.54 (7.7) F(1,2200)=302.75 <.001
Frequent use of psychotropics, n (%)
Antidepressants
- no use 117 (66.9) 1695 (82.1) Χ²(3)=25.59 <.001
- SSRI 37 (21.1) 250 (12.1)
- Tricyclic antidepressants 7 (4.0) 48 (2.3)
- SNRI 14 (8.0) 71 (3.4)
Benzodiazepines 17 (9.7) 76 (3.7) Χ²(1)=14.74 <.001
Psychostimulants 5 (2.9) 8 (0.4) Χ²(1)=17.04 .002c
Season of assessment: n (%)
Spring 36 (20.6) 466 (22.6) Χ²(3)=1.98 .576
Summer 44 (25.1) 483 (23.4)
Autumn 46 (26.3) 612 (29.7)
Winter 49 (28.0) 503 (24.4)
a. Inventory of Depressive Symptomatology (IDS) scale symptom severity in last week.
b. Beck Anxiety Inventory (BAI) scale symptom severity in last week.
c. With Fisher’s exact test.
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Table 2 shows that the Global Seasonality Score (GSS) was significantly higher in the ADHD 
group. Consistently, the ADHD group showed a positive significant association with probable 
SAD and s-SAD. Food preference across seasons, MSFsc, sleep-onset and offset times on nights 
before free days were the only variables that were not significantly different in the two groups. 
There was a trend for shorter sleep duration in the ADHD group compared to the No ADHD 
group (F = 3.59, p = .058). In a Pearson’s product-moment correlation, there was a significant 
but low correlation between ADHD symptoms and seasonality symptoms (r = 0.30; p < .001; 
R2 = 0.09).
Table 3 shows that the presence of ADHD symptoms and current depressive disorder (last year) 
were positively associated with probable SAD and s-SAD in both a multinomial and binary 
logistic regression, even after correction for covariates. 
TABLE 2. Parameters of biological rhythms: seasonal and circadian rhythm changes in two subgroups: 
Clinically significant ADHD symptoms (ADHD) and No clinically significant ADHD symptoms (No ADHD) 







Global Seasonality Score (GSS), 
mean (SD) 
7.01 (4.45) 4.42 (3.82) F=64.95 (1,2069) <.001
Seasonal changea in: n (%)
   Sleep 38 (21.7) 256 (12.4) X2=12.26 (1) <.001
   Social 62 (35.4) 356 (17.2) X2=35.12 (1) <.001
   Mood 74 (42.3) 451 (21.9) X2=37.53 (1) <.001
   Weight 47 (26.9) 244 (11.8) X2=32.25 (1) <.001
   Appetite 37 (21.1) 175 (8.5) X2=30.18 (1) <.001
   Energy 72 (41.1) 465 (22.5) X2=30.66 (1) <.001
   Food preference 60 (38.7) 704 (36.9) X2=0.202 (1) .653
Caseness of Seasonal Affective Disorder 
(SAD), n (%)
X2=36.16 (2) <.001
 No SAD and no subsyndromal SAD 118 (77.6) 1748 (92.1)
 Subsyndromal-SAD 19 (12.5) 87 (4.6)
 Probable SAD 15 (9.9) 63 (3.3)
Sleep duration free days, mean (SD) 7:41 hr (1:50) 7:57 hr (1:26) F= 3.59 (1,1754) .058
Sleep-onset free days, mean (SD) 0:15 hr (2:18) 0:09 hr (1:16) F= 0.56 (1,1780) .454
Sleep offset free days, mean (SD) 8:08 hr (1:52) 8:07 hr (1:26) F= 0.00 (1,1801) .948
MSFsc free days, mean (SD) 3:41 hr (0:44) 3:48 hr (0:36) F= 3.20(1,1754) .074
a. Indicates that seasonal change score at least moderate on the SPAQ scale
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TABLE 3. Multinomial logistic regression for caseness of Seasonal Affective Disorder (SAD) and 
subsyndromal SAD as the two levels of the dependent variable, and with clinically significant ADHD 
symptoms as independent variable, controlling for multiple covariates (N = 2,050) 
Caseness of SAD*
Subsyndromal SAD Probable SAD
OR (95% CI) P OR (95% CI) P
Clinically significant ADHD symptoms (no/yes) 2.59 (1.46-4.63) .001 2.04 (1.07-3.88) .030
Covariates:
Current depression (last year) 1.64 (1.03-2.61) .039 2.81 (1.69-4.70) .039
Current anxiety (last year) 1.11 (0.70-1.76) .670 1.46 (0.87-2.46) .149
Age (continuous) 0.99 (0.97-1.00) .011 0.99 (0.97-1.01) .206
Gender (male=ref) 1.69 (1.05-2.70) .030 1.14 (0.69-1.90) .608
Education (continuous) 1.01 (0.95-1.07) .823 1.01 (0.94-1.08) .839
Use of antidepressants and benzodiazepines 1.46 (0.93-2.29) .101 1.55 (0.94-2.57) .088
*Multinomial logistic regression with categorical outcomes s-SAD and SAD. Reference category is no 
s-SAD and no SAD. 
Most importantly, ADHD symptoms and current depression (last year) were significantly 
positively linearly associated with GSS (see Table 4). The relationship between GSS and 
ADHD was analyzed in multiple ways, but the linear relationship showed a very similar R 
squared value to parabolic estimates.
TABLE 4. Linear regressions with continuous Global Seasonality Score (GSS) as dependent variable 
and clinically significant ADHD symptoms as independent variable, controlling for multiple covariates 
(N = 2,071) 
 GSS
 B (SE) p
Clinically significant ADHD symptoms (no/yes) 1.81 (0.33) <.001
Covariates:
Current depression (last year) 1.13 (0.32) <.001
Current anxiety (last year) 0.49 (0.26) .058
Age (continuous) -0.04 (0.01) <.001
Gender (male=ref) 0.36 (0.18) .041
Education (continuous) -0.04 (0.03) .105
Use of antidepressants and benzodiazepines 0.87 (0.21) <.001
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FIGURE 1 shows the results of mediation models in which the association between ADHD 
symptoms and GSS was studied, with two mediators: sleep duration and sleep-onset time 
(nights before free days). One point increase on the CAARS resulted in 0.96 minutes shorter 
sleep (p = .005; path a), a 0.96 minutes later sleep-onset (p = .004; path a’), and an increase 
of 0.14 points on the GSS (p ≤ .001; path c). A sleep-onset time that was one hour later resulted 
in an increase of 0.26 points on the GSS (p ≤ .001; path b’). There was a direct effect of ADHD 
symptoms on seasonality (c path). The mediated path was positively significant only for sleep-
onset time (p ≤  .001; path a’b’), but not for sleep duration (CI = -0.003 – 0.002; path ab), 
explaining 14% of the relationship between ADHD symptoms and seasonality. Effect sizes of 
the mediation models were calculated following the methods described by Preacher and Kelly 
[61]. These were rather small: for sleep-onset time, Pm, (the ratio of the indirect effect to the total 
effect), was 0.30 (CI = 0.010 - 0.063); and Rm, (the ratio of the indirect effect to the direct 
effect), was 0.30 (CI = 0.010 - 0.067).  
FIGURE 1. Mediation analysis of the effect of ADHD on Global Seasonality Score (GSS), mediated by 
both sleep-onset time and sleep duration on nights before free days, adjusted for current depression (last 
year), current anxiety (last year), age, sex, education, use of antidepressants and benzodiazepines (N = 
1,738), total effects R² = 0.14.
Reported values are betas and standard errors in brackets; a = effect of ADHD on sleep duration; a’ = effect of ADHD 
on sleep-onset time;  b = effect of sleep duration on seasonality; b’ = effect of sleep-onset time on seasonality;  c = 
direct effect of ADHD on seasonality; ab = indirect effect of ADHD on seasonality through sleep duration; a’b’ =indirect 
effect of ADHD on seasonality through sleep-onset time.
* Significant with p ≤ .001. 
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5. DISCUSSION 
We explored the relationship between clinically significant ADHD symptoms and seasonal 
depressive symptoms; and the role of circadian sleep disturbances in this association. We found 
a significant relationship between ADHD symptoms and symptoms of both seasonal depression 
and circadian sleep disturbance. Furthermore, we found that seasonal depressive symptoms are 
also significantly increased in those with clinically significant ADHD symptoms, independent of 
pre-existing depression and/or anxiety. Importantly, we found that the relationship between 
ADHD symptoms and seasonality symptoms was partly mediated by the best indicator for 
circadian disturbance, sleep-onset time on nights before free days. These results indicate that 
chronotype, as demonstrated by sleep-onset time, mediates 14% of the relationship between 
ADHD symptoms and SAD symptoms. Total sleep duration did not play a significant mediating 
role. Hence, our study points to possible links between both circadian and seasonal rhythm 
disturbance in ADHD, and offers a putative explanation for these relationships.
A positive association between adult ADHD and seasonal depressive symptoms has been 
documented previously [7, 33, 62]. How ADHD and SAD are exactly related remains unclear, 
but it may be partly because of underlying biological rhythm alterations, common to both 
conditions. Factors that may explain this include an interplay between circadian clock genes 
[26], the SCN and individual responses to environmental stressors, where the circadian clock 
modulates biological responses to environmental factors [63]. Late sleep may be the factor 
common to ADHD and SAD, partly driving increased winter depression symptoms in these 
patients. Late sleep is associated with both shorter exposure to sunlight (because of the resulting 
late rising), and increased exposure to artificial light at night. These may in turn contribute to 
lowering mood [64]. As for SAD, biological clock disturbance may partially contribute to the 
development of ADHD, in individuals with heightened sensitivity to changes in light and dark 
[31]. In ADHD, significant disturbances in circadian clock gene expression have been shown, 
[31] which may result in abnormalities of endocrine secretion [20]. Indeed, melatonin secretion 
was delayed in 78% of a consecutive sample of ADHD adults [20, 65].
Late sleep has other far-reaching clinical implications in ADHD. Rhythm delay and chronic 
sleep deprivation may lead to metabolic and cardiovascular risks [66, 67]. In patients with 
current depression and a delayed sleep phase, ADHD should therefore be routinely assessed 
and treated. Furthermore, those presenting with SAD should also be screened for ADHD 
and circadian rhythm disturbances. Morning bright light therapy and/or evening melatonin 
administration may advance late sleep-onset and improve seasonal depressive symptoms [21, 
29]. A recently published study of children with ADHD and insomnia, showed that both ADHD 
and insomnia improved following a brief behavioral intervention with benefits sustained six 
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months post intervention [68]. Such behavioural and psychoeducation techniques merit further 
exploration in adults.
 
Our results suggest that a delayed sleep-onset time is only partly responsible for SAD symptoms 
in ADHD, as the direct relationship between ADHD and seasonality remained significant even 
after mediation. Other factors mediating seasonality in ADHD are not completely understood. 
A possible explanation is that mood disorders comorbid with ADHD [69] may increase the 
vulnerability for seasonal depressive symptoms. Other possible mechanisms include the retinal 
sensitivity to light in patients with SAD, shown by Roecklein [70] and polymorphisms in genes 
that are related to both ADHD and SAD, but not to delayed sleep [71]. Women are affected 
by SAD more frequently than men [11]. Female reproductive hormones may be implicated in 
the relationship between ADHD and SAD. Although data are limited for ADHD, it has been 
hypothesized that decreased estradiol levels in the ventromedial hypothalamus are associated 
with SAD symptoms in women [72]. 
Some limitations of our study should be mentioned. The cross-sectional study design allowed 
for limited causal inferences on the relationship between ADHD symptoms and SAD symptoms 
or probable DSPS. In addition, completing the CAARS-S:SV depends on retrospective self-
reporting, as ADHD starts in childhood. This may have introduced recall bias, leading to under 
or over reporting of ADHD symptoms [73]. Yet, the validity of retrospective ADHD symptom self-
reporting has been shown to be reliable [36]. In our study, there was no collateral information 
provided. ADHD also has some conceptual overlaps in symptom presentation with affective 
disorders, such as concentration problems and daytime fatigue. However, in a recent large study 
of adolescents, the association between sleep and ADHD symptoms was still significant even 
after accounting for depressive symptoms [16]. We measured ADHD symptoms 2 years after the 
other parameters. Yet by definition, ADHD is a chronic condition that is expected to be relatively 
stable across development. Symptom stability has been shown for adult ADHD [42] and it is 
believed to be related to genetic factors [74], structural brain differences [75], neural connectivity 
[76] and environmental influences [77]. Hence we believed that the fact ADHD was measured 
2 years after the other parameters would not impact on our results. We suggest that future 
research be structured to investigate all symptoms of interest measured at multiple time points, 
in order to elucidate the exact nature of the relationships between these constructs over time. 
Also, although the SPAQ is primarily a screening instrument, in our study it was used as a 
diagnostic tool [46]. Furthermore, it discriminates poorly between SAD and s-SAD [78] and 
it does not always agree with longitudinal observations [79, 80]. The circadian hypothesis 
for SAD states that most patients have a phase-delayed sleep/wake cycle [81]. Our study 
did not include a biological or objective marker for the circadian rhythm, nor did we perform 
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parabolic analyses, as in the seminal paper by Lewy et al. [21]. These analyses would be 
important to elucidate in future studies. Finally, we relied on self-report for chronotype (from 
the MCTQ) as opposed to objective measurements such as melatonin curves or actigraphy. 
However, a recent study has suggested that as proxies for determining chronotype, melatonin 
curves and MCTQ measurements correlate well [82].
In summary, we showed that in a large sample of persons, ADHD symptoms are strongly and 
significantly associated with SAD symptoms, even after correction for affective disorders. 
Delayed sleep partly mediates the association between ADHD symptoms and SAD symptoms. 
It appears to be a disturbed circadian rhythm, as opposed to a short sleep duration, that is 
one possible pathway linking ADHD to seasonal depression. Our study extends the literature 
exploring relationships between ADHD and biological rhythm disturbances. There are several 
clinical implications of these findings. Clinicians treating ADHD should routinely check for 
late sleep-onset time, DSPS and SAD symptoms; and vice versa. Where these problems 
co-exist, sleep hygiene, behavioral interventions, pharmacological strategies involving 
evening melatonin administration, and early morning bright light therapy are recommended. 
Comprehensive treatment interventions may prevent chronic disability in this complex group of 
patients. 
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1. ABSTRACT 
Objective: ADHD may predispose to obesity, a metabolic syndrome component. Affective 
disorders are also associated with MetSyn and ADHD. This study examined whether ADHD 
confers any added risk for MetSyn and obesity-related associations in a large sample with 
varying stages of affective disorders. 
Method: Participants included 2,303 adults from the Netherlands Study of Depression and 
Anxiety. Three groups were compared (controls; those with depressive/anxiety disorders 
without ADHD; and those with depressive/anxiety disorders and ADHD), for presence of 
MetSyn risk factors, body mass index and waist-hip ratio). ADHD symptoms were identified by 
using T-score > 65 (Conners Adult ADHD Rating Scale). 
Results: Multivariable analyses were additionally adjusted for sociodemographic, lifestyle, 
health factors and affective disorders. Analyses showed no significant association between 
MetSyn, obesity-related variables and comorbid ADHD. High Inattention and Hyperactivity/
Impulsivity symptoms were not associated with MetSyn. 
Conclusion: This study did not confirm that MetSyn and obesity-related parameters are 
increased in comorbid ADHD. 
Key words: ADHD, metabolic syndrome, depression, anxiety
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2. INTRODUCTION
ADHD has major public health significance, due to its multinational prevalence of 3.4% to 
4.4%, and associated educational, psychological and social impairment [1, 2]. Metabolic 
syndrome (MetSyn) is a combination of risk factors for cardiovascular disease and diabetes, 
which include obesity [3]. The criteria are at least three of the following conditions: abdominal 
obesity, raised levels of triglycerides and fasting glucose, low high-density lipoprotein (HDL) 
cholesterol and hypertension [3]. The prevalence of MetSyn has been increasing [4], and it 
presents a significant public health challenge. 
While there is theoretical discussion of a possible link between ADHD and MetSyn [5], to our 
knowledge, the relationship between these two disorders has not been clearly investigated. 
One study found that adults with ADHD have a higher risk of body mass index (BMI) > 25, 
high low-density lipoprotein, and diastolic blood pressure > 90 mmHg [6]. We now outline an 
etiological model where comorbid ADHD is linked to an increased risk for MetSyn because 
of four groups of associated symptoms: psychiatric and somatic comorbidities, core ADHD 
symptoms and sleep disturbance. 
With regard to psychiatric comorbidity, ADHD co-exists with depressive and anxiety disorders 
in 18% to 23% of cases [2, 7]. The most common comorbid psychiatric disorders in adult 
ADHD are anxiety (47%), and depressive disorders (38% [2]. In turn, affective disorders have 
also been associated with ADHD symptoms [8], higher BMI and obesity [9 - 11] and MetSyn 
[12]. Results are not uniform [13]. In practice, clinicians frequently treat ADHD in the presence 
of psychiatric comorbidities. The difficulty of studying the relationship between ADHD and 
MetSyn is that affective disorders may add to the risk of developing MetSyn.
Concerning somatic comorbidities, there are indications that a diagnosis of adult ADHD may 
increase the likelihood of developing chronic diseases [14, 15]. ADHD has been linked to an 
increased prevalence of smoking, which may partly account for this increased risk [16]. Despite 
the paucity of research on MetSyn and ADHD, the relationship between obesity and ADHD 
has been investigated [17 - 19]. Overall, the risk of obesity in ADHD for children and adults 
appears to be elevated, according to a recently published meta-analysis, which did control for 
comorbid affective disorders [20]. In children results vary with age, sex and medication status 
[21 - 26]. Some studies found increased BMI for ADHD children [21, 23, 24, 26 - 28]. From 
the literature and as reviewed by Cortese and Vincenzi [29] some studies did not account for 
comorbidities, lacked an ADHD diagnosis or controls [22, 24, 29 - 31]. Other studies have not 
found this relationship [29, 32 - 37]. Childhood psychopathology (including ADHD) has been 
associated with increased adult BMI [17, 38, 39] and obesity [40]. But some studies did not 
examine affective disorders as possible confounders [29]. 
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In adults, most studies do show a significant relationship between ADHD and obesity [17, 19, 
41 - 47], as well as overweight status [15]. Some of these studies controlled for the possible 
confounder of affective disorders, [17, 19, 42 - 46], but others did not [15, 41]. Adults with 
extreme obesity and remitted affective disorders, had a higher prevalence of ADHD [41]. 
ADHD was also more prevalent in obese women [47], and bariatric surgery patients, compared 
to the general population [42]. Impaired attention in obese participants has recently been 
linked to low-grade inflammation [48]. In contrast to studies confirming these associations, 
an epidemiological study by [49] did not show a significant relationship between persistent, 
lifetime, or remitted ADHD and obesity (N = 34,653) after controlling for affective disorders.
ADHD core symptoms may partly explain the relationship between adult ADHD and obesity, 
a component of MetSyn. These core symptoms include poor planning, impulsivity and delay 
aversion, which may influence food choices, resulting in a raised BMI [41, 50]. Unhealthy diet 
and shorter intervals between meals may be associated with MetSyn [51]. Eating at night has 
been associated with ADHD [52] and increased BMI [53]. 
Finally, sleep disturbances may also link ADHD and MetSyn and form part of the etiological 
model. They include late chronotype, delayed sleep-onset and shorter total sleep duration [54, 
55]. Sleep disturbances have been linked to increased BMI with and without ADHD [15, 56]. 
In short, according to this etiological model, ADHD is associated with a combination of 
factors, which may all increase the risk for MetSyn. The present study is the first to examine 
the potential association between MetSyn, obesity-related outcomes and clinical comorbid 
ADHD symptoms, in a large sample with different stages of affective disorders. Our hypothesis 
is that according to our etiological model, adult ADHD adds to the risk for MetSyn, beyond the 
frequently associated affective disorders. 
3. METHOD 
3.1  PARTICIPANTS
Participants took part in the Netherlands Study of Depression and Anxiety (NESDA), an 
8-year longitudinal, naturalistic cohort study of 2,981 participants, aged 18 to 65 years 
[57]. Participants were recruited from different health care settings (community, primary and 
specialized mental health care) and included a group without psychiatric symptoms (“Controls”) 
and others in different developmental stages of affective disorders. A full description of NESDA 
has been reported elsewhere [57]. Ethical Review Boards of all participating centers approved 
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the NESDA study protocol. All participants gave written informed consent at enrollment. Our 
sample comprised 2,307 respondents, in whom ADHD symptoms were checked at the 4-year 
follow-up after baseline (77.4% of total sample). 
3.2 MATERIALS
3.2.1 CONNORS ADULT ADHD ADULT RATING SCALE (CAARS)
To identify those respondents with clinical ADHD symptoms, the CAARS-Self Report: Screening 
Version (CAARS-S:SV) was used at the 4-year follow-up assessment of NESDA. As ADHD is a 
lifelong condition starting in childhood [58], we believed it was acceptable to use data from the 
4-year follow-up assessment for ADHD, and baseline data for other parameters. The CAARS-
S:SV is a 30-item questionnaire that assesses ADHD symptoms and behaviors. The 18-item 
Total symptom scale identifies Diagnostic and Statistical Manual of Mental Disorders criteria 
for ADHD (Inattention [IA] and Hyperactivity/Impulsivity symptoms [H/I]; range of possible 
scores = 0 - 54, [59]). The 12-item ADHD Index scale identifies ADHD behaviors (range of 
possible scores = 0 - 36). The CAARS-S:SV uses a 4-point Likert-scale rating current behavior 
and problems. Ratings range from 0 (not at all, never) to 3 (very much, very frequently). Several 
studies have confirmed the validity and reliability of the CAARS-S:SV [60]. For this study, the 
raw CAARS-S:SV scores were converted into standardized scores (T-scores) using age- and 
sex-corrected norm values [61]. The ADHD group was defined as those participants obtaining a 
T-score value of 65 or above (on either the Total symptom or Index scales), indicating clinically 
significant ADHD symptoms. For the analysis, we also identified a group of participants with 
a T-score of > 70 (above 98th centile) on these two scales. We calculated the CAARS-S:SV 
sum score (range = 0 - 90) by combining the Index with the Total score, permitting us to assess 
ADHD symptoms comprehensively (diagnostic criteria and behaviors). Finally, to determine 
specific risks of ADHD symptom domains, we analyzed high IA (cutoff T > 65; n = 165; 7.2%) 
and high H/I symptoms (cutoff T > 65; n = 81; 3.5%).
We chose to study only those ADHD subjects with comorbid affective disorders to estimate 
more accurately any added risk of ADHD for MetSyn. Of the 2,307 persons with CAARS-S:SV 
data, only four participants (< 1%) had ADHD without comorbid affective disorders, and these 
were excluded from the analysis as this group was too small to yield meaningful results. The 
total number used in the analyses was therefore 2,303 (77.3% of baseline sample). Two or 
fewer items were missing on either the Index or Total score for 108 participants (4.6%).  Here, 
values were imputed using simple imputation.
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3.2.2 COMPOSITE INTERNATIONAL DIAGNOSTIC INTERVIEW (CIDI-2.1)
Depressive disorder (major depressive disorder and dysthymia) and anxiety disorders (panic 
disorder, social phobia, agoraphobia or generalized anxiety disorder) were assessed at the 
baseline visit using the DSM-IV CIDI-2.1 by trained research staff [62]. The reliability and 
validity of the CIDI are high: Inter-rater agreements for all diagnoses are excellent [63] and 
test-retest reliability is also satisfactory [63]. We used lifetime diagnoses of affective disorders.
3.2.3 METSYN AND OBESITY-RELATED OUTCOMES
MetSyn was defined at baseline following the widely used adjusted Adult Treatment Panel 
III criteria [3]. MetSyn was considered present if three or more criteria were met: (a) waist 
circumference > 102 cm (men); > 88 cm (women); (b) triglycerides ≥ 1.7 mmol/l  or use of 
medication for hypertriglyceridemia; (c) HDL cholesterol < 1.03 mmol/l (men); < 1.30 mmol/l 
in women, or use of medication for reduced HDL cholesterol; (d) blood pressure ≥ 130/85 
mmHg, or use of antihypertensive medication; and (e) fasting plasma glucose ≥ 5.6 mmol/l, 
or use of anti-diabetic medication. Waist circumference was measured with a tape midway 
between the lower rib margin and the iliac crest over light clothing. Fasting triglycerides, HDL 
and glucose levels were determined using standard laboratory method. Blood pressure was 
defined as the average of two successive Omron monitor readings on the right arm, in a supine 
position. In addition, we also looked separately at the MetSyn count (number of MetSyn risk 
factors). BMI and waist-hip ratio (ratio of waist to hip circumferences) were used as measures 
of obesity-related outcomes. 
3.2.4 COVARIABLES 
Sociodemographic variables included age, sex and years of education. Potential confounders 
associated with ADHD, affective disorders, and MetSyn were also included. Lifestyle and 
health covariables included smoking (nonsmoker/current smoker [16], alcohol use (number 
of alcohol consumptions/week: Alcohol Use Disorders Identification Test [64], and physical 
activity, as assessed using the valid and reliable International Physical Activity Questionnaire 
(IPAQ, [65]). The IPAQ is a 7-item self-reporting questionnaire, which measures time spent 
on physical activity during the previous week. The overall energy expenditure estimate is 
expressed in Metabolic Equivalent Total (MET)-minutes per week. We assessed the number 
of self-reported chronic diseases diagnosed and under treatment, as determined during a 21-
item, face-to-face interview.
The use of psychotropic, lipid altering, antihypertensive, or anti-diabetic medications in the 
previous month, was recorded after drug container inspection and coded according the WHO 
Anatomical Therapeutic Chemical (ATC) classification [66]. Antidepressants included selective 
serotonin reuptake inhibitors (SSRI; ATC code: N06AB), serotonin-norepinephrine reuptake 
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inhibitors (SNRI; N06AX16, N06AX21), tricyclics (N06AA) and tetracyclics (N06AX03, 
N06AX05, N06AX11). All anxiolytics identified were benzodiazepines (N03AE). Centrally 
acting psychostimulants (N06BA) were also identified. The use of any of these medications was 
rated positive if the participant had used it on at least 50% of days during the past month. We 
defined a variable termed other psychotropic medications because of their potential impact 
on MetSyn. This group included: corticosteroids (H02, R03BA, R03AK, D07), antiepileptics 
(carboxamide and fatty acid derivates; N03AF, N03AG), anticholinergics (A03AA, A03AB) 
and antipsychotics (N05A).
3.3 STATISTICAL ANALYSES
Means and standard deviations for continuous data, and frequencies and percentages for 
categorical data, were reported. Between-group comparisons (controls, depressive and 
anxiety disorders without ADHD: D/A - ADHD; depressive and anxiety disorders with ADHD: 
D/A + ADHD) were made using Chi-square and analysis of variance (ANOVA) tests. Linear 
regressions were performed for all continuous outcome measures, with a log-transformation 
for triglycerides because of extreme skewness. In the logistic regression, presence of MetSyn 
was the outcome variable. The ADHD predictor variables used in analyses were ADHD 
(yes/no), high IA (yes/no), high H/I symptoms (yes/no), and the continuous CAARS-S:SV 
sum score. All regression models were analyzed in a univariable regression model (Model 
1), then adjusted for covariables age, sex and education (Model 2), additionally adjusted 
for depressive/anxiety disorders (Model 3), and finally adjusted for lifestyle and health 
covariables (smoking, exercise, number of chronic diseases and use of antidepressants, Model 
4). Data were analyzed using SPSS for Windows (version 16; IBM Company, Chicago, Illinois, 
USA). Statistical significance was inferred at p ≤ .05.
4. RESULTS 
General characteristics of the three groups are described in Table 1. The groups (controls, n = 
554; D/A - ADHD, n = 1,566) differed significantly in their numbers of women. Participants 
in the D/A + ADHD group (n = 183) were both significantly older, and had fewer years of 
education than in the other two groups. The D/A + ADHD group contained significantly more 
current smokers than controls. They also exercised significantly less and had three or more 
self-reported chronic diseases significantly more often than members of the two other groups. 
Apart from SSRI use, few used psychotropic drugs. While we identified 183 participants with 
clinical comorbid ADHD symptoms (T score > 65 on CAARS-S:SV scale), only three were using 
stimulant medication. 
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TABLE 1. General characteristics of the Netherlands Study of Depression and Anxiety subgroups: 











Value (df) P value
Sociodemographics
Females, n (%) 335 (61) 1,070 (68) 122 (67) Χ²(2)=11.32 .003a
Age in years at baseline, mean (SD) 41.0 (14.6) 42.3 (12.7) 44.9 (11.6) F(2,2300)=6.21 .002b,c
Years of education, mean (SD) 12.9 (3.2) 12.3 (3.2) 11.4 (3.1) F(2,2300)= 16.61 <.001b,c
Lifestyle and health
Current smoker, n  (%) 146 (26) 594 (38) 68 (37) Χ²(2)=24.46 <.001b
Number of alcoholic drinks per 
week, mean (SD)
7.51 (9.41) 6.88 (10.22) 6.80 (9.85) F(2,2279)=1.02 .362
Physical activity: MET-minutes per 
week (x1000), median  
(Inter Quartile Range)
3.08 (3.71) 2.83 (3.73) 2.35 (2.99) Kruskal-
Wallis(2)=9.42
.009b,c
Number of self-reported chronic 
diseases
Χ²(2)=50.09 <.001b,c
- None, n  (%) 315 (57) 701 (45) 55 (30)
- 1 or 2, n  (%) 214 (39) 724 (46) 107 (59)
- 3 or more, n  (%) 25 (5) 141 (9) 21 (12)
Use of psychotropics 
- Tricyclic antidepressants, n  (%) 1 (0.2) 47 (3) 6 (3) Χ²(2)=14.99 <.001b
- SSRI, n  (%) 4 (0.7) 320 (21) 48 (27) Χ²(2)=133.14 <.001b
- SNRI, n  (%) 0 (0) 73 (5) 16 (9) Χ²(2)=36.67 <.001b
- Tetracyclics, n  (%) 0 (0) 34 (2) 3 (2) Χ²(2)=12.20 .002b,c
- Benzodiazepines, n  (%) 1 (0) 87 (6) 18 (10) Χ²(2)=39.33 <.001a
- Psychostimulants, n  (%) 0 (0) 3 (0) 5 (3) Χ²(2)=33.10 <.001a
- Othersd, n  (%) 0 (0) 24 (2) 7 (4) Χ²(2)=16.44 <.001a
Note. MET = Metabolic Equivalent Total
a indicates significant difference between Controls and D/A - ADHD
b indicates significant difference between D/A + ADHD and Controls 
c indicates significant difference between D/A + ADHD and D/A – ADHD
d Other psychotropics include: corticosteroids, antiepileptics, anticholinergics and antipsychotics.
 
Table 2 shows the differences for metabolic parameters between the three subgroups. 
Triglyceride levels and waist-hip ratios were significantly higher in the D/A + ADHD group 
compared with the other groups. Participants in the D/A + ADHD group had significantly higher 
mean BMI compared to controls, although the increase was slight. This finding concurred with 
expectations from our etiological model. None of the other metabolic parameters showed 
significant group differences. 
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Table 3 shows the logistic regression for the association between the dichotomous MetSyn 
variable and ADHD measures. None of the four regression models showed significant findings: 
Lifestyle and health factors were therefore not reported in this Table. Neither the presence of 
clinical ADHD symptoms nor the ADHD symptom domains were associated with an increased 
risk for MetSyn. This contradicted our etiological model.
Greater waist circumference, triglyceride levels, BMI and waist-hip ratios were significant in the 
high IA group, with the univariable Model 1 (Table 4). However, these findings disappeared 
in the multivariable Models 2 and 3, when adjusted for age, sex, education, depressive, and 
anxiety disorders. Triglyceride levels and waist-hip ratios were also significantly higher in the 
dichotomous ADHD group, but only with the univariable model.
TABLE 2. Parameters of MetSyn, BMI, WHR and MetSyn Count in NESDA Subgroups: Controls, 
Depressive/Anxiety Disorders No ADHD, Depressive/Anxiety Disorders With ADHD, (n = 2,269)
Controls
n = 548
D/A -  
ADHD
n = 1,541




Value (df) P value
Metabolic syndrome,  
n (%)
104 (19) 306 (20) 43 (24) Χ²(2)=2.08 .384
Metabolic syndrome components: 
- Waist circumference,  
mean (SD)
87.98 (13.60) 88.86 (14.18) 90.47 (16.51) F(2,2300)=2.20 .111
- Triglycerides,  
mean (SD)a
0.03 (0.23) 0.04 (0.22) 0.09 (0.22) F(2,2258)=4.45 .012b,c
- HDL cholesterol,  
mean (SD)
1.64 (0.43) 1.64 (0.43) 1.65 (0.46) F(2,2250)= 0.04 .963
- Systolic blood pressure,  
mean (SD)
136.87(20.96) 135.39 (21.24) 134.47 (25.63) F(2,2300)= 1.27 .282
- Diastolic blood pressure,  
mean (SD)
80.57 (11.88) 81.32 (11.83) 81.43 (14.54) F(2,2300)=0.83 .437
- Fasting plasma glucose,  
mean (SD)
5.14 (0.87) 5.18 (1,00) 5.20 (0.96) F(2,2254)=0.53 .587
BMI,  
mean (SD)
25.05 (4.65) 25.57 (4.99) 26.08 (5.00) F(2,2300)=4.15 .016b
Waist Hip Ratio (WHR), 
mean (SD)
0.85 (0.08) 0.85 (0.08) 0.87 (0.09) F(2,2298)=3.26 .039b,c
MetSyn count,  
mean (SD)
1.40 (1.24) 1.42 (1.28) 1.57 (1.34) F(2,2266)=1.27 .280
Note. NESDA = Netherlands Study of Depression and Anxiety; BMI = body mass index; WHR = waist-hip ratio; HDL 
= high-density lipoprotein; MetSyn = metabolic syndrome.
a Logarithmically transformed triglyceride level 
b. Indicates significant difference between Controls and ADHD + D/A
c Indicates significant difference between ADHD + D/A and D/A
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In contrast, triglyceride levels were significantly lower in the high H/I group (multivariable 
models only). Several definitions of more severe ADHD symptoms were associated with a 
statistically significantly lower systolic blood pressure (dichotomous ADHD group: Models 2 
and 3, ADHD sum score group: all three models). Similarly, lower diastolic blood pressure 
was significantly associated with high H/I and sum score groups (multivariable Models). 
There were no other significant relationships observed and hence no increased risk for MetSyn 
was found in the comorbid ADHD group. Overall, considering the number of associations 
tested, only a few significant associations emerged, which would not survive multiple testing 
correction. Adjustment for lifestyle and health factors did not change any of the findings and 
was therefore not reported.  
TABLE 3. Logistic Regression for Presence of MetSyn (adjusted Adult Treatment Panel III Criteria) With 
Different ADHD Measures (n = 2,303) 
Metabolic Syndrome
Model 1a Model 2b Model 3c
OR (95% C.I.) p value OR (95% C.I.) p value OR (95% C.I.) p value
ADHD dichotomous 1.32 (0.90-1.92) .153 1.04 (0.70-1.55) .836 1.05 (0.70-1.57) .810
High IA 1.30 (0.85-1.98) .223 1.08 (0.69-1.69) .732 1.09 (0.69-1.70) .721
High H/I 1.03 (0.55-1.91) .936 0.85 (0.44-1.64) .633 0.85 (0.44-1.65) .637
ADHD Sum score 1.00 (0.99-1.01) .649 1.00 (0.99-1.01) .686 1.00 (0.99-1.01) .716
Note. MetSyn = metabolic syndrome; OR = odds ratio; 95% CI = 95% confidence intervals;  IA: high Inattention 
symptoms; H/I: high Hyperactivity/Impulsivity symptoms.
a Model 1: unadjusted  
b Model 2: Model 1 plus adjusted for age, sex, education 
c  Model 3: Model 2 plus adjusted for lifetime Depressive/Anxiety disorder
A previous NESDA article showed that tricyclic antidepressant use increased the odds for 
MetSyn, independent of depression severity [11]. We therefore added the frequent use of 
tricyclics as a covariate to all multivariable regressions. However, this did not change the 
relationships between ADHD and any of the MetSyn parameters. The MetSyn outcome was 
found to be independent of the lifestyle and health factors included in Model 4. To investigate 
if the severity of ADHD symptoms was linked to MetSyn, we conducted an analysis using 
a higher cut-off for CAARS-S:SV T score > 70 (> 98th percentile [61]). There were only 41 
participants in this group (1.8%), and no significant relationships with MetSyn were found. 
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TABLE 4. Linear regressions for MetSyn count and obesity-related outcomes with different ADHD 
measures (N=2303)
Model 1a Model 2b Model 3c
β p β p β p
MetSyn count ADHD dichotomous 0.15 .120 -0.02 .834 -0.01 .892
High IA 0.21 .058 0.04 .670 0.05 .634
High H/I -0.09 .544 -0.22 .118 -0.21 .123
ADHD Sum score 0.00 .764 -0.00 .255 -0.00 .300
Waist 
circumference
ADHD dichotomous 1.84 .093 0.18 .853 -0.03 .978
High IA 3.54 .004 1.39 .197 1.21 .265
High H/I -0.10 .952 -1.41 .351 -1.49 .326
ADHD Sum score 0.02 .475 -0.01 .528 -0.03 .238
Triglycerides ADHD dichotomous 0.05 .005 0.03 .083 0.03 .117
High IA 0.06 .004 0.03 .078 0.03 .109
High H/I -0.04 .167 -0.05 .037 -0.05 .033
ADHD Sum score 0.00 .186 0.00 .692 -0.00 .991
HDL ADHD dichotomous 0.01 .783 0.02 .613 0.02 .508
High IA -0.05 .187 -0.02 .589 -0.01 .690
High H/I 0.06 .280 0.09 .077 0.09 .070
ADHD Sum score 0.00 .859 0.00 .328 0.00 .163
SBP ADHD dichotomous -1.31 .432 -3.68 .012 -3.27 .027
High IA 1.29 .489 -1.75 .286 -1.34 .417
High H/I -1.58 .548 -3.02 .190 -2.84 .217
ADHD Sum score -0.11 .003 -0.14 .000 -0.13 .000
DBP ADHD dichotomous 0.31 .742 -0.96 .265 -1.06 .221
High IA 1.54 .145 0.18 .848 0.09 .930
High H/I -2.12 .152 -2.76 .041 -2.80 .038
ADHD Sum score -0.03 .121 -0.05 .017 -0.06 .005
Glucose ADHD dichotomous 0.03 .733 -0.06 .397 -0.07 .341
High IA 0.08 .313 -0.02 .849 -0.02 .782
High H/I -0.00 .983 -0.05 .668 -0.05 .649
ADHD Sum score 0.00 .925 -0.00 .482 -0.00 .332
BMI ADHD dichotomous 0.69 .074 0.12 .743 0.04 .915
High IA 0.93 .031 0.50 .230 0.42 .308
High H/I -0.03 .957 -0.48 .411 -0.51 .382
ADHD Sum score 0.01 .583 -0.01 .456 -0.01 .186
WHR ADHD dichotomous 0.02 .012 0.01 .170 0.01 .236
High IA 0.02 .001 0.01 .132 0.01 .174
High H/I 0.01 .294 0.00 .698 0.00 .730
ADHD Sum score 0.00 .102 0.00 .616 0.00 .957
a Model 1: unadjusted  
b Model 2: Model 1 plus adjusted for age, sex, education 
c  Model 3: Model 2 plus adjusted for lifetime Depressive/Anxiety disorders
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5. DISCUSSION 
We believe this is the first report which analyzes the association between all five MetSyn 
risk factors and adult ADHD comorbid with affective disorders. In this large-scale study, we 
investigated the relationship between comorbid ADHD symptoms, MetSyn and obesity-related 
parameters. According to our etiological model, we expected an increased risk of MetSyn 
among comorbid ADHD patients, but after adjusting for potential confounders, we did not find 
this. 
We used several different definitions for ADHD. In contrast to previous studies, our wide range of 
comprehensive analyses and models showed few clear associations between MetSyn, obesity-
related outcomes and clinical comorbid ADHD symptoms. We did find some significant, yet 
unexpected, associations. These were the significant relationships between lower triglyceride 
levels and hyperactivity symptoms; and lower blood pressure in the comorbid ADHD  group, 
which persisted when we adjusted for sociodemographic factors, affective disorders and 
health/lifestyle covariables. There were no other significant associations in the adjusted 
models. Contrary to our expectations, lower triglyceride levels were associated with high H/I 
symptoms in the multivariable models. This finding contradicts results from three other studies 
in which raised plasma lipids in adult ADHD patients were found [6, 67, 68]. However, two 
of these studies were small, with n = 15 and n = 72, respectively [67, 68]. Ours may well have 
been a chance finding. Another surprising finding was the negative association between blood 
pressure and comorbid ADHD. There is little research on associations between blood pressure 
and ADHD. Available data deal with blood pressure changes in controlled medication studies, 
which may exclude patients with hypertension risk [69]. Some studies found an association 
between depression, anxiety and lower blood pressure [70, 71] in participants using 
antidepressants but without controlling for ADHD [72]. Our finding may indicate the presence 
of decreased blood pressure in comorbid ADHD, which again contradicts the proposed 
etiological model linking ADHD to MetSyn.
In terms of the ADHD domains, we found high IA symptoms to be significantly associated 
with several obesity-related outcomes, (univariable model only). The two large studies which 
examined obesity and ADHD also distinguished between symptom domains in ADHD, with 
varying results [46, 49]. In the first, a population-based study (n = 15,197), a linear association 
was found between the number of IA and H/I symptoms and waist circumference, BMI, and 
blood pressure [46]. However, in the epidemiological study  where ADHD symptom domains 
were analyzed separately, no association was found between the number of Hyperactivity 
symptoms and obesity, after adjustment [49]. This concurs with our findings. 
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Possible biological mechanisms associating ADHD and obesity may relate to core ADHD 
symptoms such as poor planning, influencing diet and resulting in a raised BMI [41, 50]. Other 
mechanisms deserving further exploration include the intrauterine environment. Low birth weight 
(LBW) is associated with ADHD [73] and adult obesity [74]. Animal studies propose that LBW 
offspring are “programmed” to eat more because of reduced hypothalamic satiety pathways 
[75]. Obesity is considered a low-grade inflammatory disorder [76]. Genome-wide analysis 
of ADHD implicates genes involved in inflammation, and this may be another mechanism 
linking the two disorders. In our study, we failed to find obesity in the comorbid ADHD group, 
even though we analyzed waist circumference, BMI, and high-risk waist-hip ratio separately, 
using well-validated diagnostic methods. The studies where BMI is associated with ADHD may 
have methodological problems, including the reliance on self-reporting for measurements [19, 
45, 49, 53]. In contrast, we measured height, weight and waist circumference  objectively in 
accordance with published guidelines [77]. Raised BMI per se, as opposed to abdominal 
obesity, may not increase MetSyn risk as BMI cannot distinguish between lean mass and 
adipose tissue. Waist circumference and waist-hip ratio may give a better indication of visceral 
fat, the main factor in cardio-metabolic risk [78]. 
It is possible that associations between the risk factors for MetSyn and comorbid ADHD 
in adults are very difficult to detect and therefore we failed to find them, despite our large 
sample. The presence of comorbid affective disorders in the ADHD group may have obscured 
any increased risk of MetSyn. In addition, the risk of MetSyn increases with age [79]. In the 
comorbid ADHD group, the average age was 45 years, so it was unexpected that we found 
no correlation. The negative outcome of this study may also be related to the concept and 
definition of MetSyn, which have been questioned [80]. While cardiovascular risk factors are 
prone to cluster, they may not share unifying pathophysiological pathways. It is possible that 
not all MetSyn risk factors contribute significantly to cardiovascular diseases and diabetes, 
whether for the general population [81] or those with affective disorders and ADHD. Some 
researchers have postulated that of the five MetSyn risk factors, abdominal obesity and insulin 
resistance are major culprits [82]. Previously, an increased prevalence of dyslipidemia and 
abdominal obesity only was reported in patients with affective disorders [83]. Hence, the 
relative importance of each of the five MetSyn risk factors is still uncertain. We examined all 
MetSyn risk factors both separately and together, in order to clarify the relative contribution 
of each, yet we still failed to find an increased risk for MetSyn in the comorbid ADHD group. 
Similar to our results, the epidemiological study by Cortese, Faraone et al. (2013) also failed 
to find a significant association between ADHD and obesity in adults after adjustment for 
depression and anxiety. 
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Our study, in combination with previous work, has several clinical implications. Clinicians 
frequently encounter ADHD comorbid with affective disorders, so where ADHD is being 
treated, there should be screening for affective disorders and obesity [84]. Co-existing 
disorders should be managed in a step-wise fashion. Affective disorders should be treated 
before ADHD [85]. Patients should be informed of the potential risks of developing obesity 
and MetSyn. However, these patients may struggle to adhere to preventive measures. Hence, 
clinicians should structure and target treatment with an emphasis on good sleep hygiene, 
balanced diet, and exercise. 
Our study also has implications for future research. First, it is currently unknown whether treating 
co-existing affective disorders will lessen the risk for MetSyn in those with adult ADHD; this 
should be researched. Second, the etiological model associating ADHD with MetSyn may 
need to be modified. Future studies should investigate whether a “pure” ADHD group increases 
risk for MetSyn, as comorbid affective disorders may mask the association between ADHD and 
MetSyn. However, these patients are difficult to find. Ideally, it would be advisable to study 
MetSyn in a large ADHD cohort, with and without comorbidity. Third, ADHD may increase 
the risk for obesity, but not for MetSyn as a whole. The concept of MetSyn and its possible 
association with ADHD needs to be carefully reappraised. MetSyn is a constellation of different 
risk factors for cardiovascular disease and diabetes. ADHD may have a different impact on 
each factor and these should be individually studied. 
Our study has several limitations. The cross-sectional design did not allow us to make causal 
inferences on the relationship between ADHD and MetSyn. As we included only those with 
ADHD and comorbid affective disorders, our results cannot be generalized to all populations. 
However, clinicians rarely encounter patients with “pure” ADHD, and the inclusion of the 
comorbid ADHD group could also be seen as a study strength. In addition, completing the 
CAARS-S:SV depends on retrospective self-reporting, as ADHD starts in childhood. This may 
have introduced recall bias, leading to under reporting [86]. Yet, the validity of retrospective 
ADHD symptom self-reporting was shown to be reliable [60]. Finally, while the CAARS-S:SV 
identified those with clinical symptoms of ADHD, a diagnosis of ADHD had not been made. 
We were not able to collect collateral information, and only three people were treated with 
a psychostimulant. Despite these considerations, our study extends the literature exploring 
relationships between comorbid ADHD and MetSyn.
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6. CONCLUSION 
ADHD is a complex disorder with frequent psychiatric comorbidity. In our large sample of 
persons, with and without affective disorders, comorbid adult ADHD did not predispose to 
MetSyn. ADHD symptoms were examined comprehensively including severity and the domains 
of IA and H/I. Obesity-related parameters such as raised BMI, high waist-hip ratio and 
increased Waist Circumference, were also not associated with comorbid ADHD. Hence, those 
with comorbid ADHD do not appear to have an added risk for MetSyn and its complications, 
beyond that conferred by affective disorders. 
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1. ABSTRACT 
Study objectives: We evaluated the relationship between leukocyte telomere length (LTL) 
and sleep duration, insomnia symptoms, and circadian rhythm, to test whether sleep and 
chronobiological dysregulations are associated with cellular aging.
Methods: Data from the Netherlands Study of Depression and Anxiety cohort (N = 2,936) 
were used at two waves six years apart, to measure LTL. Telomeres protect DNA, shorten during 
the lifespan and are important biomarkers for cellular aging. LTL was assessed by qualitative 
polymerase chain reaction and converted into number of base pairs. Sleep parameters were 
sleep duration and insomnia symptoms from the Insomnia Rating Scale. Circadian rhythm 
variables were: an indication of the Delayed Sleep Phase Syndrome (DSPS), mid-sleep 
corrected for sleep debt on free days (MSFsc), sleep-onset time, and self-reported chronotype 
in adulthood and childhood, from the Munich Chronotype Questionnaire. Generalized 
estimating equation models were used to examine the associations between LTL, sleep and 
chronobiological factors.
Results: Indicators of delayed circadian rhythm showed a strong and consistent effect on 
LTL, after adjustment for sociodemographic and health indicators. Late MSFsc (B = -48.5, p 
=.005), late sleep-onset time (B = -32.0, p =.001), indication of DSPS (B = -71.8, p =.040) 
and moderately late chronotype in adulthood (B = -72.8, p =.002) were associated with 
significantly shorter LTL across both waves; whereas sleep duration and insomnia symptoms 
were not. Extremely early chronotype showed significantly longer mean LTL (B = 157.5, p 
=.042). No sleep or chronobiological predictors showed accelerated LTL attrition rate over 6 
years. 
Conclusions: Individuals with indicators of delayed circadian rhythm have significantly 
shorter LTL, but not faster LTL attrition rates.
Keywords: aging; leukocyte telomere length; delayed sleep phase; circadian rhythms; 
insomnia 
STATEMENT OF SIGNIFICANCE 
Late sleep-onset and insomnia symptoms are common. We studied the impact of sleep duration, 
insomnia symptoms, and circadian rhythm dysregulation on cellular aging by measuring 
leukocyte telomere length (LTL) in 2,936 adults, twice over 6 years. For the first time, we show 
an association between delayed circadian rhythm and shorter LTL. Persons with a late self-
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reported chronotype and indicators of delayed circadian rhythm had significantly shorter LTL 
(but not faster LTL attrition), after adjustment for sociodemographic and health indicators. Those 
with delayed circadian rhythm may thus be at risk for significant morbidity. Insomnia symptoms 
and sleep duration were not associated with shorter LTL. Extended longitudinal studies should 
focus on the lifetime risks associated with circadian rhythm disturbance and cellular aging.
2. INTRODUCTION 
Telomeres are stretches of DNA, situated at the ends of chromosomes, much like the plastic ends 
on shoelaces. Telomeres cap and protect chromosomes during successive cellular divisions [1], 
preventing end-to-end fusion, genomic instability and base pair loss of chromosomal DNA 
[2]. As humans age, telomeres shorten until they become too short for further cellular division, 
resulting in cellular senescence [3]. Critically short telomeres may also lead to carcinogenic 
transformation [4]. Leukocyte telomere length (LTL), expressed as number of base pairs, has 
been suggested as a potential biomarker for cellular aging [3]. Telomere length and rate of 
shortening with aging (attrition rate) vary enormously among individuals, and even between 
chromosomes [5, 6]. Genetic factors contribute to approximately 64 - 70% of the variability 
in LTL [7] and other factors believed to play a role are lifestyle and illness [3]. Cross-sectional 
studies have shown that shorter LTL is associated with older chronological age [5, 6, 8], male 
sex [9], non North European ancestry [10], lifestyle factors such as heavy alcohol use [11], less 
physical activity [10, 12],  psychiatric factors [13] including affective disorders, and somatic 
illnesses [3, 14, 15]. In terms of the telomere attrition rate, there appears to be a relationship 
between LTL attrition and chronological age: in the first year of life, telomere loss is very rapid 
[16]; it stabilizes from childhood to early adulthood; and begins to decrease in older adulthood 
[5, 8]. Baseline LTL appears to be an important determinant [10], as are male sex [17], greater 
age [8] and lifestyle factors such as cigarette smoking [12, 17] and less exercise [12]. Other 
determinants of accelerated LTL attrition include genetic heritability for cellular decline [7] and 
the presence of childhood trauma [10]. 
Adequate sleep is an essential requirement for health [18], yet exactly what constitutes 
adequate sleep duration varies within and between individuals [19]. The National Sleep 
Foundation, the American Academy of Sleep Medicine and the Sleep Research Society have 
issued a recommendation of 7 - 9 hours sleep per night for healthy adults aged 18 - 64 years, 
acknowledging variation in individual need [20], and emphasizing that sleeping less than this 
is associated with significant morbidity [19]. The research on LTL and sleep factors such as sleep 
duration, insomnia and obstructive sleep apnea, is scant and results are mixed. Short sleep 
duration has been associated with shorter LTL in older but not in middle-aged adults [21] or 
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middle-aged women [22], in women under 50 years [23] and in men [24]. Insomnia has also 
been associated with shorter LTL in people older than 70 years [25]. But long sleep duration 
(> 9 hours) has also been associated with shorter LTL [10, 23], hence the association between 
LTL and sleep duration appears to be non linear, with both shorter and longer sleep duration 
associated with shorter LTL. Obstructive sleep apnea syndrome and snoring are associated 
with shorter LTL [26, 27]. However, these sleep factors have not been examined in terms of LTL 
attrition over time. 
Linked to sleep duration are the disorders of the circadian rhythm. The association between 
circadian dysregulation and LTL has not been studied in humans. In animal models however, 
circadian desynchronization has already been shown to trigger premature cellular aging 
[28] and has been suggested as a mechanism underlying telomere activity control, linking 
the chronobiological systems to the aging process [29]. The circadian rhythm is set by the 
master biological clock, situated in the suprachiasmatic nuclei in the brain. One’s chronotype 
refers to the behavioral manifestation of underlying circadian rhythms, as evidenced by regular 
rising and sleep-onset times on free days (i.e. without daytime obligations) [30]. People can 
have early, intermediate, or late chronotype [31]. People with a late chronotype may have 
the persistent delayed sleep phase syndrome (DSPS), in which there is a chronic (> 3 months) 
pattern of delayed sleep-onset, difficulty getting to sleep at a desired earlier time, difficulty 
awaking in the morning, resulting in daytime sleepiness and impaired social and occupational 
functioning [32]. Where morning obligations exist, it may also result in chronic short sleep and 
sleep debt.  
Disturbed circadian rhythm may result in sleep and energy metabolism disturbance, 
cardiovascular disease [33] and increased carcinogenesis [34, 35]. On a cellular level, 
disturbed circadian rhythm affects the oscillatory behaviour of many blood metabolites, which 
fluctuate in accordance with the circadian rhythm [36]. We hypothesize that late sleep (indicating 
disturbed circadian rhythm) will be a significant predictor of both short LTL and accelerated LTL 
attrition. We investigated whether sleep duration, insomnia and chronobiological variables 
were related to LTL across two time points over a six-year time period, in a large cohort of 
adults participating in an epidemiological study on anxiety and depression.




Subjects participated in the Netherlands Study of Depression and Anxiety (NESDA), an 
ongoing longitudinal, naturalistic cohort study of 2,981 participants at wave 1, aged 18 - 
65 years. Participants were recruited from different health care settings (community, primary 
and specialized mental health care) and included a group without lifetime affective disorders 
(‘controls’) and others with current and remitted affective disorders. A full description of NESDA 
has been reported elsewhere [37]. Ethical Review Boards of all participating centers approved 
the NESDA study protocol and it was carried out in accordance with the latest Declaration of 
Helsinki. All participants gave written informed consent at enrolment after the study procedures 
had been fully explained. Measures in this study were taken from the baseline (wave 1), 2-year 
(wave 3) and 6-year (wave 5) follow-up assessments of NESDA, where the response rates 
were 87.1% at wave 3 (N = 2,596) and 75.7% (N = 2,256) at the wave 5. Our initial sample 
was 98.5% (N = 2,936) of the wave 1 group, which included those who had LTL measured and 
their sleep assessed. At wave 5, 1,883 participants had LTL measured (83.4% of the sample). 
Those who had LTL measurement at waves 1 and 5 were significantly: older, less likely to be 
current smokers, had more years of education, less severe anxiety and depression  symptoms, 
shorter baseline LTL, less short and long sleep duration, and fewer insomnia symptoms than 
those without wave 5 LTL measurement.   
3.2 SLEEP MEASURES
Sleep duration was measured at waves 1 and 5 as part of a self-report questionnaire where 
participants were asked to estimate the average number of hours of sleep during the past 4 
weeks. Answer options were: “10 or more hours”, “9 h”, “8 h”, “7 h”, “6 h”, “5 or less h.” In 
descriptive analyses, the single variable sleep duration was sub-categorized short (≤ 6 h per 
night), normal (7 - 9 h per night), and long (≥ 10 h per night). This classification was followed 
in previous NESDA studies [10, 38, 39]. Insomnia symptoms were measured at waves 1 and 
5 with the Women’s Health Initiative Insomnia Rating Scale (IRS) [40] which consists of five 
questions addressing sleep in the last 4 weeks (trouble falling asleep, waking up during the 
night, early morning awakening, difficulty getting back to sleep after waking up, and sleep 
quality). Answers are on a 4-point scale, with a sum score ranging from 0 to 20. The IRS has 
good test-retest reliability and has high convergent correlation with objective actigraphy sleep 
measures [41]. In our sample, the IRS showed good internal validity (Cronbach’s α = 0.83). In 
all analyses, IRS scores were dichotomized at the cut-off point of 9 or higher, which indicates 
clinically significant insomnia symptoms [40]. 
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3.3 CHRONOTYPE
Chronotype was assessed with the Munich Chronotype Questionnaire (MCTQ) [30] at wave 
3, which we deemed acceptable as chronotype is considered to be relatively stable over the 
lifespan [42]. The MCTQ is a self-report measure with questions on sleep timing on nights before 
work and free days, both in adulthood and ‘as a child’. Subjects rated their chronotype on a 
7-point Likert scale ranging from ‘extremely early’ to ‘extremely late’. Parameters of circadian 
rhythm used were the continuous measures sleep-onset time on nights before free days, and the 
time of mid -sleep on free days corrected for sleep debt during the work week (MSFsc) [30]. For 
self-reported chronotype in adulthood, we created a 5-category variable, where slightly early, 
normal and slightly late were grouped together, forming the middle, intermediate chronotype 
category. The other categories were extremely early, moderately early, moderately late and 
extremely late. We defined “indication for DSPS” as the combination of an inability to fall 
asleep before 12.30 a.m. on work days, and a sleep-onset latency of 30 minutes or more on 
work days or a self-rating of being an extremely late chronotype in childhood or adulthood, 
as reported on the MCTQ. 
3.4 LEUKOCY TE TELOMERE LENGTH
LTL was measured at waves 1 and 5. An extensive description of LTL assessment in our study 
has been reported before [43]. In summary, DNA was prepared from fasting blood samples 
drawn in the morning and stored in a −20◦C freezer. Subsequently, quantitative polymerase 
chain reaction (qPCR) was used to determine baseline and 6-year LT at the laboratories of 
Telomere Diagnostics (Menlo Park, Calif.) and the University of California, San Francisco, in 
2012 and 2014, respectively. The qPCR was adapted from the published original method by 
Cawthorn [44].  Telomere sequence copy number (T) in each patient’s sample was compared 
to a single-copy gene copy number (S), relative to a reference sample, where the resulting T/S 
ratio is proportional to mean LTL [45]. As previously described in our study [43], T/S ratios 
were converted into number of base pairs (bp) with the following formula: bp = 3274 + 2413 
× ((T/S − 0.0545)/1.16). The wave 5 T/S ratios were adjusted relative to the wave 1 samples 
for systematic differences caused by different reference samples, by rerunning and comparing 
samples from wave 1 sample plates (N = 226, up to eight samples from each of the wave 1 
plates), together with wave 5 samples. On average, the T/S ratios of the wave 5 follow-up 
runs were at 76% of the T/S ratios of wave 1; consequently, the follow-up T/S ratios were 
divided by 0.76. DNA samples were de-identified, and the laboratories that performed the 
assays were blind to all other measurements, and thus samples for case patients and control 
subjects were randomly distributed over the plates [46]. Of the entire NESDA cohort, 2,936 
subjects had LTL measurement at wave 1 and 1,883 at wave 5. Of these, 1,860 had complete 
LTL data at both time points. 
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3.5 COVARIATES
Sex, age, years of education and ancestry were determined at the wave 1 interview. Smoking 
status was categorized as current or not current smoker. Alcohol use was defined as number 
of alcohol consumptions/week. The majority of published studies have found statistically 
significant inverse associations between Body Mass Index (BMI) and LTL [47]. Observational 
and experimental sleep studies have related poor sleep quality and short sleep duration to 
obesity and shortened LTL [48, 49]. We based our choice of BMI as a proxy for lifestyle 
following other studies in the NESDA cohort [46, 50]. Measured BMI (calculated by mass 
divided by height2) was categorized as underweight (< 18.5), normal (18.5 – 24.9), overweight 
(25.0 – 30.0), and obese (> 30.0). The number of self-reported chronic diseases diagnosed 
and under treatment was determined with a 21-item, face-to-face interview. Physical activity 
was assessed with the International Physical Activity Questionnaire, expressed in Metabolic 
Equivalent Total (MET)-minutes per week.
We assessed depressive and anxiety disorders using the DSM-IV Composite International 
Diagnostic Interview (CIDI-2.1), administered by trained clinical research staff [51]. Affective 
disorders fell into three categories: no lifetime diagnosis; remitted (present during the lifetime 
history but not in the last year) and current (present in the last 6 months). Depressive and 
anxiety symptom severity were investigated using the Inventory of Depressive Symptomatology 
(IDS-SR) [52] and the Beck Anxiety Inventory (BAI) scales, [53] respectively. We excluded 
the four sleep-related items of the IDS-SR because of overlap with our predictor variables, 
resulting in a range of 0-72. The Cronbach α for this adjusted scale was 0.83 [54]. Results 
from this cohort showed that associations were similar for depressive and anxiety symptom 
severity. Due to multicollinearity we did not additionally correct for anxiety severity. We used 
the Childhood Trauma Interview (CTI), in which participants were asked whether they were 
emotionally neglected; psychologically, physically or sexually abused before the age of 16, 
as previously described [55]. The CTI reports the sum of the categories scored from 0 to 2 (0: 
never happened; 1: sometimes; 2: happened regularly); resulting in an index score between 0 
and 8, which was used as a continuous variable.
3.6 STATISTICAL ANALYSES
We reported general characteristics using means and standard deviations for continuous data, 
and frequencies and percentages for categorical data. Correlations between predictor variables 
were tested. The relationship between sociodemographic factors, lifestyle, depression, childhood 
trauma and LTL was tested using generalized estimating equations (GEE) with LTL as outcome 
variable. We used unstructured GEE analyses with an exchangeable correlation structure as 
these take within-person correlations into account when examining multiple observations per 
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participant [56]. We included all participants who had an LTL and a sleep/chronobiological 
assessment at least once, because GEE analyses tolerate missing observations. We performed 
two separate GEE analyses. The first examined the cross-sectional associations between LTL 
and sleep/chronobiological indicator using both waves of data. Wave was defined as the 
within subject variable defining the order of measurements, categorized as 1 (wave 1) and 2 
(wave 5). The second type of GEE analyses tested whether wave 1 measures of sleep duration 
and insomnia, as well as chronobiological measurements from wave 3, were associated with 
LTL change over time using both waves of data. Here, predictor-by-time interaction terms were 
added to both partially and fully adjusted models. Adding time interactions allowed us to 
investigate LTL attrition over 6 years. In all GEE analyses, we adjusted for age at baseline, 
sex and North European ancestry (partially adjusted), and additionally for current smoking, 
depression severity (both time-dependent) and childhood trauma index (fully adjusted), as 
these have previously been associated with longitudinal change in LTL in this cohort. To account 
for multiple testing, in all GEE analyses, the Benjamini-Hochberg false discovery rate was 
calculated for significant findings [57]. Data were analyzed using SPSS for Windows (version 
23.0); IBM Company, Chicago, IL, USA). Statistical significance was inferred at α = .05.
4. RESULTS 
4.1 DESCRIPTIVE ANALYSES
Table 1 shows the sample characteristics of the 2,936 subjects who had complete LTL 
measures at wave 1, those who had LTL measures at wave 5 (N = 1,883) and those who had 
chronobiological characteristics assessed at wave 3 (N = 2,561). LTL was 5,467 base pairs at 
wave 1 (SD = 617) and 5,386 base pairs at wave 5 (SD = 433), indicating a mean LTL attrition 
of 60 base pairs over the 6 years of the study (SD = 573). 
Table 2 shows correlations between the different sleep indicators. Late sleep-onset was 
significantly positively correlated with later MSFsc (r = 0.46; p <.001). Longer sleep duration 
was significantly and negatively correlated with later sleep-onset time on free days (r = -0.37; 
p <.001), meaning that longer sleepers tended to fall asleep earlier. Long sleep was also 
positively correlated with later MSFsc (r = 0.43, p <.001), indicating that midsleep is very much 
affected by sleep duration. Therefore, sleep-onset time may be a more important indicator 
of chronotype. There was also a moderate association between self-reported chronotype in 
adulthood and childhood (not shown, Spearman’s correlation coefficient = 0.47, p <.001), 
which corresponds to the description of chronotype as a lifelong trait [58].
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Value (df) P value
Demographics
Age, mean (SD) 41.8 (13.1) 48.6 (12.9) t=17.7 (4817) <.001
Years of education, mean (SD) 12.2 (3.3) 12.9 (3.3) 7.2 (4817) <.001
Sex, female % (n) 66.4 (1950) 65.4 (1232) χ²=0.50(1) .479
North European ancestry, % (n) 94.8 (2783) 96.0 (1807) χ²=3.50(1) .061
Lifestyle and health
Current smoker, % (n) 38.7 (1136) 28.1 (529) χ²=57.0(1) <.001
No. of alcoholic drinks per week, mean (SD) 7.0 (10.0) 6.2 (8.6) t=2.8 (4817) .004
Body Mass Index, mean (SD) 25.6 (5.1) 23.5 (9.5) t=9.95(4817) <.001
- Underweight, % (n) 64 (2.2) 29 (1.5)
- Normal, % (n) 1,489 (50.7) 802 (45.1)
- Overweight, % (n) 889 (30.3) 599 (33.4)
- Obese, % (n) 492 (16.8) 354 (19.8)
No. of chronic diseases under treatment,  
mean (SD)
0.61 (0.88) 0.60 (0.86) t=0.39(4817) .678
Physical Activity (in 1000 MET-minutes p/wk), 
mean (SD)a
3.7 (3.1) 4.0 (3.4) t=3.16(4817) .001
Psychiatric characteristics
IDSb mean (SD) 17.6 (14.3) 9.9 (17.4) t=16.7(4817) <.001
BAIc mean (SD) 11.9 (10.6) 7.9(8.7) t=13.7(4817) <.001
Depressive or Anxiety disorder, % (n): χ²=529.4(5) <.001
- No lifetime diagnosis 21.9 (644) 19.8 (388)
- Remitted 21.1 (620) 51.4 (967)
- Current (last 6 months) 56.9 (1672) 28.0 (528)
Childhood trauma index, mean (SD) 0.87 (1.12) Not measured
Leukocyte telomere length (LTL), mean (SD) 5467.8 (617.0) 5386.8 (433.2) t=4.97(4817) <.001
Sleep durationd χ²=10.2(5) .006
- Short sleep duration, % (n) 24.0 (535) 25.0 (452)
- Normal sleep duration, % (n) 70.1 (1441) 72.4 (1312)
- Long sleep duration, % (n) 3.5 (79) 2.6 (47)
Insomnia symptoms, % (n)   44.4 (1128) 38.2 (662) χ²=5.23(1) .022
Chronobiological characteristics wave 3 (N = 2,561)
Sleep-onset time, free days, mean (SD) 00:10 a.m. (1h 07 min)
Midsleep on free days (MSFsc), mean (SD)
e 03:47 a.m. (37 min)







Value (df) P value
Indication of Delayed Sleep Phase Syndrome, % (n) 7.9 (147)
Chronotype adult (self-reported)
- extremely early, % (n)   2.3 (50)
- moderately early, % (n)   18.0 (387)
- intermediate, % (n)   48.6 (1043)
- moderately late, % (n)   26.2 (562)
- extremely late, % (n)   4.9 (106)
Chronotype child (self-reported)
- extremely early, % (n)   3.5 (74)
- moderately early, % (n)   22.2 (473)
- intermediate, % (n)   57.5 (1222)
- moderately late, % (n)   14.1 (300)
- extremely late, % (n)   2.7 (57)
a. Metabolic Equivalent Total minutes (MET-minutes)
b. Inventory of Depressive Symptomatology (IDS) 
c. Beck Anxiety Inventory (BAI)
d. Self-rated sleep duration is one variable where duration of short sleep is 6 hours or less, normal sleep is 7-9 hours, 
long sleep is 10 hours or more on Insomnia Rating Scale 
e. MSFsc: Mid sleep on free days corrected for sleep debt on working days
4.2 CROSS-SECTIONAL ASSOCIATIONS WITH LTL
In Table 3, the GEE analyses show that LTL was significantly shorter in those with delayed 
circadian rhythm, in both the partially and fully adjusted models. Specifically, those with later 
MSFsc, later sleep-onset time or an indication of DSPS had significantly shorter LTL compared 
to those without these disturbances in both models (fully adjusted model: MSFsc B = -48.5, p = 
.005; sleep-onset time B = -32.0, p =.001; indication of DSPS B = -71.7, p =.040). Moderately 
late self-reported chronotype in adulthood was significantly associated with shorter LTL, 
compared to the reference of intermediate chronotype (B = -72.7, p =.002). In contrast, self-
reported extremely early chronotype (in adulthood) was associated with significantly longer 
LTL (fully adjusted model: B = 157.5, p =.042, Table 3). Accounting for multiple testing using 
the Benjamini-Hochberg false discovery rate did not affect any of the significant findings. In 
contrast, GEE analyses with sleep duration, insomnia symptoms and self-reported chronotype 
in childhood did not show a significant relationship with LTL in either model.
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In terms of the covariates age, sex, North European ancestry (not shown), in all GEE analyses, 
in both models, older age was consistently significant (p < .001). In all analyses in the fully 
adjusted model, significance of p < .05 was attained for female sex, except where self-
reported chronotype in childhood was the predictor. Similarly, in all analyses, North European 
ancestry showed significance of p < .05, except where sleep-onset time was the predictor. 
Current smoking (not shown) attained significance of p < .05 in analyses where sleep duration, 
insomnia symptoms and DSPS were the predictors. Childhood trauma and depression severity 
were not significant in any analyses.
4.2 LTL AT TRITION RATE OVER 6 YEARS
Associations between the wave 1 measures of sleep duration and insomnia, as well as 
chronobiological measurements from wave 3, and repeatedly measured LTL are shown in Table 
4, with group-by-time interaction terms. GEE analyses did not show any associations between 
sleep variables with LTL change over time. While LTL did shorten on average over the 6 years 
of the study, and time was significant throughout the GEE analyses, no substantial difference 
in slopes of LTL over time were shown for any predictor, indicated by the non-significant 
interaction terms. The overall picture emerging from these analyses is that chronobiological 
dysregulations are consistently associated with shorter LTL throughout the entire follow-up, and 
this relationship remains consistent over time. Figure 1 illustrates these results in four panels, 
in fully adjusted models. We plotted the estimated means from the GEE models of LTL at 
both time points according to different chronobiological predictors. For illustrative purposes, 
continuous predictors MSFsc and sleep-onset time were categorized into quintiles ranging from 
early to late. For MSFsc, there were no significant differences for any quintiles compared to 
the intermediate reference group. However, sleep-onset time in quintiles showed significant 
differences between the latest 2 quintiles and the intermediate reference quintile. An indication 
of DSPS at both time points showed significantly shorter mean LTL, in the fully adjusted model. 
From these results, it appears that the presence of DSPS accelerates cellular aging by 6 years. 
While moderately late chronotype showed significant significantly shorter means for LTL, 
extremely early chronotype shows significantly longer means for LTL (both compared to the 
intermediate chronotype, in adulthood). In the panel showing significant differences between 
mean LTL, the slopes are parallel, illustrating the finding that there was no difference in LTL 
attrition rate over time (see Table 4). In other words, wave 1 values of sleep duration and 
insomnia, and wave 3 measurement of chronobiological variables did not predict accelerated 
cellular aging.
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TABLE 4. Associations between sleep and chronobiological parameters with leukocyte telomere length 





B(SE) P value B(SE) P value
Sleepa
- Short sleep duration -50.61(28.76) .078 -39.86(29.15) .171
- Normal sleep duration reference reference 
- Long sleep duration -8.74(74.33) .906 2.49(75.53) .974
Time -64.25(15.13) <.001+ -70.52(15.38) <.001+
time*short sleep duration 34.45(28.60) .228 32.53(28.74) .258
time*normal sleep duration reference reference 
time*long sleep duration -64.00(70.19) .362 -72.14(72.51) .320
Insomnia symptomsb -39.30(26.12) .132 -29.24(27.24) .283
Time -72.94(16.39) <.001+ -78.70(16.56) <.001
time*insomnia 37.28(25.71) .147 34.93(25.98) .179
Chronobiologyc
Midsleep on free days  (MSFsc, hours)d -61.84(23.11) .007 -61.19(23.24) .008
Time -184.74(91.46) .043 -185.47(92.04) .044
time*MSFsc 30.47(23.52) .195 28.66(23.65) .226
Sleep-onset time (free days, hours) -44.43(11.84) <.001+ -41.60(12.08) .001
Time -580.27(290.44) .046 -593.14(291.20) .042
time*sleep-onset time 21.11(11.98) .078 21.42(12.02) .075
Indication of Delayed Sleep Phase Syndrome  -124.51(47.19) .008 -109.28(48.21) .023
Time -68.61(15.06) <.001+ -73.22(15.70) <.001+
time*DSPS 77.89(52.91) .141 81.50(53.37) .127
Chronotype adult  (self-reported)
- extremely early 205.10(102.52) .045 213.67(103.94) .040
- moderately early 59.92(39.40) .149 57.59(39.40) .144
- intermediate reference reference 
- moderately late -98.16(31.49) .002 -89.85(31.53) .004
- extremely late -61.79(62.27) .321 -46.43(62.21) .455
Time -60.63(18.62) .001 -65.56(18.86) .001
time*extremely early -123.62(104.22) .236 -128.93(104.55) .217
time*moderately early -68.52(38.97) .079 -69.10(38.97) .076
time*intermediate reference reference 
time*moderately late 43.48(30.34) .152 37.91(30.35) .212
time*extremely late 37.43(65.18) .566 33.43(65.02) .607







B(SE) P value B(SE) P value
Chronotype child (self-reported) 
- extremely early 7.79(78.41) .921 20.40(79.62) .798
- moderately early 13.29(33.76) .694 14.64(33.76) .665
- intermediate reference reference 
- moderately late -57.07(40.55) .159 -49.53(40.71) .224
- extremely late -109.73(83.80) .190 -103.06(83.04) .215
Time -76.59(18.09) <.001+ -76.63(18.07) <.001+
time*extremely early 108.85(75.60) .357 106.72(75.49) .157
time*moderately early 7.38(32.55) .821 5.67(32.52) .862
time*intermediate reference reference 
time*moderately late 25.96(38.61) .501 20.65(38.94) .596
time*extremely late 69.83(75.74) .357 67.92(75.11) .366
N of observations range = 2987 - 3804
partially adjusted: corrected for age at wave 1, female sex, North European ancestry, wave, group-by-time 
interaction
fully adjusted: additionally corrected for current smoker, depression severity, childhood trauma
a. Self-rated sleep duration is one variable where duration of short sleep is 6 hours or less, normal sleep is 7-9 hours, 
long sleep is 10 hours or more on Insomnia Rating Scale, at wave 1 
b. Insomnia Rating Scale score of 9 or more at wave 1 
c. All chronobiology parameters assessed at wave 3
d. MSFsc: Mid sleep on free days corrected for sleep debt on working days
+ remained significant when applying the Benjamini-Hochberg false discovery procedure
































































































































































































































































































































































































































































































































































































































































































































































































LATE SLEEP AND INCREASED CELLULAR AGING | 143
7
5. DISCUSSION 
While circadian dysregulation has been associated with many deleterious health consequences, 
to our knowledge there are no published data on circadian desynchronization and cellular 
aging. In this large-scale study, we explored the relationship between leukocyte telomere 
length (LTL) and measures of sleep length, insomnia symptoms and markers of circadian 
dysregulation. We also examined whether these factors were associated with accelerated LTL 
attrition over 6 years, taking into account baseline LTL [10]. Our results uniformly show that 
delayed circadian rhythm is associated with shorter LTL, rather than short sleep duration or 
insomnia. Indicators of delayed circadian rhythm included late MSFsc, later sleep-onset time 
(on free days), indication of DSPS and moderately late self-reported chronotype in adulthood. 
Cross-sectionally, these were all significantly associated with shorter LTL across wave 1 and 
six-year time points, after correction for wide-ranging sociodemographic and lifestyle factors. 
When we examined LTL attrition rate over time, there was no evidence of accelerated LTL 
attrition rate for any predictor over 6 years. 
Our significant findings of shorter LTL in those with delayed circadian rhythm may have important 
consequences for health. Circadian desynchrony has been related to several psychiatric 
disorders (ADHD, bipolar and other mood disorders) [59 - 62]; age [63], environmental 
actors such as night shift work [64] and metabolic changes (obesity, cardiovascular risk) [18, 
33]. Recent research has highlighted that nurses with long periods of consecutive night shifts 
have telomere shortening associated with an increased breast cancer risk [35]. While it is 
recognized that the large inter-individual variation in LTL is explained by genetic factors in over 
two-thirds [6, 7], research has shown that age [8], lifestyle, night shift work [35] and illness also 
play a role [3]. Our results further show that other possibly modifiable factors, such as delayed 
sleep-onset time, appear to play a significant role too. Identifying those at high risk for delayed 
circadian rhythm may be a first step in addressing these deleterious consequences.
The mechanism linking the circadian and metabolic systems is an intriguing area of study, 
and is only partially understood [reviewed in Ray, 18]. The effects of the circadian rhythm 
dysregulation on telomeres may relate to oxidative stress. Telomere length is associated with 
inflammation [65] and possibly shorten as a result of increased oxidative stress [66]. Senescent 
cells with shortened telomeres also show increased secretion of pro-inflammatory cytokines 
and extracellular matrix-degrading enzymes [1, 67]. This may drive accelerated disease 
progression. Hence telomeres may be active and dynamic structures, increasingly considered 
to be a reflection of a (long-term) state [68].  Dysregulated sleep is also associated with 
chronic inflammation [69], which can be seen on a cellular level [70, 71]. For example, sleep 
deprivation in humans adversely affects the oscillatory behavior of many blood metabolites, 
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which fluctuate in accordance with the circadian rhythm [36]. Healthy humans deprived of 
sleep show significant elevations in inflammatory activity compared to an undisturbed sleep 
condition [72, 73], even after one night of sleep deprivation [74]. A cumulative sleep debt 
frequently ensues from delayed sleep-onset in those with a late chronotype. Mechanisms 
underlying the shorter LTL seen in delayed circadian rhythm may include increased inflammation 
and circadian alteration of cellular metabolites, leading to cellular damage and premature 
cellular aging. Ultimately, this may increase risk for carcinogenic transformation and somatic 
disease [4]. In contrast, shorter LTL itself may predispose to delayed circadian rhythm: the 
direction of the relationship is not certain. 
We also showed that persons with self-reported, extremely early chronotype in adulthood, 
had significantly longer LTL than those with intermediate chronotype. While these results are to 
be interpreted with caution, they may imply a protective role of having an early chronotype. It 
should be noted that this finding is preliminary. Therefore, we consider our results promising but 
replication in follow-up studies is required [75, 76]. 
While we demonstrated an association between indicators of delayed circadian rhythm and 
shorter LTL, we found no association between LTL, sleep duration and insomnia symptoms. As 
regards these associations, the literature is scant and study populations are diverse in terms of 
sex, age, obesity and disease status. Our results concur with the findings of some studies [21, 
22, 50, 77] but contradict others [23, 24, 78]. Sleep duration was unrelated to LTL in a sample 
of healthy women aged between 50 and 65, although sleep quality was inversely related to 
LTL [22]. In another study among healthy women, average sleep duration was not associated 
with LTL after controlling for BMI, activity, stress, and smoking [77]. Among middle-aged 
adults, sleep duration was unrelated to LTL, but adequate sleep duration on LTL was beneficial 
for those 60 years of age or older [21]. Another important study investigated LTL in multiple 
immune cell subsets in obese adults. Here, it was poorer subjective sleep quality but not sleep 
duration that was associated with shorter LTL [50]. Unlike our results, short sleep duration was 
associated with shorter LTL in three studies: in women under 50 years (but not in older women) 
[23], in men sleeping 5 hours or less [24] and in HIV positive adults with sleep duration of at 
least 7 hours, measured with wrist actigraphy [78]. Although some of these findings suggest a 
relationship between LTL and sleep duration in the same direction (shorter LTL = shorter sleep 
duration), such an association might be dependent on age, sex and presence of affective 
disorder, or may even disappear when a circadian sleep parameter is taken into account. There 
is less published on insomnia and LTL, barring one negative study in breast cancer survivors 
with and without insomnia [79]. Another study of older adults found an association between 
insomnia and LTL in those aged 70 - 88 years, but not in those aged 60 - 69 years [25]. As 
regards mortality associated with sleep dysregulation, both persistently short (≤ 5 h) and long 
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sleep (≥ 9 h) were recently associated with an increased risk of all-cause mortality [80]. Night 
or evening shift work were also associated with increased mortality, compared to day shift 
[81]. The consequences of delayed sleep and circadian dysregulation of the sleep-wake cycle 
are severe. Our hypothesis that late sleep (indicating disturbed circadian rhythm) would be a 
significant predictor of short LTL was shown to be true. However, disturbed circadian rhythm did 
not predict accelerated LTL attrition over the 6 years of the study.
On average, mean LTL did shorten over the 6 years of the study, but this was not a substantial 
change, a finding extensively discussed by Révész et al. in a previous longitudinal NESDA 
study [10]. Our mean telomere attrition rate of 8 bp per year was lower than that described in 
a systematic review, (32 – 46 bp per year in longitudinal studies, and 20 – 30 bp in the larger 
cross-sectional studies) [8].  In short, this may be due to our relatively young and healthy study 
sample compared to the longitudinal studies reviewed where samples were smaller, older and 
had higher morbidity and mortality rates during follow-up [8]. Our sample also showed a 
large variation in TL change, with a considerable number of subjects who had stable TL or 
even lengthened their LTL, similar to those reported in earlier research, as previously outlined 
by Révész et al. [10]. 
Some questions remain to be answered concerning LTL attrition rate in delayed circadian 
rhythm. It is possible that we did not find faster LTL attrition because the 6 years of this study 
were too short a time period to measure any significant difference. Secondly, the timing of 
LTL attrition may not have been captured in our study. It may have occurred earlier in the 
lifespan. It is known that in the first year of life, telomere loss is very rapid [16], perhaps more 
so in those with circadian dysregulation, a lifelong trait [58]. Thirdly, genetic factors are known 
to determine cellular decline [7] and baseline LTL (which we corrected for) is an important 
determinant for LTL attrition [10]. Subjects with delayed circadian rhythm may be born with 
shorter LTL with less subsequent attrition. LTL has been postulated to be determined well before 
adulthood, and possibly in utero [82]. 
The large sample size, wide age range, variety of sleep variables and longitudinal design are 
strengths of this study. However, some limitations should be noted. First, we did not include 
an objective marker for the circadian rhythm, such as melatonin curves or actigraphy, and 
relied on self-report for chronotype. However, a recent study has suggested that as proxies 
for determining chronotype, melatonin curves [83] correlate well with MCTQ measurements. 
Objectively measured sleep (with polysomnography or actigraphy) is also associated with self-
reported sleep duration [84]. Second, we did not measure obstructive sleep apnea, which has 
been linked to shorter LTL in adults [26, 27]. Third, we measured TL over 6 years, while ideally 
studies should track telomere length over a lifetime, hence limiting our ability to draw long-
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term conclusions. Fourth, TL was measured in in leukocytes as opposed to multiple immune cell 
subsets. It has been shown in vivo that TL attrition occurs at different rates in different cell types, 
such as T-cells, B-cells and monocytes, which are also differentially distributed [85]. This may 
have biased our findings, making it impossible to distinguish what proportion of the lengtheners 
in NESDA showed actual lengthening and what proportion was a result of differences in cell 
composition, or alternatively, measurement error [76]. However, it has been shown that TL in 
leukocytes, muscle, skin and fat tissue display similar rates of age-dependent attrition [86], 
which suggests that results from LTL studies may be applicable to other cell types. Finally, 
another limitation is that we did not measure telomerase activity (the enzyme that lengthens 
LTL), and hence cannot comment on the telomere maintenance system, giving further insight in 
the dynamics of LTL [87]. 
In conclusion, delayed circadian rhythm rather than insomnia or altered sleep duration, seems 
to be deleterious for cellular aging and therefore perhaps for general health and disease status. 
While a genetically driven late chronotype may not be entirely modifiable, delayed sleep phase 
advancement can be achieved with sleep hygiene interventions [88]. Other therapies include 
timed evening melatonin administration, morning bright light therapy, and chronotherapy [89]. 
An initial open-label report suggests that delayed sleep phase advances with the use of blue 
light-blocking glasses in the evening [90]. Such interventions may protect against or even 
reverse accelerated cellular aging and the morbidity with which it is associated. However, the 
protective effect of such measures on cellular aging should be studied in a large prospective 
study. Further longitudinal studies of cellular aging in sleep and circadian dysregulation may 
clarify if the process of telomeric attrition can be slowed or reversed.
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“One cannot think well, love well, sleep well, if one has not dined well.”  Virginia 
Woolf [1]
The aim of this thesis is to explore the associations between adult Attention-Deficit/Hyperactivity 
Disorder (ADHD) and certain health risks. It is well known that ADHD is a highly comorbid 
psychiatric condition. We are interested in comorbid disturbances of biological rhythm, and 
whether they add any health risk to ADHD. We focus on sleep disturbances (insomnia and 
circadian rhythm disorders), Seasonal Affective Disorder (SAD) and the disturbed physiology 
associated with developing cardiovascular disease and diabetes (Metabolic Syndrome, or 
MetSyn). 
Specifically, the research explores relationships in these areas: 
1. Adult ADHD and insomnia - analyzed firstly in a literature review of recent cross-sectional 
and longitudinal studies. Secondly, we test the associations between ADHD, insomnia and 
sleep duration in a general population sample.
2. Is the well-recognized association between SAD and adult ADHD mediated by markers of 
circadian rhythm disturbance?
3. The relationship between MetSyn, obesity-related outcomes and adult ADHD.
4. The relationship between cellular aging and insomnia, sleep duration and circadian rhythm 
disturbance, using the biomarker, leukocyte telomere length (LTL).
We propose that (some of) these health risks may be explained if we view ADHD as a 
disorder of biological rhythm. This chapter summarizes, discusses and contextualizes the main 
findings of our research. Methodological considerations are discussed, as well as the potential 
application of the findings to clinical practice. Ideas for future research are also suggested, and 
the chapter ends with an overall conclusion. 
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2. SUMMARY OF MAIN FINDINGS
“Everybody’s individual music has its own rhythm.” Yo Yo Ma [2]
Sleep disturbance in the form of insomnia, excessively short or longer sleep duration, or 
delayed circadian rhythm has serious consequences for health. Chapter 2 explores the 
rhythm of the sleep-wake cycle in adult ADHD, focusing on insomnia in particular. We review 
papers written in English and published between January 2012 and March 2017. Three cross-
sectional studies report a prevalence of insomnia in ADHD adults ranging from 43 - 80% (N 
ranges from 470 - 3,188). The deductions made from the longitudinal studies are not entirely 
comparable: one large twin study (N = 2,232) confirms that the persistence of ADHD into early 
adulthood is strongly associated with insomnia symptoms at age 18, while another study shows 
no association between childhood or adolescent ADHD and insomnia at age 38 (N = 1,037). 
Only persistent ADHD (diagnosed in childhood and present at age 18), or late-onset ADHD 
(diagnosed at 18 years only), are associated with insomnia at age 18. However, childhood 
ADHD that has remitted by age 18 shows no increased risk for insomnia in early adulthood. 
There are significant effects of insomnia as a side-effect of some pharmacological treatments for 
adult ADHD. Interestingly, animal studies show that chronic use of the stimulant methylphenidate 
delays the circadian rhythm in diurnal rodents [3 - 6]. Although not a “psychostimulant”, daily 
atomoxetine also exerts similar effects in mice [6].
Continuing with the theme of sleep in ADHD, Chapter 3 investigates the association 
between ADHD symptom severity and ADHD symptom dimensions (hyperactivity and 
inattention), sleep duration and insomnia symptoms. We use data from 4,618 subjects from 
the Netherlands Mental Health Survey and Incidence Study-2 (NEMESIS-2) cohort. Our 
results show two main findings. Firstly, clinically significant insomnia symptoms are strongly 
and consistently associated with increasing severity of ADHD symptoms, and with both the 
symptom dimensions of hyperactivity and inattention. Of the group with ADHD symptoms, 43% 
report significant insomnia symptoms (OR = 2.66, 95% CI = 1.74 - 4.07). There is also a dose-
response relationship between insomnia symptoms and both ADHD symptom severity and 
the two ADHD symptom dimensions. Secondly, self-reported short sleep duration (≤ 6 hours) 
is significantly associated with both inattentive and hyperactive symptom dimensions, while 
long sleep duration (≥ 10 hours) is only associated with inattention and not with hyperactivity. 
Insomnia is strongly and consistently associated with adult ADHD.
We present a short letter in Chapter 4, which is an invited response to a comment on our 
ADHD and insomnia study (Chapter 3). We agree with the plea to view ADHD and sleep 
disorders as the consequence of a pro-inflammatory state. Specifically, we mention our own 
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work investigating the relationship between adult ADHD and MetSyn. Here, we did not find that 
in ADHD there are increased correlations between MetSyn and obesity-related parameters. 
However, obesity, which is one of the components of MetSyn, is associated with inflammation, 
and does have a significant association with ADHD. 
The aim of Chapter 5 is to explore the rhythm of seasonal mood changes in ADHD, and the 
influence of delayed circadian timing in that relationship. In 2,239 persons from the Netherlands 
Study of Depression and Anxiety (NESDA) cohort, the prevalence of probable SAD is three 
times greater in the ADHD group compared to the No ADHD group (9.9% vs. 3.3%). Regression 
analyses show consistently significant associations between ADHD symptoms and probable 
SAD, even after full adjustment (B = 1.81, p < .001). An indicator for circadian disturbance, 
sleep-onset time on nights before free days, is a mediator in the significant relationship between 
ADHD symptoms and probable SAD. Total sleep duration does not play a significant mediating 
role. Hence, our study points to possible links between both circadian and seasonal rhythm 
disturbance in ADHD.
Chapter 6 investigates whether MetSyn shows any particular “rhythm” in ADHD, using data 
from the NESDA cohort. We expected the prevalence of MetSyn to be increased in ADHD. 
After studying 2,303 adults with and without ADHD, in varying stages of depressive and anxiety 
disorders, we were surprised to find no added risk for MetSyn and obesity-related outcomes 
in adults with ADHD. A meta-analysis published subsequent to our study does show that 
obesity is related to ADHD in both children and adults [7]. Our analyses reveal no significant 
cross-sectional associations between ADHD symptoms and MetSyn, Body Mass Index (BMI) 
and Waist-Hip ratio. Furthermore, we show the symptom domains of high Inattention and 
Hyperactivity/Impulsivity are also not associated with MetSyn. Hence, this study does not 
confirm our hypothesis that MetSyn and obesity-related parameters are increased in ADHD.  
The final study of this thesis examines the impact of disturbed sleep on the “rhythm of aging”. 
In Chapter 7, our study of 2,936 subjects from the NESDA cohort shows that shorter LTL was 
associated with delayed circadian rhythm, rather than with short sleep duration or insomnia. 
Late mid-sleep corrected for sleep debt on free days (MSFsc, B = -48.5, p = .005), late sleep-
onset time (B = -32.0, p = .001), indication of a Delayed Sleep Phase Syndrome (DSPS, B 
= -71.8, p = .040) and moderately late chronotype in adulthood (B = -72.8, p = .002) are 
all associated with significantly shorter LTL, even after correction for sociodemographic and 
lifestyle factors. However, we find no evidence of accelerated LTL attrition rate associated with 
any predictor over the six years of the study. Hence, a delayed circadian rhythm appears to be 
deleterious for cellular aging and therefore perhaps for general health status.
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3. DISCUSSION OF MAIN FINDINGS
“I am not absentminded. It is the presence of mind that makes me unaware of 
everything else.” G.K Chesterton [8]
3.1 HEALTH RISKS ASSOCIATED WITH ADULT ADHD:  
INSOMNIA
Sleep disorders are highly comorbid with ADHD and are associated with negative health 
consequences. Our results focus on insomnia and circadian rhythm disorders in adult ADHD. We 
confirm this association in our literature review (Chapter 2) and from our general population 
study, using the NEMESIS cohort (Chapter 3). In the latter, we show that those with clinically 
relevant ADHD symptoms have more than double the risk of insomnia symptoms than the group 
without ADHD symptoms. Clinically significant insomnia symptoms are strongly associated with 
increasing severity of ADHD symptoms, suggesting a dose-response relationship. 
These results are consistent with both earlier studies [9 - 11] and those recently published. 
In a large study from the Netherlands Sleep Registry study (N = 942), the prevalence rate 
of insomnia in ADHD was 60.3%. Self-reported ADHD symptom severity and hyperactivity 
symptoms were associated with a current presence and persistent history of insomnia disorder, 
amongst other disorders (obstructive sleep apnea, restless legs syndrome and periodic limb 
movement disorder) [12]. This year, the first meta-analysis on sleep in adults with ADHD also 
replicated our conclusions [13]. The authors included 13 case-control studies comparing 
subjective and/or objective sleep parameters in adults, with and without a diagnosis of ADHD. 
They demonstrated that adults with ADHD had significantly worse sleep outcomes in seven out 
of nine subjective sleep parameters; and two out of five actigraphic parameters. (Actigraphy 
involves the patient wearing an ‘actiwatch’ on the wrist. This will continuously measure limb 
movement and light intensity, from which a computerized scoring system is used to determine 
periods of sleep and being awake). However, no significant differences were detected for 
polysomnographic parameters [13]. Another recent clinical study also confirmed the high 
prevalence of insomnia in ADHD patients [14]. Interestingly, this study compared three groups: 
controls, participants with comorbid ADHD + borderline personality disorder (ADHD+BPD) 
and those with BPD alone. Both patient groups had higher insomnia and lower sleep quality 
scores than control subjects. For BPD patients, sleep symptoms were mainly explained by 
depressive symptoms. For ADHD patients, depressive symptomatology explained only some 
sleep complaints, but sleep efficiency (total sleep time/total time lying ratio) was significantly 




ADHD SYMP TOMS ARE SIGNIFICANTLY ASSOCIATED WITH 
INSOMNIA SYMP TOMS IN CROSS-SECTIONAL STUDIES.
3.2 HEALTH RISKS ASSOCIATED WITH ADULT ADHD:  
ALTERED SLEEP DURATION
In addition to insomnia, the presence of short and to a lesser extent, long sleep duration, are of 
significance in adults with ADHD. In a large, representative study of the U.S. adult population, 
the odds of having ADHD were 50% among respondents reporting ≤ 6 hours or ≥ 9 hours 
sleep duration, as opposed to those reporting 8 hours of sleep. Short sleep in ADHD has been 
attributed to increased nocturnal motor activity [15 - 18], suggesting that it is a result of ADHD. 
Alternatively, short sleep duration has been suggested to arise from a comorbid delayed sleep 
phase syndrome (DSPS) [19]. In our NEMESIS study, we found that self-reported short sleep 
was significantly associated with both inattentive and hyperactive symptom dimensions. Short 
sleep carries significant health risks, including chronic cardiovascular disease, stroke, diabetes, 
obesity, asthma and arthritis [12, 21]. Sleep restriction or loss also impairs performance on 
attention and executive control tasks [22]. 
Although less prevalent in our NEMESIS study, long self-reported sleep duration was also 
significantly associated with ADHD symptoms. We demonstrated a dose-response relationship 
between long sleep and both ADHD symptom severity and inattention symptoms. This implies 
that an (atypical) subgroup of those with long sleep may be at increased health risk on the 
continuum of adult ADHD. It has been shown previously that dim-light melatonin onset (the time 
in the evening when circulating melatonin levels reach a certain threshold) is delayed in adults 
who have inattentive symptoms predominantly. These adults also had longer sleep duration 
than those with the hyperactive/impulsive symptom dimension [23].
Why long sleep in ADHD? Long sleep does initially appear to be difficult to explain in ADHD. It 
may result from a comorbid disorder such as hypersomnia, affective disorder, or medical illness 
[19]. Long sleep also predicts all-cause mortality [24] and is associated with an increased risk 
for atherosclerosis [25]. This implies that an underlying metabolic dysregulation is associated 
with long sleep and its consequences.
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CONCLUSION 2 
WHILE SELF -REPORTED SHORT SLEEP DURATION IS SIGNIFICANTLY 
ASSOCIATED WITH BOTH INAT TENTIVE AND HYPERACTIVE 
SYMP TOM DIMENSIONS, LONG SLEEP DURATION IS ONLY 
ASSOCIATED WITH INAT TENTION AND NOT WITH HYPERACTIVITY. 
3.3  SLEEP AND THE ADHD SUBTYPES:  
INAT TENTION AND HYPERACTIVITY SYMPTOMS
To date, correlations described in the literature between sleep disturbance and the ADHD 
symptom dimensions have been mixed. We show a strong association between clinically 
significant insomnia symptoms and the symptom dimensions of hyperactivity and inattention. 
Similar to our results are those of Fisher et al., where insomnia was related to both ADHD 
subtypes [26]; and those of Yoon et al. [27], where sleep quality was worse in the inattentive 
subtype than in the combined group (using the Pittsburgh Sleep Quality Index). Interestingly, 
a recently published paper showed that patients with the inattentive subtype had better sleep 
quality than those with the combined and hyperactive/impulsive subtype ([28], using the 
Global Sleep Assessment Questionnaire). These different sleep instruments may account for 
the conflicting results. In addition, it is well recognized that the inattentive subtype is more 
common in adulthood than the hyperactive/impulsive subtype [29]. Several studies excluded 
the hyperactive/impulsive subtype from analysis as numbers were too low [9, 12, 28], which 
may also explain these different findings.
CONCLUSION 3
 CLINICALLY SIGNIFICANT INSOMNIA SYMP TOMS ARE ASSOCIATED 
WITH INCREASING SEVERITY OF ADHD SYMP TOMS, AND 
WITH BOTH SYMP TOM DIMENSIONS OF HYPERACTIVITY AND 
INAT TENTION. 
3.4  HEALTH RISKS ASSOCIATED WITH ADULT ADHD:  
MOOD DISORDERS 
Adults with ADHD have an increased risk for depression and SAD [30, 31]. In our studies, we 
adjust for mood and anxiety disorders, but this did not affect our findings. We confirm that SAD 
was three times as prevalent in the ADHD group versus the No ADHD group (Chapter 5). We 
also report significant insomnia symptoms in ADHD, which are not explained by the presence 
of depressive symptoms. 
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Comorbid affective disorders and seasonal depression worsen outcome in ADHD. Some 
preliminary research suggests there is increased metabolic disturbance when seasonality 
scores are higher. In a large Norwegian study, high self-reported seasonal changes in mood 
and behavior in men were associated with greater BMI and total cholesterol [32]. Women with 
higher seasonality scores had greater BMI, exercised less and smoked more. The SAD-ADHD 
comorbidity adds another layer to the health risk associated with adult ADHD.
CONCLUSION 4
 WE CONFIRM THAT SEASONAL MOOD DISTURBANCES ARE 
SIGNIFICANTLY ASSOCIATED WITH ADHD SYMP TOMS.
3.5 HEALTH RISKS ASSOCIATED WITH ADULT ADHD:  
CIRCADIAN RHY THM DISTURBANCE
“All of western society is a little bit sleep deprived …, I mean chronically.” Michael 
Robash, joint recipient Nobel Prize in Physiology/Medicine 2017  [33]
Night-time lighting is not what it used to be. In modern times, increasing the ambient electric 
light exposure everywhere has delayed the circadian clock and allowed for work and social 
activities to occur outside of typical daytime hours, resulting in “social jet lag”. Here, sleep debt 
is likely to occur following different sleep timing on work and free days [34]. Genetic variations 
in CLOCK genes also contribute to the distribution of late chronotype in the general population 
[34]. 
When the sleep-wake rhythm is disturbed, consequences are widespread and dire. Circadian 
rhythm desynchronization may result in cardiovascular disease [35], metabolic abnormalities, 
increased carcinogenesis [36] and cognitive dysfunction in adults [37, 38], older adults [39], 
adolescents [40] and children (reviewed in [41]). People with delayed circadian rhythm more 
often report poor sleep quality and frequent daytime sleepiness [34]. Students with delayed 
circadian rhythm achieve less well in school [42]. 
Circadian rhythm disturbances are highly prevalent in ADHD [43, 44]. Our work explores the 
associated health risks of late sleep, where SAD and ADHD co-exist (Chapter 5), and in terms 
of cellular aging (Chapter 7). We show that sleep-onset time (an indicator of delayed circadian 
rhythm) is a significant positive mediator in the relationship between ADHD symptoms and 
seasonality. Fourteen percent of this relationship is explained by sleep-onset time. Underlying 
biological rhythm alterations may be common to both conditions [45]. Late sleep-onset time 
in ADHD may drive the increased winter depression symptoms in these patients. On the other 
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hand, sleep duration is not a significant mediator. One explanation for this finding could be 
that late sleep-onset time is associated with both shorter exposure to sunlight (because of 
the resulting late rising after sunrise), and increased exposure to artificial light at night. These 
have been shown to worsen depressive symptoms [46]. When the days become short and 
dark in winter, it is believed that the biological clock becomes desynchronized, with longer 
sleep in SAD [45]. Hence it would be unlikely that shorter sleep duration would mediate in the 
association between ADHD and SAD. 
CONCLUSION 5
 CIRCADIAN RHYTHM DISORDERS ARE SIGNIFICANTLY ASSOCIATED 
WITH ADHD SYMP TOMS. DELAYED SLEEP-ONSET TIME IN ADHD 
PARTLY EXPLAINS THE INCREASE IN SAD SYMP TOMS IN ADULT 
ADHD.
3.6  HEALTH RISKS ASSOCIATED WITH ADULT ADHD:  
OBESITY AND METSYN
ADHD is a lifelong disorder, with associated comorbidity and dysfunction in many life domains 
[47]. In addition to educational, relationship and employment difficulties, many psychiatric and 
chronic somatic diseases disorders coexist with ADHD [19, 31]. A systematic review showed 
consistent associations between ADHD and migraine, asthma, celiac disease and obesity [19]. 
Obesity makes headlines. Worldwide, the prevalence of obesity has nearly tripled since 1975 
– and most of the world’s population lives in countries where overweight kills more people than 
underweight does [48]. Obesity also affects all ethnicities and socioeconomic groups, but to 
varying degrees. On a positive note, obesity is preventable and to some extent, reversible. 
In the last decades, obesity has been recognized as a risk factor for cardiovascular disease 
and diabetes [49]. According to the International Diabetes Federation, central obesity is a 
prerequisite for MetSyn [50]. Beyond increasing the risk of type 2 diabetes mellitus five fold, 
and for cardiovascular disease three fold, MetSyn is also associated with several cancers [51]. 
Hence understanding and preventing MetSyn are of critical public health importance.
Earlier studies from NESDA had shown that depressive disorders are associated with obesity, 
Waist-Hip ratio and (certain) serum lipid profiles [52]. Anxiety-related somatic arousal is 
strongly associated with waist circumference, triglyceride levels and blood pressure in NESDA 
[53]. Some other studies have associated affective disorders with higher BMI and obesity [54 
- 57], but not all [58]. As we were interested in investigating risk factors associated with ADHD, 
and it had been clearly shown that ADHD is comorbid with affective disorders in over a fifth of 
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cases [31, 59], we were drawn to investigating any added risk for MetSyn in an adult ADHD 
population with depressive and anxiety disorders. 
Underlying our hypothesis that those with adult ADHD might be at increased risk for MetSyn, 
are several clues from the literature connecting ADHD and obesity, and possibly MetSyn. Firstly, 
maternal metabolic status has been shown to impact on the neurophysiology of the developing 
child: maternal obesity increases the chance of having a child with ADHD behaviors by up 
to 2.8 fold [60]. Pre-pregnancy BMI and gestational weight gain are also associated with a 
2-fold increased risk of ADHD symptoms in offspring [61]. Secondly, we hypothesize that the 
symptoms of ADHD may predispose to MetSyn in adults. This has been shown by others, where 
poor planning and impulsivity in ADHD result in poor food choices [62, 63]. Eating at night, 
skipping meals and sleep disturbances (all associated with ADHD) have also been linked 
to increased BMI [64, 65]. Neurobiological studies highlight the disturbed dopaminergic 
neurotransmission in ADHD and obesity, where pathways involving reward processing, 
response inhibition, and emotional regulation are implicated [66]. In animal models, perinatal 
exposure to maternal obesity and a high fat diet have been demonstrated to alter the 
dopaminergic systems in offspring [67]. Finally, both ADHD and MetSyn have been linked to 
alterations in circadian CLOCK genes and environmental factors (MetSyn [68 - 70], ADHD 
[69 - 71]). Two meta-analyses have been published, with somewhat different outcomes with 
regards to children [7, 72]. One showed a significant ADHD-obesity association, regardless 
of a number of confounding factors, including age and gender [7]. The other indicated a non-
significant association in children, a possible clinically significant association in girls, and a 
significant association in adults [72]. For all these reasons we expected a disturbed metabolic 
rhythm (MetSyn) to be associated with ADHD in adults.
However, our study was negative: there was no significant association between ADHD 
(defined in several different ways) and MetSyn or obesity-related parameters. Despite the 
association between adult ADHD and obesity, we found no increased risk for MetSyn. An 
explanation of this finding is not easy to provide. Firstly, the associations between MetSyn and 
ADHD may be very difficult to detect and therefore we could not confirm our hypothesis. There 
may simply be no added risk for developing MetSyn in the presence of affective disorders. In 
addition, the concept of MetSyn is evolving and there is still discussion in the literature as to its 
best definition [51]. The pathophysiology underlying MetSyn is also not clear [49] and the list 
of risk factors may not be complete. For example, a very recent study suggests that increased 
blood levels of both the amino acid homocysteine and C-reactive protein (indicating systemic 
chronic inflammation, a pro-inflammatory state) correlate with MetSyn [73]. The authors 
suggest these are co-founding factors of MetSyn, although they are currently excluded from 
the definition. In fact, the International Diabetes Federation recommends measurements of a 
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pro-inflammatory state for the “platinum standard”definition of MetSyn, including C-reactive 
protein, inflammatory cytokines and adiponectin plasma levels [74]. Finally, MetSyn is not a 
disorder, but rather the clustering of risk factors which may exert different effects. Of the five 
risk factors associated with MetSyn, some authors consider obesity fundamental as it appears 
to precede the others [51], and others emphasize insulin resistance [75, 76]. Reaven, who 
first connected insulin resistance and cardiovascular risk, followed up with a critique of the 
contemporary criteria for MetSyn, arguing that any cardiovascular risk factor present in a 
patient should be be monitored and treated clinically if necessary [77]. Other relationships 
between ADHD, MetSyn and obesity-related parameters will perhaps emerge once these 
definitions and underlying pathophysiology are elucidated.
CONCLUSION 6 
IN OUR STUDY, ADHD (EVEN WHEN DEFINED SEVERAL WAYS) 
IS NOT ASSOCIATED WITH METABOLIC SYNDROME. UNLIKE THE 
RESULTS OF OTHER RESEARCH, OBESITY-RELATED PARAMETERS ARE 
ALSO NOT SIGNIFICANTLY RELATED TO ADHD, IN A SAMPLE OF 
PATIENTS WITH DEPRESSION AND ANXIETY.
3.7  HEALTH RISKS ASSOCIATED WITH LATE SLEEP-ONSET: 
LEUKOCY TE TELOMERE LENGTH
“Think in the morning. Act in the noon. Eat in the evening. Sleep in the night”. 
William Blake
Unfortunately, for many people, a stable sleep/wake rhythm is very difficult to achieve. While 
disturbed sleep has serious implications for somatic health, we question whether it is associated 
with cellular aging (Chapter 7). Genetic factors contribute to most of the variability in LTL 
(approximately 64 - 70%, [78, 79]). However, some other factors (including lifestyle and 
illness) may be remediated. In our final study from the NESDA cohort, we show that indicators of 
delayed circadian rhythm are associated with significantly shorter LTL, whereas sleep duration 
and insomnia symptoms are not. Further, no sleep or chronobiological predictors showed 
accelerated LTL attrition rate over 6 years. In other words, late sleep was consistently associated 
with shorter LTL throughout the entire follow-up, and this relationship remained consistent over 
time, with no evidence of faster LTL attrition rate. Our results point to an association of delayed 
circadian rhythm with shorter LTL, which is of extreme concern given the current trend towards 





 LATE MSFSC, LATE SLEEP-ONSET TIME, INDICATION OF DSPS AND 
MODERATELY LATE CHRONOTYPE IN ADULTHOOD ARE ASSOCIATED 
WITH SIGNIFICANTLY SHORTER LTL. SLEEP DURATION AND 
INSOMNIA SYMP TOMS ARE NOT ASSOCIATED WITH SHORTER LTL.
CONCLUSION 8
 EXTREMELY EARLY CHRONOTYPE SHOWS SIGNIFICANTLY LONGER 
MEAN LTL.
CONCLUSION 9
 NO SLEEP OR CHRONOBIOLOGICAL PREDICTORS SHOW 
ACCELERATED LTL AT TRITION RATE OVER 6 YEARS.  
3.8 IMPLICATIONS OF OUR STUDIES ON HEALTH RISK IN ADHD
CLOCK genes and inflammatory processes may be factors linking ADHD and SAD, insomnia, 
late sleep and shorter LTL. Single-nucleotide polymorphisms of CLOCK genes have been 
associated with several psychiatric disorders, although the underlying functional mechanisms 
for these associations remain to be clarified [71]. In ADHD, CLOCK genes are implicated [69, 
70, 80 - 82], and single-nucleotide polymorphisms described [69, 70]. ADHD patients also 
show a flattened rhythmic expression of CLOCK genes, which is significantly correlated with 
increased nocturnal hyperactive behavior [82]. Conversely, CLOCK gene disruption elicits a 
hyperactive, impulsive and attention deficit-type behaviors in animal models, with a deficit in 
dopaminergic neurons [83]. 
 
CLOCK genes are also implicated in animal models of SAD [80, 84 - 86] and in human 
susceptibility to SAD ([86, 87], reviewed in [88]). Preliminary experimental research links 
insomnia to CLOCK gene polymorphism [89]. The role circadian CLOCK genes play in obesity 
and energy metabolism was recently reviewed [90]. Abnormal expression of CLOCK genes 
may affect brain maturation and development, sleep, cognition and mood [71].
While CLOCK genes have been implicated in the disorders we studied, a pro-inflammatory 
state may also play a role. Furthermore, control of the inflammatory response is also under 
circadian control. Chronic inflammation is a maladaptive response to tissue damage 
involving tissue destruction, where cytokines are released [91]. The pro-inflammatory state, 
or systemic low-grade inflammation, is typically defined by a two- to threefold increase in 
plasma concentrations of interleukin (IL)-1, tumor necrosis factor-α (TNF-α), and IL-6 [92, 93]. 
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When levels of inflammation markers are raised, this leads to peroxidation of plasma and 
mitochondrial membranes, resulting in cell death by apoptosis or necrosis [94]. The master 
clock, located in the suprachiasmatic nucleus (SCN), controls the immune system in a rhythmic 
manner. Circulating immune cells and cytokines show circadian rhythmicity [95]. 
Recently, several studies have found evidence of a pro-inflammatory state in SAD [96, 97]. 
Initial research suggests that sleep dysregulation affects two systems: the sympathetic nervous 
system (SNS) and hypothalamic-pituitary-adrenal (HPA) axis [98]. Together, these shift basal 
gene expression, promoting inflammation [98]. In more detail, the SNS involvement is through 
enhanced β-adrenergic signaling, which in turn induces production of pro-inflammatory 
cytokines. As regards the HPA axis, sleep disturbance may increase release of cortisol, type 1 
cytokines, and possibly inflammatory cytokines [99].
Sleep deprivation may result in obesity [100] and the increased production of pro-inflammatory 
cytokines ([98, 101], reviewed in [102]). Sleep duration is also implicated. Short (< 6 hours) 
and long (> 9 hours) nightly sleep durations have been associated with higher levels of 
inflammation than normal sleep (7 - 8 hours) in large epidemiological studies [103 - 105]. Both 
long and short sleep are considered pro-inflammatory states [104]. Conversely, inflammation 
can produce sleep disturbance [106].
Melatonin secretion from the pineal gland is potentially a bridge between the circadian 
sleep-wake rhythm and a pro-inflammatory state. The pineal gland (mainly) synthesizes 
melatonin, and melatonin secretion is under control by the SCN, the master biological clock. 
Melatonin regulates the sleep/wake cycle but also the temporal organization of immunity 
[107]. Melatonin is considered to be an active anti-inflammatory molecule due to its inhibition 
of TNF-α production [108] and its downregulation of cortisol secretion [107]. Following 
surgical excision of the pineal gland (pinealectomy), there is extensive immunosuppression 
[109]. We show that a delayed circadian rhythm is associated with shorter LTL. Senescent 
cells with shortened telomeres show increased secretion of pro-inflammatory cytokines [110, 
111]. Shortened telomeres have also been associated with a dysregulated stress system [112] 
and increased oxidative stress [113]. The mechanisms underlying the shorter LTL seen in late 
sleep may include circadian alteration of cellular metabolites, leading to cellular damage, 
a pro-inflammatory state and premature cellular aging. Ultimately, this may increase risk 
for carcinogenic transformation and somatic disease [114]. In contrast, shorter LTL itself may 
predispose to delayed circadian rhythm: the direction of the relationship is not certain.
It is enticing to speculate that a pro-inflammatory state may be another pathway linking 
disorders of attention, seasonal depression and delayed circadian rhythm. The comorbid nature 
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of ADHD may increase vulnerability to inflammation and possibly, advanced cellular aging. 
However, this interpretation should be made with caution until confirmed by further research. 
4.  METHODOLOGICAL CONSIDERATIONS
4.1 STUDY DESIGN
Of the studies we conduct, three use epidemiological data from the Netherlands Study of 
Depression and Anxiety (NESDA) and one from the Netherlands Mental Health Survey and 
Incidence Study-2 (NEMESIS-2). Three studies have a cross-sectional design, which limits the 
ability to make causal inferences on the relationships found. So these studies may predominantly 
reflect short-term associations and be more subject to reporting bias. From an epidemiological 
point of view, results from cross-sectional surveys are best suited to generate hypotheses. 
Longitudinal studies on the other hand, are more suitable to test such hypotheses. Longitudinal 
data may have given better insight into the relationship between ADHD and MetSyn. We use 
six year, longitudinal data in the LTL study, but inevitably we encountered attrition of the number 
of participating subjects, a built-in disadvantage of this design. Ideally, LTL studies should track 
telomere length over a lifetime, because of the changes in attrition rate at different ages [115]. 
As regards our review of insomnia in adult ADHD, the results of population-based studies may 
not be applicable in the clinical setting – hence both settings should ideally be investigated. 
In terms of the pharmacological studies reviewed, the varying designs of the trials may have 
affected the frequency of insomnia. Furthermore, where improvement in sleep quality was 
reported in these trials, it may be because medications improve daytime functioning, resulting 
in better sleep. Medications may have no direct (ameliorating) effect on sleep at all. 
4.2  MEASUREMENT TOOLS
We use two different instruments to identify ADHD in our studies, each of which is associated 
with specific limitations. In the NESDA studies, the Connors Adult ADHD Adult Rating Scale – 
Self report: Screening Version is used, which relies on retrospective self-reporting, as ADHD 
starts in childhood (Chapters 5, 6). This may have introduced recall bias, leading to under 
reporting [116]. Yet studies of the concordance between childhood symptoms reported 
by study subjects versus informants have shown mixed results. Four studies showed that 
adults underestimate their childhood symptoms [117 - 120], but one study demonstrated an 
overestimation [121]. The NEMESIS study uses the Adult ADHD Self-Report Scale screener 
(ASRS, Chapter 3). This instrument determined hyperactivity by only two questions and there 
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was no assessment of impulsivity, a component of ADHD. This means that we are unable to 
comment on the relationship between impulsivity symptoms and insomnia/sleep duration. The 
ASRS does not include a question about childhood-onset of the symptoms, which is necessary 
for the diagnosis of ADHD [122]. A clinical diagnosis of ADHD was not made in any of our 
studies, nor could we collect collateral information on the diagnosis. However, in terms of the 
validity of self-reported symptoms, two studies revealed equally reliable reporting of attention 
symptoms between subjects and informants [123, 124]. Very few people in our studies (n = 
3, NESDA; n = 11, NEMESIS) were treated with a psychostimulant, so we did not correct for 
this medication use, as we felt the results would not be meaningful. In contrast, most patients in 
clinical practice receive pharmacotherapy for ADHD. 
We also used retrospective self-reporting to measure sleep and chronobiological variables, 
which introduced the same limitations. 
4.3 STUDY SAMPLES
Our research used data from two large epidemiological cohorts. While this approach has 
enormous advantages in terms of statistical power, the samples were not specifically collected 
to analyze the health risks associated with ADHD, which is another limitation.   
5. POTENTIAL APPLICATION OF FINDINGS  
TO CLINICAL PRACTICE
ADHD is a challenging condition to treat. Its social stigma remains high and it is not considered 
a “real disorder” by many clinicians. It is highly comorbid with disorders of biological rhythm, 
which may increase morbidity. 
As we show in our review of insomnia and ADHD, the pharmacological agents so frequently 
used in the treatment of ADHD may worsen [126] or improve insomnia symptoms [127 - 
130]. Long-acting stimulant medications shorten sleep duration and delay sleep-onset, which 
negatively affects executive function and attention [131, 132]. Recently, two placebo-controlled 
studies of triple-bead Mixed Amphetamine Salts confirmed that insomnia was a frequently 
reported treatment-emergent adverse event [133]. When stimulant medication is administered 
in the late afternoon or evening (which is often necessary: ADHD is a 24 hour condition), 
insomnia may be exacerbated [134]. However, in clinical practice, many patients report that 
they can fall asleep more easily with short-acting methylphenidate taken before bedtime. This 
appears to relieve the rebound ADHD symptoms that occur when the medication wears off. 
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Stimulant treatment during the day has been shown (in an open label study) to reduce motor 
restlessness during sleep, and improve sleep quality [17]. Hence, before selecting treatment 
for an ADHD patient, clinicians should appraise comorbid sleep-related disorders using 
standardized instruments. Any changes in sleep patterns should be carefully monitored during 
therapy. Any advice for the patient should be tailored to that individual. Finally, in assessing 
sleep, treating physicians should note that subjective perception of sleep is not necessarily 
consistent with EEG indications. This mismatch is referred to as “sleep state misperception” 
[135] and occurs in those with primary or psychophysiological insomnia [13].
Our results suggest that those treating this complex condition should also screen for comorbid 
circadian rhythm sleep disorder and SAD. Insomnia should be treated with psychoeducation, 
sleep hygiene interventions and cognitive behavioral therapy (CBT) [136]. Adjunctive agents 
such as melatonin and/or light therapy may treat insomnia based on a circadian disturbance 
[137]. Digital health interventions (such as portable phone applications) may help adults with 
ADHD to monitor and adjust their sleeping patterns [138]. 
Delayed circadian rhythm may have significant effects on health. While a genetically-driven 
late chronotype may not be entirely modifiable, delayed sleep phase advancement can be 
achieved with sleep hygiene interventions [139], timed evening melatonin administration and 
morning bright light therapy [140]. The treatment of choice in SAD is morning light therapy, 
first described over thirty years ago [141]. Serotonergic antidepressants such as the Selective 
Serotonin Reuptake Inhibitors are the main pharmacological agents used, although there is also 
evidence for the efficacy of the dopaminergic agent, buproprion [142]. Cognitive behavioral 
and other therapies and exercise have shown benefit [143]. 
Where mood and anxiety disorders co-exist with ADHD, MetSyn and obesity should be 
excluded, and all comorbidities treated. ADHD patients with comorbid disorders may 
struggle to adhere to good sleep hygiene, balanced diet, and exercise. They should receive 
therapeutic scaffolding in the form of coaching or CBT interventions, in a structured treatment 
program. 
6. FUTURE RESEARCH
The 20th century saw the introduction of electric lights, forever changing the spectrum, intensity 
and timing of ambient light exposure. The effect of light pollution on sleep quality and sleep 
duration is of great interest, particularly in ADHD, where there is already a vulnerability to 
circadian rhythm disturbance. Future research should explore the impact of artificial light 
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and blue-enriched, emitting light emitting diodes on ADHD symptom severity, sleep quality, 
metabolic parameters and cellular aging. 
The role of inflammation in the biological rhythm disorders is intriguing for many reasons. 
Circadian rhythm has been shown to affect immune responsiveness [96]. Dim-light melatonin 
onset is delayed in ADHD [23, 144]. However, to our knowledge, the relationship between 
melatonin secretion, circadian rhythm and immune responsiveness in ADHD has not been 
studied. This is an area meriting further attention, for it is possible it may greatly increase 
understanding of auto-immune malfunction.  
The importance of inflammation extends beyond the circadian rhythm. Initial research has 
revealed a pro-inflammatory state in SAD [95], with normalization after light therapy [96]. 
These findings would be interesting to confirm with further investigation. Inflammatory processes 
may also be a factor linking cellular aging with delayed circadian rhythm. A pro-inflammatory 
state appears to be common to ADHD [143, 144], SAD (summarized in [96]), metabolic [73] 
and sleep disorders [99, 101, 105, 106, 147] and circadian rhythm disturbance [148]. Further 
studies will reveal the importance of these associations and may reveal further relationships. 
For example, a recent study has linked a pro-inflammatory state to poor attention, MetSyn and 
depression [146].
ADHD is a highly comorbid condition and the presence of co-existing psychiatric disorders 
may confound future studies. Hence, the presence of (seasonal) affective disorders and sleep 
disorders should be included when studying ADHD and MetSyn. Other factors contributing to 
the increased vulnerability to biological rhythm disorders in ADHD deserve further clarification. 
Ideally, studies should be specifically designed to research the health risks associated with 
ADHD.
Some fascinating and recent findings stress the importance of longitudinal studies in studying 
ADHD and LTL, as both appear to be determined in part before birth. Older paternal age 
appears to predict longer telomere length in children [149]. Maternal obesity [150], depression 
and sleep disorders during pregnancy have been associated with an increased risk of ADHD 
in offspring [151]. Furthermore, both ADHD and one’s chronotype can extend from childhood 
into old age [152, 153]. Ideally, longitudinal studies with multiple assessments over time would 
illuminate the course of these conditions and their associations. Similarly, the examination of 
other possible influences during pregnancy may increase overall understanding of the topics 
considered in this thesis. The following questions could possibly then be answered: what is the 
nature of the associations between ADHD and insomnia, SAD and delayed circadian rhythm, 
and are they consistent over the lifespan? Is delayed circadian rhythm consistently associated 
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with shortened LTL, and can this telomeric attrition be slowed or reversed? Longitudinal studies 
of ADHD and insomnia should consider the age-of-onset of ADHD and the persistence of 
ADHD symptoms, which appear to be relevant where insomnia is comorbid in early adulthood 
(Chapter 2). 
 
We would be interested to confirm whether early chronotype truly has a protective role on cellular 
aging, as suggested by our findings (Chapter 7). Ideally in future studies, delayed circadian 
rhythm should also be measured with objective measures (actigraphy and polysomnography, 
and dim-light melatonin onset) to confirm the results obtained with self-reporting. Evidence-
based management strategies may protect against or even reverse accelerated cellular aging 
and the morbidity with which it is associated, but these need to be studied in much more detail. 
Concerning sleep problems in ADHD, several interesting questions remain unanswered by the 
research to date: why are ADHD and sleep disorders so frequently associated? What is the 
direction of causality in this relationship? The subtype dimensions of ADHD also deserve more 
study, in order to assist with tailored treatments where one or other predominates. 
In addition, it would be of great interest to study the rhythm of people with ADHD who do not 
develop sleep and seasonal affective disorders. This may shed light on protective factors and 
influence new treatments.
Undertaking this research on MetSyn and ADHD made us aware of the debate in the literature 
around the list of risk factors for MetSyn (Chapter 6). While MetSyn is a very useful concept, 
current understanding of the risk factors may not be complete [49]. Future research into MetSyn 
and inflammation will clarify whether inflammatory factors need to be included as risk factors 
[73].
Finally, we feel that future intervention studies would be of great interest. For example, our 
group is currently exploring the clinical benefits of improving a delayed sleep phase in adult 
ADHD with melatonin and/or light therapy. The outcomes measured include ADHD severity, 
sleep parameters, mood, appetite and indicators of metabolic disorders. Such an approach 
will hopefully provide preliminary guidelines for new treatments, helping future generations of 
patients.
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7. CONCLUSION:  
THE RHYTHM OF ADHD
This thesis considered ADHD broadly as a disorder of circadian rhythm disturbance. Our results 
show that there is a close relationship between ADHD symptoms and insomnia symptoms, as 
well as self-reported altered sleep duration. The more severe the ADHD symptoms, the worse the 
insomnia symptoms. Those with adult ADHD have increased risk for one of both short and long 
sleep duration. Insomnia is sometimes related to ADHD treatment: different pharmacological 
agents used in ADHD management show varying rates of insomnia in clinical trials. We found 
a connection between the sleep-wake rhythm (delayed sleep-onset time) and seasonal mood 
changes (SAD) in adult ADHD. While adult ADHD is a highly comorbid diagnosis, ADHD 
symptoms were not found to be significantly related to Metabolic Syndrome. On a cellular 
level, we showed that indicators of delayed circadian rhythm were associated with significantly 
shorter Leukocyte Telomere Length. The presence of DSPS symptoms accelerated cellular aging 
during the 6 years over which it was observed, whereas altered sleep duration and insomnia 
symptoms showed no significant effect on LTL. We are on the cusp of an exciting time in 
biological rhythm research: in the future, these associations will surely be further studied so that 
more finely tailored treatment strategies can be achieved. The ADHD symptom dimensions may 
guide specific interventions, and could alert clinicians to recognize and treat comorbidities. 
With a refined understanding of the underlying pathophysiology, future ADHD patients may 
benefit from early recognition, deceleration of the usual advancement in these conditions and 
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Attention-Deficit /Hyperactivity Disorder (ADHD) is a neuropsychiatric developmental 
disorder, characterized by a lifelong pattern of inattention, impulsivity and hyperactivity. Adults 
with ADHD often suffer from comorbid psychiatric and somatic conditions. These may lead to 
a poorer quality of life, high costs for society and the need for lifelong treatment. ADHD and 
several of its comorbidities are associated with disturbances in biological rhythm. The circadian 
(24 hour) rhythm synchronizes certain behaviors, metabolic processes and physiological 
functions (such as heart rate and blood pressure) with particular times of the day. Most cells 
have an inbuilt circadian “clock”, which is controlled by the master clock in the brain. The 
circadian clock follows the day and night rhythm, according to cycles of light and dark. This is 
possible through the action of CLOCK genes, which are able to turn on and off, or “express,” 
in rhythmic patterns throughout the body, regulating physiological conditions and behavior 
during a 24-hour cycle.  
The aim of this thesis is to explore the associations between adult Attention-Deficit/Hyperactivity 
Disorder (ADHD) and certain health risks. We focus on sleep disturbances (insomnia and 
circadian rhythm disorders), Seasonal Affective Disorder (SAD) and the disturbed physiology 
associated with developing cardiovascular disease and diabetes (Metabolic Syndrome, or 
MetSyn). Specifically, the research explores relationships in the following areas: 
1. Adult ADHD and insomnia - analyzed firstly in a literature review of recent cross-sectional 
and longitudinal studies. Secondly, we tested the associations between ADHD, insomnia 
and sleep duration in a general Dutch population sample.
2. Whether the well-recognized association between winter depression (SAD) and adult 
ADHD is mediated by markers of circadian rhythm disturbance.
3. The relationship between MetSyn, obesity-related outcomes and adult ADHD.
We propose that some of these health risks may be explained if we view ADHD as a disorder 
of biological rhythm. 
We also examined the relationship between cellular aging and insomnia, sleep duration and 
circadian rhythm disturbance, using the biomarker, leukocyte telomere length (LTL). Telomeres 
are short pieces of DNA found on the end of chromosomes, which shorten with aging.
To pursue these research topics, we used two Dutch population studies: the Netherlands Study 
of Depression and Anxiety (NESDA) and the Netherlands Mental Health Survey and Incidence 
Study-2 (NEMESIS-2).
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ADHD AND INSOMNIA
Sleep disturbance in the form of insomnia, excessively short or long sleep duration, or delayed 
circadian rhythm has serious consequences for health. Chapter 2 explores insomnia in adult 
ADHD. We review papers written in English and published between January 2012 and March 
2017. Three cross-sectional studies report a prevalence of insomnia in ADHD adults ranging 
from 43 - 80%, independent of psychopharmacological treatment of ADHD.
The deductions made from the longitudinal studies were not entirely comparable: one large twin 
study confirms that the persistence of ADHD into early adulthood is strongly associated with 
insomnia symptoms at age 18, while another study shows no association between childhood 
or adolescent ADHD and insomnia at age 38.
There are significant effects of insomnia as a side-effect of some pharmacological treatments 
for adult ADHD.
Continuing with the theme of sleep in ADHD, Chapter 3 uses the NEMESIS-2 data (N = 4,618) 
to investigate the association between self-reported insomnia symptoms and the following: 
ADHD symptom severity, ADHD symptom dimensions (hyperactivity and inattention), and 
self-reported sleep duration. Self-reported short sleep duration was defined as ≤ 6 hours and 
self-reported long sleep duration was defined as ≥ 10 hours. Our results indicate that more 
severe ADHD symptoms are significantly associated with more severe insomnia symptoms. 
Those with ADHD also have an increased risk for short and long sleep duration. Insomnia 
symptoms are also clearly and consistently associated with both inattentive and hyperactive 
symptom dimensions. Of the group with clinically significant ADHD symptoms, 43% report 
serious insomnia symptoms. There is also a dose-response relationship between the number 
of insomnia symptoms, the severity of ADHD and its two symptom dimensions. Short self-
reported sleep duration is significantly associated with both inattentive and hyperactive 
symptom dimensions, while long sleep duration is only associated with inattention and not with 
hyperactivity.  
We present a short letter in Chapter 4, which was an invited response to a comment on our 
ADHD and insomnia study (Chapter 3). We agree with the plea to view ADHD and sleep 
disorders as the consequence of a pro-inflammatory state.
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ADHD AND SEASONAL AFFECTIVE DISORDER
The aim of Chapter 5 was to explore the influence of delayed circadian rhythm in the 
relationship between ADHD and SAD. In 2,239 persons from the NESDA cohort, the 
prevalence of probable SAD was three times greater in the ADHD group compared to the No 
ADHD group. There were consistently significant associations between ADHD symptoms and 
probable SAD. An indicator for circadian disturbance, sleep-onset time on nights before free 
days, was a mediator in the significant relationship between ADHD symptoms and probable 
SAD. Total sleep duration did not play a significant mediating role. Our results point to a link 
between circadian and seasonal disorders in adult with ADHD.
ADHD AND METSYN
Chapter 6 investigated the relationship between ADHD and MetSyn, in a group of 2,303 
adults from the NESDA study, with and without ADHD, in varying stages of depressive and 
anxiety disorders.  We were surprised to find no added risk for MetSyn and obesity-related 
outcomes in adults with ADHD. A meta-analysis published subsequent to our study did show 
that obesity is related to ADHD in both children and adults. Furthermore, we showed the 
symptom domains of high Inattention and Hyperactivity/Impulsivity were not associated with 
MetSyn. Hence, this study did not confirm our hypothesis that MetSyn and obesity-related 
parameters are increased in ADHD.  
SLEEP DISORDERS AND CELLULAR AGING
In Chapter 7, we investigated the influence of circadian rhythm disturbance on cellular aging, 
in a group of 2,936 subjects from the NESDA cohort. We showed that significantly shorter LTL 
was associated with several indicators of a delayed circadian rhythm, including an indication 
for the Delayed Sleep Phase Syndrome, even after correction for sociodemographic and 
lifestyle factors. However, short sleep duration and insomnia were not associated with shorter 
LTL. We also found no evidence of accelerated LTL attrition rate associated with any predictor, 
over the six years of the study. 
Symptoms of a delayed sleep phase disorder were associated with an accelerated cellular 
aging of 6 years. Altered sleep duration and insomnia symptoms over the 6 years did not 
appear to affect the rate of cellular aging.
The outcome of this research implies that a delayed circadian rhythm appears to be deleterious 
for cellular aging and therefore perhaps for general health status.
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DISCUSSION
CLOCK genes and inflammatory processes may be factors linking ADHD and SAD, insomnia, 
late sleep and shorter LTL. Tissue damage can result in chronic inflammation, where cytokines 
are released. The central biological clock partly controls the immune response. Recently, 
several studies have found evidence of a pro-inflammatory state in SAD, obesity and long and 
short sleep duration. Melatonin secretion is potentially a bridge between the circadian sleep-
wake rhythm and a pro-inflammatory state. Melatonin regulates the sleep/wake cycle and is 
considered to be an active anti-inflammatory molecule.
Our results suggest that those treating this complex condition should also screen for comorbid 
circadian rhythm sleep disorder and SAD. Insomnia should be treated with psychoeducation, 
sleep hygiene interventions and cognitive behavioral therapy (CBT). Adjunctive agents such 
as melatonin in the late afternoon or early evening, and/or light therapy may be effective in 




Aandachtstekortstoornis met hyperactiviteit (Attention-Deficit/Hyperactivity Disorder, 
ADHD) is een neuropsychiatrische ontwikkelingsstoornis. ADHD wordt gekenmerkt door een 
levenslang patroon van o.a. onoplettendheid, impulsiviteit en hyperactiviteit.  Volwassenen 
met ADHD  hebben vaak comorbide psychiatrische en medische aandoeningen. Deze 
leiden tot een slechtere kwaliteit van leven, hoge maatschappelijke kosten en levenslange 
behandeling. ADHD en een aantal comorbide aandoeningen hangen samen met problemen 
in het biologische ritme. Ons circadiane (24-uurs) ritme zorgt ervoor dat ons gedrag, 
de fysiologie van bijvoorbeeld hartslag en bloeddruk, en de stofwisseling optimaal zijn 
afgestemd op het moment van de dag. De lichaamscellen hebben elk een circadiane klok, 
die worden aangestuurd door de centrale biologische klok in de hersenen. De circadiane klok 
volgt het ritme van dag en nacht onder invloed van de licht en donkercyclus, maar wordt ook 
bepaald wordt door een set van klokgenen die elkaar ritmisch aan- en uitschakelen, met een 
doorlooptijd van ongeveer 24 uur. 
Het doel van dit proefschrift is meer inzicht te krijgen in de associaties tussen ADHD en het 
circadiane ritme, en of deze samenhangen met bepaalde gezondheidsrisico’s. De focus 
ligt op slaapstoornissen, zoals insomnia of slapeloosheid, en circadiane ritmestoornissen, 
de seizoensgebonden stemmingsstoornis (’winterdepressie’), en verstoorde fysiologische 
processen die risicofactoren vormen voor hart- en vaatziekten, diabetes en het metabool 
syndroom. Wij onderzochten de samenhang tussen ADHD bij volwassenen en verschillende 
gezondheidsrisico’s op de volgende gebieden: 
1. ADHD en slapeloosheid:  deze associatie werd eerst geanalyseerd door middel van een 
review van recente cross-sectionele en longitudinale studies. Daarnaast hebben we de 
associaties tussen ADHD, slapeloosheid en slaapduur onderzocht in de Nederlandse 
algemene bevolking.
2. ADHD en de seizoensgebonden stemmingsstoornis: we onderzochten of circadiane 
ritmestoornissen een mediërende rol spelen in de welbekende relatie tussen ADHD en de 
seizoensgebonden stemmingsstoornis.
3. De relatie tussen ADHD, maten voor overgewicht en obesitas, en metabool syndroom.
We veronderstellen dat sommige van deze gezondheidsrisico’s verklaard zouden kunnen 
worden door ADHD te beschouwen als een stoornis van het biologische ritme. 
We onderzochten ook de samenhang tussen cellulaire veroudering, insomnia, slaapduur en 
de circadiane ritmestoornis, met behulp van de biomarker Leukocyt Telomeer Lengte (LTL). 
Telomeren zijn de uiteinden van de chromosomen, die inkorten naarmate we ouder worden.
194 | CHAPTER 9
Om deze vraagstellingen te onderzoeken, is er gebruikt gemaakt van gegevens van twee 
verschillende Nederlandse bevolkingsstudies: de Netherlands Study of Depression and Anxiety 
(NESDA) en de Netherlands Mental Health Survey and Incidence Study-2 (NEMESIS-2).
ADHD EN SLAPELOOSHEID 
Slaapstoornissen zoals slapeloosheid, een te korte of te lange slaapduur en een verstoord 
circadiaan ritme kunnen ernstige gevolgen hebben voor de gezondheid. Hoofdstuk 2 gaat 
over slapeloosheid bij volwassenen met ADHD. We beoordeelden de Engelstalige literatuur 
gepubliceerd tussen januari 2012 en maart 2017. Drie cross-sectionele studies rapporteerden 
een prevalentie van slapeloosheid bij ADHD volwassenen, variërend van 43% tot 80%, 
onafhankelijk van de farmacologische behandeling van de ADHD. 
De uitkomsten van de longitudinale onderzoeken waren gemengd: een grote tweelingstudie 
bevestigde dat het voortduren van ADHD tot op 18-jarige leeftijd sterk was geassocieerd 
met symptomen van slapeloosheid. Een andere studie vond geen verband tussen ADHD bij 
kinderen of adolescenten, en slapeloosheid op de leeftijd van 38 jaar.
Slapeloosheid is ook duidelijk geassocieerd met de behandeling van ADHD: verschillende 
farmacologische middelen hebben slapeloosheid als bijwerking.
Voortbouwend op het thema slaap bij ADHD, onderzochten we in Hoofdstuk 3 binnen het 
NEMESIS-2 cohort (N = 4,618), de relaties tussen de ernst van de ADHD symptomen, de 
twee ADHD symptoom dimensies (hyperactiviteit en onoplettendheid), de zelf-gerapporteerde 
slaapduur en symptomen van slapeloosheid. Een korte slaapduur was gedefinieerd als ≤ 6 uur 
en een lange slaapduur als ≥ 10 uur. 
Uit de resultaten blijkt dat hoe meer ADHD-symptomen, hoe ernstiger de symptomen van 
slapeloosheid zijn. Degenen met ADHD hebben een verhoogd risico op zowel een korte 
als een lange slaapduur. Symptomen van slapeloosheid waren ook duidelijk en consistent 
geassocieerd met de symptoom dimensies van zowel hyperactiviteit als onoplettendheid. Van 
de groep met ADHD-symptomen rapporteerde 43% een ernstige mate van slapeloosheid. Er 
was ook een dosis-responsrelatie tussen het aantal symptomen van slapeloosheid, de ernst 
van de ADHD en de ernst van de twee ADHD-symptoom dimensies. Een korte slaapduur was 
geassocieerd met zowel onoplettendheid als hyperactiviteit. Een lange slaapduur was alleen 
geassocieerd met onoplettendheid, maar niet met hyperactiviteit. 
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Hoofdstuk 4 is een ingezonden brief als reactie op een commentaar op onze studie over 
ADHD en slapeloosheid (Hoofdstuk 3). We zijn het met de commentatoren eens dat zowel 
ADHD als slaapstoornissen als de gevolgen van een pro-inflammatoire toestand beschouwd 
kunnen worden.
ADHD EN DE SEIZOENSGEBONDEN STEMMINGSSTOORNIS
In Hoofdstuk 5 werd de mediërende rol van een verlaat circadiaan ritme tussen de 
seizoensgebonden stemmingsstoornis en ADHD bestudeerd. In de groep van 2,239 personen 
uit het NESDA-cohort was de prevalentie van de seizoensgebonden stemmingsstoornis 
driemaal verhoogd in de ADHD-groep vergeleken met de groep zonder ADHD. Er was een 
consistente associatie tussen ADHD-symptomen en indicatoren voor de seizoensgebonden 
stemmingsstoornis. De inslaapduur op nachten vóór vrije dagen, een indicator voor een verlate 
slaapfase, was een mediator in de relatie tussen ADHD-symptomen en de seizoensgebonden 
stemmingsstoornis. De totale slaapduur had geen mediërende rol. Vandaar dat onze studie 
wijst op een verband tussen circadiane en seizoensgebonden stoornissen bij volwassenen met 
ADHD.
ADHD EN HET METABOOL SYNDROOM
Hoofdstuk 6 onderzocht de relatie tussen ADHD en het metabool syndroom in een groep 
van 2,303 volwassenen in de NESDA studie met en zonder ADHD, met verschillende 
stadia van depressie en angststoornissen. In tegenstelling tot onze verwachting was er geen 
verhoogd risico voor het metabool syndroom noch voor aan obesitas gerelateerde parameters 
bij volwassenen met ADHD. Een meta-analyse kort na ons onderzoek gepubliceerd, had juist 
aangetoond dat obesitas geassocieerd is met ADHD bij zowel kinderen als volwassenen. 
Ook waren de symptoom dimensies  van onoplettendheid en hyperactiviteit/impulsiviteit 
niet geassocieerd met het metabool syndroom. Dit onderzoek kon dus onze hypothese dat 
metabool syndroom en obesitas gerelateerde parameters vaker voorkomen bij ADHD, niet 
bevestigen. 
 
SLAAPSTOORNISSEN EN CELLULAIRE VEROUDERING
Hoofdstuk 7 laat de invloed zien van circadiane ritmestoornissen op cellulaire veroudering 
binnen een groep van 2,936 personen uit het NESDA-cohort. Een significant kortere LTL hing 
samen met diverse indicatoren voor een verlaat circadiaan ritme, waaronder een verlate 
slaapfase, ook na correctie voor sociodemografische en leefstijlfactoren. Een korte slaapduur 
of slapeloosheid hadden geen invloed op de LTL. Er waren echter geen aanwijzingen voor een 
versnelde LTL verkorting onder invloed van enige predictor gedurende de 6 jaar van de studie. 
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Symptomen van een verlate slaapfase waren geassocieerd met het equivalent van een 
versnelde cellulaire veroudering van 6 jaar. Veranderde slaapduur over een duur van 6 jaar 
en symptomen van slapeloosheid hadden geen significant effect op kortere LTL. 
Dit onderzoek impliceert dat een verlate slaapfase schadelijke effecten kan hebben op 
cellulaire veroudering, en mogelijk op de gezondheid in het algemeen. 
DISCUSSIE
Klokgenen en inflammatie kunnen de verbinding vormen tussen ADHD, de seizoensgebonden 
stemmingsstoornis, slapeloosheid, de verlate slaapfase, en kortere LTL. Weefselbeschadiging 
kan leiden tot chronische ontsteking, waarbij cytokines worden afgescheiden. De centrale 
biologische klok in de hersenen bestuurt gedeeltelijk ook de immuunrespons. Onlangs hebben 
verschillende onderzoeken aangetoond dat een pro-inflammatoire toestand een rol speelt bij 
de seizoensgebonden depressie, obesitas, en bij een zowel lange als korte slaapduur. De 
melatoninesecretie vormt een mogelijke verbinding tussen de verlate slaapfase en een pro-
inflammatoire toestand. Melatonine is een biomarker voor de slaap/waak cyclus, en speelt 
een belangrijke rol in het immuunsysteem als ontstekingsremmer.
Clinici die ADHD behandelen zouden ook moeten screenen op comorbide slaapstoornissen, 
een verlaat circadiaan ritme en seizoensgebonden depressie. Slapeloosheid kan worden 
behandeld met psychoeducatie, slaaphygiëne-interventies en cognitieve gedragstherapie. 
Melatonine in de late middag of vroege avond en/of lichttherapie in de ochtend kunnen 
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en rustig (zelfs als je te weinig hebt geslapen!) Je toewijding aan onderzoek is opvallend, je 
bereidheid om te helpen en samen te werken met de mensen om je heen is grenzeloos. Op 
jouw bescheiden manier was jij mijn anker.
 
Mijn promotors, prof. dr. Aartjan Beekman en prof. dr. Brenda Penninx: Vergeet nooit de 
patient, was mijn les van Aartjan. Hoe gecompliceerd het “verhaal” van dit onderzoek ook is 
geworden, je herinnerde me altijd aan de klinische relevantie. Bedankt voor je heldere denken, 
voortdurende steun en vriendelijkheid. Je grote humor en menselijkheid moeten beïnvloed zijn 
door Bergvliet High, in Kaapstad! Je glimlach en lach zijn aanstekelijk!
Brenda, het was een grote eer voor mij om met iemand van jouw statuur samen te werken. 
Ik waardeer je bereidheid om je kennis te delen en mij zo goed te begeleiden. Geen vraag 
was te onbelangrijk voor jou. Bedankt dat je gedurende dit hele traject voor mij een rots in de 
branding bent geweest.
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family-like friends. À mes très chères amies à la Haye: Isa, Flo, Natacha et Vanessa : Votre 
amitié a enrichi ma vie. Un grand merci à vous toutes ! J’ai beaucoup apprécié nos échanges 
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tout votre gentillesse et aide. Anna, Jim, Ana, Sjakie, Yarona, Sheryl, Leyla: we laughed and 
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